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Asthma is a chronic inflammatory disorder of the airways. Remodelling in asthma is defined 
as the structural changes seen in the airways of asthmatics in comparison to healthy controls. 
Progressive loss of lung function also seen in asthma might be caused by remodelling. The 
research aims of this thesis were to investigate inflammation and remodelling in the airways 
of different types of asthmatics and smokers. The association between inflammation and 
remodelling was also examined in a mouse model of allergic airway inflammation. 
Bronchoscopy and lung function tests were performed on patients with newly diagnosed 
asthma, with asthma symptoms but no asthma diagnosis, with diisocyanate-induced asthma 
(DIA), and on smokers and control subjects. Biopsies and bronchoalveolar (BAL) samples 
were collected. Inflammatory cell numbers were quantified in the biopsies and the BAL 
samples from smoking and non-smoking controls and patients with DIA, and tenascin-
C immunoreactivity was measured in the bronchial basement membrane (BM). mRNA 
expression of a wide variety of inflammatory mediators was assessed in BAL cells with 
relative quantitative real-time RT-PCR. DIA patients were followed-up for 2–3 years and 
they were on inhaled corticosteroid (ICS) medication. Laminin expression was examined 
by semiquantitative immunohistochemistry in the BM of patients with newly diagnosed 
asthma, those with asthma symptoms and non-smoking controls. Tenascin-C expression in 
allergic airway inflammation was studied in wildtype (wT), STAT4-/- and STAT6-/- mice 
that were sensitised and challenged with OVA or PBS (controls). The expression of mRNA 
for inflammatory mediators, laminin and tenascin-C was investigated in the lung. Laminin 
and tenascin-C protein expression was evaluated with immunohistochemistry. The results of 
mouse model studies were confirmed in vitro with human fibroblasts. 
Healthy smokers showed increased numbers of macrophages in the BAL with no changes 
in the inflammatory cells in biopsies. Macrophages seemed to be quite quiescent, since 
mRNA expression for a wide variety of inflammatory mediators, especially chemokines 
CCL3, CCL4, CCL5 and CCL20, secreted by macrophages was significantly lower than 
in healthy non-smokers. Attenuated macrophage activity in the airway lumen may render 
smokers more susceptible to airway infections and have an impact on the development of 
other airway pathology. 
DIA patients had elevated numbers of IL-4-producing cells in the lamina propria at the 
beginning compared to controls, probably as a sign of Th2-type inflammation, but the 
difference disappeared during the follow up. Patients with DIA on ICS who still had non-
specific bronchial hyperreactivity (NSBHR) at the end of the follow-up showed increased 
expression of TNF-α, IL-6 and IL-15 mRNA in BAL cells compared to those without 
NSBHR. In addition to being markers for poor prognosis and possible slight glucocorticoid 
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resistance, these cytokines might aid in guiding the treatment of DIA. DIA patients had only 
a slight but significant increase in the thickness of the tenascin-C immunoreactive layer 
under the epithelium without correlation with NSBHR. The increase in the thickness was 
much less than usually seen in other types of asthma, which might not make tenascin-C a 
good marker for DIA, and probably reflects different mechanisms in disease pathogenesis in 
comparison to classic allergic asthma.
OVA-induced tenascin-C expression in the lung was attenuated in STAT4-/- mice with 
impaired Th1-type immunity compared to wT mice. Interestingly, STAT6-/- mice with 
impaired Th2-type immunity showed tenascin-C expression levels similar to those of wT 
mice. The clearest difference between these two knockout strains in response to OVA was 
that STAT4-/- mice exhibited no upregulation of IFN-γ and TNF-α mRNA expression. Thus, 
tenascin-C expression was unexpectedly more related to Th1 type reactions. In vitro studies 
confirmed the results. Human fibroblasts stimulated by TNF-α and IFN-γ showed increased 
expression of tenascin-C. 
Patients with newly diagnosed asthma showed increased expression of laminin α2 in 
comparison to patients with asthma symptoms only and healthy controls. Both patients with 
asthma and those with only asthma symptoms showed increased expression of the laminin 
β2 chain in comparison to controls. Thus, laminin α2 expression differentiated patients with 
clinical asthma from patients with symptoms only. Furthermore, the expression of laminin 
α2 and β2 was associated with NSBHR, linking very specific remodelling events to clinical 
disease.
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1. review of the literature
1.1 Inflammation in the airways
1.1.1 inflammatory mediators
Inflammatory reactions in the airways are orchestrated by inflammatory and stationary cells 
as well as inflammatory mediators secreted by them. Study of the basic actions of these 
mediators in animal models and cell cultures has aided in understanding inflammatory diseases 
of the lungs (Chung 2001, Commins et al. 2010, Holgate 2008). Cytokines are small secreted 
cell-signalling proteins with paracrine, autocrine and even endocrine functions.  Chemokines 
are an important subgroup of cytokines and are here discussed separately. Chemokines have 
been named for their ability to attract cells, a phenomenon called chemotaxis. Cytokines and 
chemokines are essential mediators of inflammation and immunity and are produced and 
secreted in response to various stimuli (Chung 2001, Commins et al. 2010). The original 
names for cytokines and chemokines derive from their history. Interleukins (IL) are typical 
cytokines. Their name points to the connection between leukocytes, which were the first 
cells to be discovered to secrete ILs. Moreover, the name tumour necrosis factor (TNF) 
indicates how the TNF superfamily was discovered. Cytokines and chemokines can be 
categorised in many ways. Traditionally, they are classified into proinflammatory cytokines, 
Th (T-helper) 1, Th2 and Th17 cytokines, and chemokines according to their function and 
the cells they are secreted by (Borish and Steinke 2003, Commins et al. 2010, Dinarello 
2000). The numbers of known cytokines and chemokines have constantly been growing. 
The categorisations are artificial and simply intended to help in understanding the complex 
network of inflammatory mediators. Cytokines and chemokines are also secreted by many 
other cell types than inflammatory cells. The field is so vast that only the cytokines important 
for this thesis are covered.
Cytokines
The proinflammatory cytokines, such as TNF-α, IL-1 and IL-6, promote inflammation 
by activating a variety of inflammatory mediators that are crucial in the cascade of events 
leading to tissue inflammation, even directly promoting matrix metalloproteinase (MMP) 
release (Borish and Steinke 2003, Chung 2001). They are mostly secreted by macrophages 
and other antigen presenting cells (APC), although many other cells can also secrete them. 
Proinflammatory cytokines are produced and released in response to various stimuli from 
bacterial products to other cytokines. TNF-α has numerous effects, such as an antitumor 
capacity, and it is an important mediator in innate immunity. (Berry et al. 2007, Chung 2001, 
Commins et al. 2010). It has direct cytotoxic effects and induces further immune responses. 
It is the primary mediator in septic shock and chronic inflammation-related cachexia. TNF-α 
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stimulates the expression of other proinflammatory mediators, leukocyte adhesion factors, 
and CCL (CC chemokine ligand) 5, among others. TNF-α inhibitors are mainly used in the 
treatment of rheumatoid arthritis and other autoimmune diseases (Sfikakis 2010). They have 
additionally been tested in the treatment of asthma and COPD, mainly with negative results 
(Matera et al. 2010). However, some patients with severe asthma have been reported to 
benefit from the inhibition of TNF-α (Berry et al. 2007, Matera et al. 2010). IL-1 and TNF-α 
are often released together and they have similar actions making it sometimes difficult to 
separate the functions of these cytokines from each other (Commins et al. 2010, Dinarello 
2000). In addition to activities in common with TNF-α, IL-1 stimulates T-lymphocytes 
similarly to IL-6. The latter is secreted by various cells, including macrophages and epithelial 
cells, and has multiple functions, many of which are quite similar to TNF-α and IL-1. IL-
6 stimulates acute phase protein synthesis, induces fever, promotes a Th1-type immune 
response and also inhibits IL-1 and TNF-α production (Borish and Steinke 2003, Dodge et 
al. 2003, Jirapongsananuruk et al. 2000, yu et al. 2002). 
Th1 and Th2 cytokines promote cell-mediated immunity and allergic responses, respectively. 
They are named after the subsets of CD (cluster of differentiation) 4+ Th cells secreting 
them, although they are also produced by other cells (Borish and Steinke 2003). Classic 
Th1 cytokines include IFN-γ and TNF-β, among others, while IL-4, IL-5 and IL 13 are the 
primary Th2 cytokines. New members of the latter include IL-9, IL-23 and IL-31. 
IL-12 is a primary cytokine driving Th1 cell polarisation. It induces the expression of 
interferon (IFN) –γ, which is a major Th1 cytokine primarily secreted by T cells upon antigen 
challenge, natural killer (NK) cells and macrophages. It activates macrophages, dendritic 
cells, NK cells and neutrophils (Antoniou et al. 2003, Commins et al. 2010). Thus, IFN-γ is 
very important in combating intracellular pathogens. It inhibits collagen synthesis and has 
been proposed as a treatment for patients with diseases manifesting as fibrosis (Antoniou et 
al. 2003). IL-15 is classified in this review with the Th1 cytokines because of its functions, 
although it is mainly secreted by APC cells, similarly to proinflammatory cytokines. Most 
importantly, IL-15 activates NK cells. It is also a growth factor of T-lymphocytes and, to a 
lesser extent, mast cells. IL-15 is responsible for the survival of CD8+ memory cells and it 
attracts T cells and neutrophils (Commins et al. 2010, D’Acquisto et al. 2010). 
Th2 cytokines IL-4, IL-5 and IL-13 are able to induce most of the hallmarks of atopic asthma: 
mucus overproduction, goblet cell hyperplasia, non-specific bronchial hyperreactivity 
(NSBHR; synonyms are airway hyperreactivity, AHR, or bronchial hyperreactivity, BHR) 
and eosinophilia (Holgate 2008, Paul and Zhu 2010). NSBHR is measured as a reduction in 
airway flow in response to increasing concentrations of histamine or metacholine (Sovijarvi 
et al. 1993) and is a central feature of asthma. IL-4 is the most important cytokine in the 
initiation of Th2-type responses. It induces Th0 lymphocytes to differentiate into Th2 cells 
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and down-regulates the production of proinflammatory cytokines. Eosinophils are the 
main target for IL-5, which is involved in almost every aspect of eosinophil proliferation, 
maturation and activity (Commins et al. 2010). As elevated numbers of eosinophils are a key 
feature of asthma (Holgate 2008), inhibition of the action of IL-5 was considered to be an 
obvious choice for the treatment of asthma (Foster et al. 1996). Despite a fall in circulating, 
sputum and airway eosinophil counts, the results of human trials were disappointing, with 
only patients suffering from severe eosinophilic asthma with exacerbations having some 
benefit from blocking the actions of IL-5 (Flood-Page et al. 2003b, Haldar et al. 2009, 
Nair et al. 2009). This outcome weakened the suspected role of eosinophils in asthma and 
highlighted the diversity of the disease (see also the section “Allergic asthma and mouse 
models of airway inflammation” for eosinophil).  IL-13, referred to as the effector in Th2-
type adaptive immunity, is important in the defence against parasites and a well-characterised 
and widely expressed mediator of allergic inflammation and tissue fibrosis (Commins et al. 
2010, wynn 2003). 
Chemokines
Chemokines have a wide variety of actions in inflammation, mostly related to the 
chemotaxis of inflammatory cells (Borish and Steinke 2003, Commins et al. 2010, Conti 
and DiGioacchino 2001). For clarity, the chemokines referred to in this thesis with their 
nomenclature are listed in Table 1. Systematic names were introduced because the same 
chemokine might have been discovered in different instances and thus had several common 
names. They also participate in guiding T-cell differentiation and tissue homeostasis. 
Chemokines can be divided according to the position of cysteine residues in the N-terminal 
into two main groups that comprise almost all chemokines: CXC (α-chemokines) and CC 
(β-chemokines). Those included in the former group chiefly attract neutrophils, while 
mediators in the latter group attract the other inflammatory cells. X stands for a variable 
amino acid. Other small groups include C- and CX3C-chemokines. CCL3, CCL4 and 
CCL20 are macrophage inflammatory proteins (MIPs) that belong to the CC chemokines 
and are produced by activated macrophages and other inflammatory cells (Commins et al. 
2010, Driscoll 1994, Maurer and von Stebut 2004). In addition, many other cells, including 
peripheral blood leukocytes and vascular smooth muscle cells, are capable of producing 
MIPs under stimulation. CCL3 and CCL4 attract activated T-cells, monocytes, dendritic 
cells and NK cells bearing chemokine receptor 1 (CCR1) and CCR5 on their surface, as 
well as CCL3- and CCR1-positive cells. CC chemokines functioning through CCR5 can 
stimulate the development of IFN-γ-producing Th1 cells (Commins et al. 2010). CCL20 
recruits CCR6-positive dendritic cells and possesses an antimicrobial capability (yang et al. 
2003). Regulated on activation, normal T-cell expressed and secreted RANTES, also known 
as CCL5, is a CC chemokine expressed in various cells including fibroblasts, macrophages 
and epithelial cells (Berkman et al. 1996, Casola et al. 2002, Chung 2001). It mainly recruits 
eosinophils and basophils, and to lesser extent T-lymphocytes. Eotaxin/CCL11 is a potent 
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eosinophil chemoattractant. Immunoglobulin (Ig) E receptor crosslinkage on the mast cell 
surface translocates CCR3 to the cell surface, and binding of the CCL11 to this CCR3 
potentiates IgE-dependent IL-13 production (Price et al. 2003). CCL11 is released by roughly 
the same cells as CLL5 (Commins et al. 2010). Asthmatics have more CCL11-positive 
fibroblasts in bronchial biopsies than controls (wenzel et al. 2002). Many cells possess the 
ability to release the powerful neutrophil chemoattractant and activator CXCL8 in response 
to various stimuli, the most important cells in the airways probably being macrophages and 
epithelial cells (Commins et al. 2010). Expression of CXC-chemokine ligand (CXCL) 8 
is especially stimulated by bacterial products, TNF-α, IL-1 and viral infections. It induces 
neutrophil adherence to endothelial cells and respiratory burst. 
  
Table 1. Nomenclature for chemokines referred to in this thesis
Systematic name Common name(s) Receptor(s)
CCL3 MIP-1α/LD78α CCR1, CCR5
CCL4 MIP-1β CCR5
CCL5 RANTES CCR1, CCR3, CCR4,CCR5
CCL11 Eotaxin CCR3
CCL20 MIP-3α, LARC CCR6
CCL22 MDC, STCP-1 CCR4
CCL24 Eotaxin-2, MPIF-2 CCR3
CCL26 Eotaxin-3 CCR3
CXCL8 IL-8 CXCR1, CXCR2
Adapted from Commins et al. (2010)
1.1.2 The role of smoking in airway inflammation
Among the many other detrimental consequences, cigarette smoke has a major impact on 
inflammation in the airways (Amin et al. 2003, Aoshiba et al. 2001, Barbers et al. 1987, 
Barnes 2010, Di Stefano et al. 1998, Dippolito et al. 2001, Ekberg-Jansson et al. 2000, 
Hagiwara et al. 2001, Kotani et al. 2001, Lams et al. 1998, Lams et al. 2000, Linden et al. 
1993, Mio et al. 1997, Takizawa et al. 2000). Smoking is associated with a longer duration 
of respiratory infections (Huttunen et al. 2010) and a high incidence of chronic obstructive 
pulmonary disease (COPD) (Eisner et al. 2010). Depending on the diagnostic criteria, 
smoking status and age, 12–50% of smokers develop COPD, but 60–80% of COPD cases 
are evaluated to be attributed to smoking (Eisner et al. 2010, Lundback et al. 2003, weiss 
et al. 2003). As with other multifactorial diseases, it is far from clear why some smokers 
develop COPD while others do not, although much has been discovered about the genetic 
background predisposing to COPD (Molfino 2004). 
COPD is an immunological and inflammatory disease of the smaller airways with systemic 
manifestations (Cosio and Agusti 2010). In COPD the limitation of airway flow is partly 
16
irreversible, in contrast to asthma, although elderly people often have a double diagnosis 
(Gibson and Simpson 2009). Although the inflammation in asthma and COPD is not similar, 
there might be common factors for susceptibility to both. For instance, IL-13 promoter 
polymorphisms have been linked to both COPD and asthma (Molfino 2004). Furthermore, 
NSBHR and a family history of asthma are risk factors for COPD (de Marco et al. 2010). 
Patients with COPD seem to be as heterogeneous a population as those with asthma (Garcia-
Aymerich et al. 2010). Depending of the severity and stability of the disease, macrophages, 
CD8+ cells and neutrophils are variably deposited in the airway wall and lumen in the upper 
and lower parts of the respiratory tract (Barnes 2000, Jeffery 2004, Saetta 1999). In COPD 
the expression of proinflammatory cytokines and chemokines such as IL-6, IL-1β, TNF-α,  
CXCL8, CCL2 and CCL5 is elevated in the airways (Chung 2001).  
In asymptomatic smokers, inflammation in the airways is not as well defined. A consistent 
finding in bronchoalveolar lavage (BAL) samples from asymptomatic smokers is elevated 
numbers of macrophages compared to non-smokers (Barbers et al. 1987, Hagiwara et 
al. 2001, Kotani et al. 2000, Kotani et al. 2001, Linden et al. 1993). However, smoking 
suppresses macrophage function against pathogens in asymptomatic smokers (Kotani et al. 
2000, Kotani et al. 2001, McCrea et al. 1994, Ohta et al. 1998, yamaguchi et al. 1993). 
Alveolar macrophages participate in recognizing foreign antigens as pathogens and they 
secrete a variety of cytokines and chemokines, which are involved in the initiation and 
maintenance of inflammatory responses (Borish and Steinke 2003, Driscoll 1994, Gordon 
and Read 2002). They phagocytise foreign material as well as release reactive oxygen 
species, antibacterial products and leukotrienes. Healthy smokers have shown ineffective 
alveolar macrophage function compared to non-smokers measured by the response to LPS: 
lower TNF-α (McCrea et al. 1��4, �amaguchi et al. 1��3), IL-6 (McCrea et al. 1��4), IL-1β               
(Sauty et al. 1994) and CXCL8 release (Ohta et al. 1998). Consistently with this, smokers 
in previous studies have exhibited increased macrophage aggregation but decreased IL-
1β, IFN-γ, and TNF-α mRNA expression and lowered phagocytic as well as microbicidal 
activity during anaesthesia compared to non-smokers, even if patients stop smoking six 
months before operation (Kotani et al. 2000, Kotani et al. 2001). There have been few biopsy 
studies comparing inflammatory cell numbers in asymptomatic smokers and non-smokers 
without any other pulmonary pathology (Amin et al. 2003, Ekberg-Jansson et al. 2000). 
Likewise, the cytokine and chemokine profile in the BAL fluid (BALF) of asymptomatic 
smokers is not very clear (Hagiwara et al. 2001, Kotani et al. 2000, McCrea et al. 1994, 
Ohta et al. 1998, Takizawa et al. 2000, Tanino et al. 2002). Only a few mediators have been 
studied. Even more heterogeneous have been the in vitro results with cigarette smoke extract 
exposure, as reported in a recent review by Smith et al. (2010).
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1.1.3 allergic asthma and mouse models of allergic airway 
inflammation
Asthma is a very common disease with a global burden affecting an estimated 300 million 
people worldwide. According to the definition of the Global Initiative for Asthma (GINA), 
asthma is “a chronic inflammatory disorder of the airways” and “the chronic inflammation 
is associated with airway hyperresponsiveness” leading to asthma symptoms (GINA. 
2009). Thus, airways become obstructed under suitable conditions and the obstruction is 
usually reversible. This is of course a very broad and descriptive statement. In everyday life, 
diagnosis is mainly based on symptoms and the verification of airflow limitation in lung 
function tests such as spirometry, peak expiratory flow (PEF) follow-up, and in some cases 
by determining NSBHR. Symptoms include a history of cough (at night), chest tightness, 
wheezing and difficulties in breathing. Spirometry aims at confirming the reversibility of the 
obstruction. According to the GINA guidelines, the diagnostic criteria for asthma include 
a post-bronchodilator increase in the forced expiratory volume in 1 s (FEV1) ≥12% and at 
least 200 ml. In PEF follow-up, diurnal variation over 20% is regarded as diagnostic when 
recurring in 10% of measurements or a bronchodilator response ≥20% / 60 l/min. As the 
diversity of the disease has become evident, guidelines handling asthma as one disease with 
different degrees of severity have not always been adequate (Hargreave and Nair 2009). 
As with other common multifactorial diseases, there are many environmental risk factors 
acting on certain genetic backgrounds leading to various phenotypes (Meyers 2010). These 
phenotypes present with the same symptoms and clinical findings. This is problematic 
when modelling the disease. Currently, routine treatment roughly relies on suppressing 
the inflammation (glucocorticoids, leukotriene inhibitors as additional medication) as well 
as relieving bronchoconstriction (β2 agonists, anticholinergics). Glucocorticoids suppress 
inflammation very widely, which explains their efficacy in different types of asthma and 
other inflammatory diseases (Barnes 2010). In addition to the main effects, every drug has 
other functions in the airways (Mauad et al. 2007). The relationship between symptoms 
and inflammatory markers is not consistent (Tillie-Leblond et al. 2009). Symptom-based 
guidance of treatment may predispose to an increased number of exacerbations. Thus, 
patients might benefit from inflammatory marker-directed therapy (Tillie-Leblond et al. 
2009). 
Although it is even more artificial to divide asthma into allergic (or atopic) and non-allergic 
forms based on the atopic history or IgE production in clinic, this section will focus on 
typical asthmatic airway inflammation most strongly associated with allergic asthma. The 
ovalbumin (OVA)-induced mouse model of asthma used in this thesis simulates eosinophilic, 
IgE-dependent airway inflammation leading to NSBHR. 
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Airway inflammation in (allergic) asthma
In humans, asthmatic airway inflammation is governed by an increased number of 
eosinophils, mast cells, CD4+ lymphocytes, neutrophils, macrophages and cytokines of 
Th2-type inflammation (Holgate 2008). The inflammation covers the whole airway from 
allergic rhinitis to mild asthma in the bronchial mucosa always down to the small airways and 
inflammation in the submucosa and muscle in more severe asthma. All the real inflammatory 
cells are derived from bone marrow.
Eosinophils are considered to have a key role in allergic inflammation. They are circulatory 
cells that are activated by various stimuli ranging from complement and tissue injury to 
cytokines. Their well-known ability in innate immunity is to chemically attack the body’s 
own tissues as well as parasites by releasing the components of their granules: major 
basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and 
eosinophil-derived neurotoxin (EDN, also known as eosinophil protein X, EPX). In addition, 
eosinophils secrete a wide variety of mediators capable of further inducing inflammation 
and tissue fibrosis, including leukotrienes (LT), transforming growth factor–β (TGF-β), 
granulocyte macrophage colony-stimulating factor (GM-CSF), neuromediators and the 
classic Th2 immune response-related cytokines and chemokines (IL-4, IL-5, IL-13, CCL5, 
CCL11), among others. Moreover, they have the ability to act as APCs, increase the reactivity 
of smooth muscle and activate mast cells (Rothenberg and Hogan 2006). Thus, eosinophils 
may influence Th1/Th2 polarization and NSBHR, underlining their importance in the Th2-
type inflammatory response and contribution to many of the features of asthma. The only 
slight effect of IL-5 antibodies on asthma symptoms and clinical parameters has also been 
attributed to the fact that the inhibition of eosinophil activity and recruitment is only 50% 
in biopsies (see also the section “Inflammatory mediators – Cytokines”) (Flood-Page et al. 
2003b, Holgate 2008). Eosinophils are also recruited by other mediators such as CCL5 and 
CCL11, CCL24 and CCL26 (Rothenberg and Hogan 2006). Although IL-5 antibodies had 
little effect on asthma symptoms, remodelling of the airways was reduced when measured 
in terms of the expression of tenascin, lumican and procollagen III (Flood-Page et al. 
2003a), which further associates eosinophilic airway inflammation with remodelling. It is 
notable that an excess of eosinophils in the airways does not necessarily lead to NSBHR 
(eosinophilic bronchitis), and NSBHR can exist without eosinophils (Bradding et al. 2006, 
Kim et al. 2010b, Rothenberg and Hogan 2006)
Mast cells are another prominent and important cell type in asthma. The total numbers are 
not necessarily increased, but the activation and localisation of mast cells seems to be more 
important, i.e. their presence in deep/superficial or upper/lower parts of the airways (Bradding 
et al. 2006). Mast cells are stationary cells in tissues and are best known as mediators of 
allergy. when an IgE-primed mast cell meets an allergen, IgE receptors crosslink and the 
mast cell releases its granules into the tissue, as well as secreting de novo mediators. Other 
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stimuli such as complement, viral antigen or tissue injury can also activate degranulation 
and mast cells (Bradding et al. 2006, Okayama et al. 2007, Theoharides and Kalogeromitros 
2006). In asthma, mast cells are constantly active. Histamine, LTs and prostagalandin (PG) 
D2 released by mast cells are important effectors in asthma pathology, since they can cause 
bronchoconstriction, mucosal oedema, and mucus secretion. In addition, mast cells can 
secrete a wide diversity of substances, many with importance in asthma, including cytokines 
(also IL-4, IL-5, and IL-13), chemokines (also CCL5), peptides, proteoglycans, enzymes 
(also MMPs) and growth factors. Mast cells can be divided into two groups: mucosal and 
connective tissue types (Bradding et al. 2006, Holgate 2008, Okayama et al. 2007). Mucosal 
mast cells function under the guidance of T-lymphocytes. Deeper connective tissue mast cells 
are more dependent on stem cell factor (SCF), which is upregulated in asthma. More research 
attention has been focused on the deep connective tissue mast cells (Bradding et al. 2006). 
These are situated in close connection with smooth muscle and may interact with smooth 
muscle cells. Thus, mast cells also provide a connection between airway inflammation and 
remodelling, although with little evidence in humans. 
T-lymphocytes have long been at the centre of attention in asthma research. Enormous 
progress has been made during the last decade in understanding the role of T cells in 
asthma and other diseases (Lloyd and Hessel 2010). As T cell research has advanced, the 
number of different subgroups has grown and all may have a role in asthma. Different T-
cell subtypes and phenomena related to their action and asthma are listed in Table 2, with 
the main cytokines they secrete. Asthma is mainly characterised by increased numbers of 
CD4+ lymphocytes, also known as Th cells, which have been thought to be of the Th2 
subtype. However, it is probably not this simple, as demonstrated in Table 2. Moreover, cells 
have been also recognised in the lungs capable of secreting IL-13 and IL-4 under cytokine 
stimulation, i.e. from the epithelium, without adaptive immunity and T cell receptors (TCR) 
(Lloyd and Hessel 2010). These are innate immune cells that do not bear markers of any 
known leukocyte lineage (Neill et al. 2010, Price et al. 2010). It was previously thought that 
when CD4+ cells commit, they are no longer able to change their secretion of cytokines, 
but this has also been questioned, as Th2 cells were shown to be able to transform into IL-9 
producing cells (Lloyd and Hessel 2010, Veldhoen et al. 2008). TGF-β seems to have a key 
role (Veldhoen et al. 2008).
Although allergic asthma has been considered an eosinophilic phenomenon without 
increased numbers of neutrophils in the stable phase, neutrophils are often found in patients 
with severe and glucocorticoid-unresponsive asthma as well as in relation to exacerbations 
(Barnes 2007). Neutrophils are among the first cells at the site of inflammation and are 
active phagocytes. They secrete substances such as elastase, thromboxane A2, MPO, MMPs 
and LTB4, directly causing features of asthma including bronchoconstriction, oedema 
and mucus hypersecretion, and possibly participating in remodelling (Monteseirin 2009). 
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Neutrophils also increase chemotaxis and the activation of other cells important in asthma 
by secreting cytokines and chemokines. New interest in neutrophils has also been raised by 
neutrophil recruiter IL-17, a cytokine produced by a subset of CD4+ lymphocytes designated 
as Th17cells (Alcorn et al. 2010, Harrington et al. 2005, Park et al. 2005b). To a lesser 
extent, neutrophils, eosinophils, γδ cells and CD8+ T cells are able to secrete IL-17. Its 
expression is increased in asthmatics, although the cellular source is not entirely clear. More 
interestingly, IL-17 might be more related to allergic than non-allergic asthma (Alcorn et al. 
2010, wang et al. 2010).
Table 2. T cell subtypes, cytokines secreted by them and action in asthma models
T cell subtype Cytokine(s)  Actions






• Mast cell recruitment 
• Eosinophilia




• Mast cell recruitment





• Role in glucocorticoid resistant asthma?





• Correlates with disease severity
• Eosinophilia 
• NSBHR
• Role in viral exacerbations
NKT IFN-γIL-13
• Eosinophilia







• Vγ1 subtype: proinflammatory, secrete IL-5 and 13, promote NSBHR
• Vγ4: suppressors, produce IL-17A, suppress NSBHR
Adapted from Lloyd and Hessel (2010). 
The number of macrophages is often elevated in the airway mucosa in asthma, but rather 
little is known about their eventual role in the pathogenesis of allergic asthma. However, the 
role of macrophages and especially dendritic cells has begun to be clarified during the past 
few years, as they have also been shown to be able to polarize towards driving the Th2-type 
immune response (Lambrecht and Hammad 2010). Traditionally, they are seen as promoters 
of Th1-type immunity. Macrophages and dendritic cells differentiate from monocytes under 
the influence of GM-CSF. They serve as APCs (dendritic cells), phagocytes (macrophages), 
an important source for cytokines and other mediators, and are considered the key cell 
21
between innate and adaptive immunity (Gordon and Read 2002). Antigen presentation 
to lymphocytes is a crucial step in the development and activation of adaptive immunity. 
Macrophages are thought to have a role in glucocorticoid-resistant asthma (Barnes and 
Adcock 2009), severe asthma in children (Fitzpatrick et al. 2011) and in animal models of 
chronic Th2-type inflammation and NSBHR (Byers and Holtzman 2010, yang et al. 2010). 
The number of basophils, circulating effectors of IgE-mediated allergic reactions, is also 
elevated in biopsies from asthmatic subjects (Macfarlane et al. 2000). As with mast cells, 
IgE receptor-mediated triggering is not the only way to activate basophils, and they also 
have the ability to function as APCs driving Th2 polarisation (yoshimoto 2010). The role of 
basophils in asthma is not clear. 
The airway epithelium and other stationary cells also have implications in inflammation, 
as they are affected by inflammatory cells and mediators in the airways. Stationary cells 
secrete inflammatory mediators and can respond directly to external stimuli. The epithelium 
is the barrier between the lumen and tissue in the airways and thus has an important role 
in the defence against external threats. According to one view, in susceptible individuals 
under suitable environmental conditions, this might be not as effective and well directed, 
resulting in the progression of asthma (Holgate 2008, Lambrecht and Hammad 2010, Lloyd 
and Hessel 2010) see the section on remodelling. 
Immunity
For many years after the discovery of inflammation in the airways, asthma was considered 
almost solely a disease of disturbed adaptive immunity, while in recent years the role of 
innate immunity has also become evident (Bonilla and Oettgen 2010, Holt and Strickland 
2010, Turvey and Broide 2010). Innate immunity is the reaction of organisms to threats they 
are facing for the first time. These responses are nonspecific, ranging from enzymes in saliva 
to pattern recognition by cells involved in innate immunity. The cells participating include 
granulocytes (eosinophils, neutrophils and basophils), NK cells (cytotoxic lymphocytes 
distinct from NKT cells) and cells of the monocyte lineage such as macrophages. Depending 
on the point of view, the epithelium and other barriers and stationary cells may sometimes be 
categorised as components of innate immunity, although the role of the epithelium is much 
more besides that (Lambrecht and Hammad 2010). 
Cells involved in innate immunity also phagocytose material and present it to T-lymphocytes 
in lymph nodes, thus linking innate and adaptive immunity. In adaptive immunity, APCs 
(macrophages, dendritic cells, B-cells and some epithelial cells) present antigens received 
from the digestion and processing of foreign material in major histocompatibility class 
(MHC) II to Th cells in the presence of co-stimulatory signals in lymph cell accumulations 
(Bonilla and Oettgen 2010). These co-stimulatory signals define how strong a response is 
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elicited. The APC and cytokine milieu defines the orientation of Th cells. T cells recognise 
antigens with their TCR. T cells proliferate and are ready to elicit a much greater response 
on the next counter. CD8+ cells recognise antigens bound to MHC I molecules and are 
important in recognising the body’s own tissues and intracellular pathogens. B-cells have Ig 
on their surface which functions as a B-cell receptor (BCR). Antigen binds to this and with a 
co-stimulatory signal from Th cells activates B cells, which proliferate and begin producing 
antibodies, establishing a new antigen-specific clone. Under the influence of IL-4, B cells 
undergo class switching, changing the type of Ig they produce to IgE. Both T cells and B 
cells undergo selection during development in order to prevent immune reactions that are too 
strong or wrongly guided. In normal situations, tolerance towards inhaled antigens should 
develop, but something goes wrong in asthma (Holt and Strickland 2010). Both B and T 
cells have effector and memory cells. This is, of course, a very simplified view nowadays.
Allergen challenge in the airways
In allergen challenge, the above machinery is orchestrated to produce allergic inflammation. 
when an allergen and cells with allergen-specific IgE and dendritic cells meet, rapid activation 
of macrophages and mast cells follows (Bousquet et al. 2000, Holgate 2008, Paul and Zhu 
2010). These activated cells provoke immediate allergic inflammation, as discussed above, 
resulting in contraction of ASM, vasodilation, exudation of plasma into the airway wall and 
lumen, and mucous overproduction. This is a simplified view of the early-phase reaction 
that occurs immediately. In the late-phase reaction, over 6 h after the challenge, CD4+ cells, 
neutrophils, basophils and eosinophils join the reaction with their specific actions, as above, 
recruited by mast cells and macrophages. Dendritic cells that have travelled to lymph cell 
collections present the allergen as antigens. The importance of eosinophils and basophils 
as APCs is not very clear in vivo. In this phase, a Th2-type inflammatory mediator pattern 
may already be seen, but is probably dependent on other cells than Th2 cells. The infiltration 
of cells also requires an increase in endothelial adhesion molecules for inflammatory cells. 
After the first 24 hours, activated T cells are seen, resulting in an adaptive immune response 
by the previously sensitised immune system.
Animal models
Animal models of allergic inflammation should mimic the features of human asthma and 
preferably represent remodelling under chronic exposure. Furthermore, the development of 
an allergic response should be similar with sensitisation and challenge to that in humans. A 
late-phase reaction should be seen. On the other hand, most of the data on the mechanisms 
of inflammation in asthma are from animal studies (Kips and Pauwels 1999). Differences 
are apparent between species, and even mouse strains, in the way they react to antigen 
sensitisation and challenge (Hylkema et al. 2002, Kirschvink and Reinhold 2008). Mice 
are probably not the best model species, but are quite close to humans, are an economical 
species for research, and numerous genetically manipulated strains are available (Bates et 
23
al. 2009, Ricciardolo et al. 2008). Agents used to elicit an allergic response should also have 
similarities with human allergens, but then again mice have no spontaneous asthma. Balb/c 
mice are born with a strong tendency for atopy. They are highly reactive to ovalbumin 
(OVA) and present remodelling changes after prolonged challenge, in addition to Th2-type 
eosinophilic inflammation, NSBHR, goblet cell hyperplasia and elevated plasma levels 
of IgE (Kumar and Foster 2002). Even in OVA sensitised and challenged mice, the dose, 
duration, adjuvants, route of sensitisation and challenge, and the time of sacrifice, among 
other factors, affect the result (Kumar et al. 2008). Variation might occur within the same 
strain with the same experimental protocol between mice from different suppliers and 
between sexes (Allen et al. 2009). The model should be chosen according to the phenomenon 
intended to be studied (Zosky and Sly 2007). Below is a list (Table 3) of the best known 
animal models of asthma. 
Table 3. Animal models of asthma. 
Species Antigen Reference
Mouse
OVA Renz et al. 1992
House dust mite Johnson et al. 2004
Cockroach antigen Lundy et al. 2003
Aspergillus fumigatus Kurup et al. 1992
Ragweed Sur et al. 1996
Sheep red blood cells Gavett et al. 1994
Hexamethylene diisocyanate Herrick et al. 2002
Rat
OVA Hylkema et al. 2002
House dust mite Singh et al. 2003
Ascaris Misawa et al. 1987
Guinea pig
OVA Thorne and Karol 1989
Toluene diisocyanate Karol 1987
Dog
Ascaris Booth et al. 1970, Hirshman et al. 1980
Ragweed Redman et al. 2001
Sheep Ascaris Abraham et al. 1988
Non-human primate 
House dust mite Plopper and Hyde 2008
Ascaris Patterson and Harris 1992
1.1.4 diisocyanate-induced asthma
Patients with occupational asthma comprise 10–15% of all asthma patients (Bardana 2008). 
Diisocyanates (DI) are used in the synthesis of polyurethane, which is used in paints, adhesives, 
plastics and foam. The three most used DIs are toluene diisocyanate (TDI), diphenylmethane 
diisocyanate (MDI), and hexamethylene diisocyanate (HDI). work-related diisocyanate-
induced asthma (DIA) is one of the most common forms of occupational asthma. It has 
many similarities to atopic asthma, but a poor prognosis despite discontinued exposure to 
DIs and adequate treatment with ICS (Liu and wisnewski 2003). DI exposure may result in 
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hyperreactivity to diisocyanates and NSBHR. The correlation with diisocyanate-specific IgE 
in serum or total IgE levels is not as strong as in allergic asthma (Liu and wisnewski 2003, 
Pronk et al. 2007). Besides biological factors, one reason for the contradictory results might 
be in the assays use to detect specific IgE (Campo et al. 2007, Ott et al. 2007). The short 
duration of exposure, IgE positivity to DIs, and low level of NSBHR are factors that seem to 
predict a good outcome (Padoan et al. 2003, Park and Nahm 1997, Piirila et al. 2000, Pisati 
et al. 2007, Rachiotis et al. 2007). Elevated IL-8 and neutrophil-derived myeloperoxidase 
levels are associated with a worse outcome (Maghni et al. 2004). Even after the cessation of 
exposure and with inhaled corticosteroid treatment, NSBHR, inflammation and symptoms 
may persist (Padoan et al. 2003, Piirila et al. 2000).
The number and size of biopsy and BAL studies in humans have been limited. Inflammation 
in the airways has characteristics of atopic asthma, although there is evidence of a mixed 
Th1/Th2 response (Liu and wisnewski 2003). An excess of mast cells, eosinophils and 
activated T cells has been found in the bronchial mucosa (Bentley et al. 1992, Saetta et al. 
1992), while an excess of neutrophils and eosinophils has been recorded in BAL (Fabbri et 
al. 1987). Elevated numbers of CD8+ cells in the bronchial mucosa are a more consistent 
finding in DIA, while in allergic asthma CD4+ cells are overrepresented (Maestrelli et al. 
1��4, Wisnewski et al. 2003). Increased expression of TNF-α, IL-1β, IL-4 and IL-5 has been 
shown in bronchial biopsies (Jones et al. 2006, Maestrelli et al. 1994, Maestrelli et al. 1995, 
Maestrelli et al. 1997). 
1.1.5 sTaT4 and sTaT6 
Signal transducers and activators of transcription (STAT) are a family of transcription 
factors important in the signalling of cytokines (Pfitzner et al. 2004). Janus kinases (JAK) 
are intracellular mediators of receptor binding. Binding of cytokine to its receptor activates 
JAK, which causes STAT to translocate to the nucleus. STAT4 is a key transcription factor 
in the development of Th1-type inflammation, while STAT6 is critical for the Th2-type 
response. Both STAT4 and STAT6 have been shown to play a role in Th2-type inflammation 
(Akimoto et al. 1998, Hoshino et al. 2004, Raman et al. 2003, Syrbe et al. 2006). 
STAT6
STAT6 is activated when IL-4 or IL-13 bind to the α chain of the IL-4 receptor (IL4Rα) 
(Kuperman and Schleimer 2008). Many gene variations of the IL-4 and IL-13 pathways 
have been linked to asthma. For example, the presence of asthma-associated polymorphisms 
of IL-13 and IL-4Rα together was reported to increase the risk of asthma five-fold in the 
Dutch population (Howard et al. 2002). STAT6 activates many genes important in Th2-type 
polarisation and allergic inflammation, including IL-4 (Curiel et al. 1997) and CCL11 (Hoeck 
and Woisetschlager 2001), and suppresses the expression of IFN-γ. Recently, STAT6-
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dependent signalling was shown to induce RhoA expression in cultured human bronchial 
smooth muscle cells in experimental studies by Chiba et al. (Chiba et al. 2010). RhoA is 
a small GTP-binding protein that has been suggested to play a role in smooth muscle cell 
hypercontractibility in asthma. STAT6-/- mice have impaired Th2-cell differentiation and 
IgE-class switching, as well as a decreased response to allergens and parasites (Akimoto et 
al. 1998, Kaplan et al. 1996, Shimoda et al. 1996, Takeda et al. 1996). STAT6-/- mice exhibit 
no airway hyperreactivity and eosinophilic inflammation in response to allergen challenge. 
STAT6 has been found to be increased in the bronchial epithelium in patients with severe 
asthma (Mullings et al. 2001). Although STAT6 has been under extensive research as a target 
for new medications for asthma, with promising results (McCusker et al. 2007, walker et 
al. 2009), there have been concerns. In a chronic asthma model induced by OVA, STAT6-
/- mice unexpectedly had AHR, remodelling comparable to wT mice and Th1 polarisation 
(Foster et al. 2003). In IL-4/IL13-/- mice, these changes were not seen. Alternative routes 
may overtake the actions of STAT6 (Zimmermann et al. 2004).  An explanation for the 
controversial results may also be differences between mouse strains in signalling cascades 
downstream of IL13 and IL4 (Hirota et al. 2009), or different experimental protocols (Olmez 
et al. 2009). Although IL-4 also has STAT6-independent targets, IL-4 and STAT6 signalling 
seem to be connected to each other in Th2-type inflammation, while IL-13 has other routes 
of action (Elo et al. 2010, Foster et al. 2003, Kim et al. 2010b, Sehra et al. 2008, wills-Karp 
and Finkelman 2008).
STAT4
STAT4 was first described as a mediator of the effects of IL-12, an important Th1 cytokine 
(Thierfelder et al. 1996). The most important consequence of STAT4 activation is increased 
expression of IFN-γ. Accordingly, IFN-γ expression is suppressed in STAT4-/- mice. Thus, 
the importance of STAT4 in inflammation was first shown in models of autoimmune diseases 
(Pfitzner et al. 2004), but evidence for its involvement in asthma has now also begun to 
emerge. Polymorphisms of the STAT4 gene are associated with an increased risk of asthma 
in the Chinese population (Li et al. 2007, Park et al. 2005a), but not in Finns (Pykalainen et 
al. 2005). One group has proposed DNA methylation as a way to regulate the expression of 
both STAT4 and STAT6, instead of allelic variation in T cells (Kim et al. 2010a, Shin et al. 
2005). Although the administration of IL-12 or IFN-γ suppresses inflammation and AHR in 
mouse models of asthma (Behera et al. 2002, Schwarze et al. 1998), the role of STAT4 is 
more complicated. Cockroach antigen sensitized STAT4-/- mice showed decreased AHR, 
eosinophilia and chemokine production compared to wT mice, implying a role for STAT4 in 
allergic inflammation (Raman et al. 2003). Furthermore, IFNγ has been shown to contribute      
to the priming of CD4+ cells as IL-4-producing cells (Bocek et al. 2004). Supporting the 
dual role of STAT4, it seems that inhibition of the IL-12/STAT4/IFN-γ axis during allergen 
sensitisation leads to an elevated Th2 inflammatory response, but its inhibition during 
challenge attenuates inflammation (Meyts et al. 2006). A very interesting recent article by 
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Kim et al. (2010b) suggested that IL-12/STAT4/IFN-γ is a downstream pathway of IL-13-
dependent IL-4Rα-independent asthma phenotypes such as NSBHR and non-eosinophilic 
inflammation, suggesting a new role for STAT4 in airway inflammation.
1.2 Remodelling in the airways
1.2.1 general
Although the presence and importance of airway inflammation in asthma is clear, structural 
changes in the airway wall are also considered important (Holgate 2008). According to 
the most enthusiastic remodelling researchers, we have come to a dead end in the study of 
Th2-type inflammation and in trying to identify targets for asthma treatment from signs and 
consequences of the disease, instead of trying to target the reasons for the observed changes 
(Holgate and Davies 2009). Remodelling in asthma is the same as the structural changes 
seen in the airways of asthmatics in comparison to healthy controls. This is the result of 
coordinated interaction between resident and infiltrating cells and extracellular matrix (ECM) 
proteins (Holgate 2008). Thus, remodelling is very tightly related to inflammation, although 
remodelling and inflammation may be seen separately in vivo. Remodelling is normally seen 
during wound healing and development. Classically, remodelling is considered to follow 
inflammation, as in wound healing (Eming et al. 2007). It has been known for long that the 
airways do not look the same in fatal asthma compared to those of non-asthmatics, but the 
actual golden years of remodelling research began a little over a decade ago. Remodelling 
in the human airways includes changes such as thickening of the airway wall, the deposition 
of ECM proteins beneath the epithelium and changes in the epithelium (Bousquet et al. 
2000, Holgate 2008, Jeffery 2004, Laitinen et al. 2000). An increase and changes in the 
vasculature and neural networks have also been demonstrated. Thickening of the airway 
wall is a consequence of many changes, such as an increase in airway smooth muscle (ASM) 
and ECM proteins, especially the thickening of the bronchial basement membrane (BM), 
oedema, and an elevated number of mucosal glands. Remodelling is evident in allergic 
asthma, as well as in DIA (Boulet et al. 1994, Holgate 2008, Saetta et al. 1992, Saetta et al. 
1992).
Although not directly associated with the severity of remodelling and all phases of it, the 
progressive loss of lung function also seen in asthma (Grol et al. 1999, Lange et al. 1998), 
might be caused by remodelling (Holgate 2008, Pascual and Peters 2005). In HRCT, the 
airway wall area is inversely correlated with FEV1 and asthma severity in asthma, but not 
in eosinophilic bronchitis (Niimi et al. 2000, Park et al. 2006). This thickening, causing 
rigidity into the airway wall, is also regarded as a possible defence mechanism protecting 
the airways from repeated bronchoconstriction (Holgate 2008).
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1.2.2 asm
ASM hyperplasia and hypertrophy are among the most prominent features in the airway 
wall and correlate with the severity of disease (Ebina et al. 1993, James and Carroll 
2000). Extensive research has been carried out on the mechanisms of ASM modulation, 
as bronchoconstriction is a cardinal feature of asthma (Dekkers et al. 2009, Halayko and 
Solway 2001, Panettieri 2003). ASM has two different major phenotypes, contractile and 
proliferating. ASM from asthmatic individuals has different contractile properties and an 
increased capacity to proliferate. Although ASM is very plastic, modifying its properties 
according to external signals (Halayko and Solway 2001), something is different in these 
cells from patients with asthma compared to those from controls. ASM cells can respond 
to various stimuli from other cells in asthmatic lung tissues and changes in the ECM. They 
can secrete a variety of mediators, including cytokines and chemokines, and the ECM. 
Changes in ASM also seem to be directly associated with inflammation. In addition, inhaled 
corticosteriods (ICS) probably partly act by affecting muscle, while thermoplasty of ASM, 
reducing the muscle mass through heating, is under research as a new treatment for asthma 
(Mauad et al. 2007).
1.2.3 mediators
In addition to inflammatory mediators, many other mediators of tissue homeostasis have 
been implicated in asthma pathogenesis, including a disturbed balance between MMPs 
and their inhibitors (tissue inhibitors of matrix metalloproteinases,TIMP) (Mautino et al. 
1999) and disturbed expression of growth factors such as vascular endothelial growth factor 
(VEGF), epidermal growth factor (EGF) and TGF-β (Holgate 2008, Pascual and Peters 2005). 
TGF-β, a member of the TGF-β superfamily, is among the most studied (Bosse and Rola-
Pleszczynski 2007, Howell and McAnulty 2006). Three different splice variants of TGF-β 
exist, TGF-β1–3. As with many other growth factors, TGF-β1 is secreted as a latent form 
into the ECM, where it attaches. It is activated by several mechanisms, including MMPs, 
and has numerous activities in cell proliferation and differentiation, immunomodulation, 
and wound healing. It is a mediator of tissue fibrosis. Recently, TGF-β1, a masterswitch 
of epithelial-mesenchymal transition (EMT), has been proposed to drive EMT of bronchial 
epithelial cells to mesenchymal cells with myofibroblast characteristics (Doerner and Zuraw 
2009). An excess of myofibroblasts has been demonstrated in asthma (westergren-Thorsson 
et al. 2010). 
 
1.2.4 Bronchial Bm
Pathological changes in asthma include the thickening of the lamina reticularis of the BM, 
consisting of glycoproteins such as tenascin-C, fibronectin (FN), collagen I, III and V, 
and proteoglycans (Holgate 2008, Jeffery 2004, Laitinen et al. 2000, Roche et al. 1989). 
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The thickening is greater in atopic than in non-atopic patients (Amin et al. 2000). It may 
even be seen after allergen challenge in asthmatics, and persists after the inflammatory 
response is silenced (Kariyawasam et al. 2007). The thickening is of same magnitude in 
severe childhood asthma as in adults, and the thickness of the BM is not defined by the 
duration of the disease (Payne et al. 2003). 
The terminology is slightly misleading. when discussing the basement membrane in the 
lung, it can mean two things: the lamina lucida and lamina densa +/- lamina reticularis. 
The lamina lucida and lamina densa are the real basement membranes described next, and 
the lamina reticularis is the ECM, devoid of cells under it. The lamina densa and lamina 
reticularis are connected through anchoring fibrils of collagen VII. They can be separated in 
electron microscopy, but not in light microscopy. However, the lamina lucida might be an 
artefact from the handling of the tissue and lamina densa could be the real structural layer. 
Basement membranes were characterised between the epithelium and ECM as acellular 
structures separating these two compartments, but have also been found in other locations, 
serving the same functions (Kruegel and Miosge 2010, Paulsson 1992, Timpl 1996). They are 
composed of self-assembling collagen IV and laminin networks connected by other proteins 
such as nidogen. Although capable of self-assembly, reciprocal interactions with cells are 
important for the formation of BMs. Collagen IV is essential for the stability of BMs, while 
laminins are essential for their assembly. Other major components include proteoglycans 
high in heparin sulphate, although numerous molecules have been recognised. Cells bind 
and recognize constituents of the BMs through cell surface receptors such as integrins. 
The composition of basement membranes is tissue- and time-specific. They are not just 
barriers, scaffolds for attachment and filters, but are involved in many processes such as 
cell migration, development, growth, signalling and differentiation. Changes in basement 
membrane composition have been implicated in various diseases, including cancers. 
There is a layer of flat fibroblasts directly under the BM in asthmatic as well as in normal 
subjects, which may serve as one means of communication between the epithelium and 
lamina propria, may transform to myofibroblasts in response to injury to the epithelium 
(Morishima et al. 2001), and may be responsible for the thickening of the lamina reticularis 
(Evans et al. 1999).
1.2.5 epithelium
Shedding of the epithelial cells is a common finding in asthma, but not seen in patients 
with the mildest form of the disease (Jeffery 2004, Laitinen et al. 1985). One current view   
introduced (or reintroduced) at the beginning of the 21st century proposes that the initial 
damage is in the epithelium, which guides the mesenchyme (together called the epithelial-
mesenchymal trophic unit, EMTU), and the view has since been refined (Holgate et al. 
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2000, Holgate et al. 2004, Holgate and Davies 2009, Holgate et al. 2009). The damaged 
epithelium begins to produce a pool of cytokines, chemokines and growth factors. The 
barrier function is also jeopardized. The initial damage might result from factors such as 
virus infection or pollutants in wrongly programmed epithelium. These, in turn, activate 
the ECM/mesenchymal cells, including dendritic cells, fibroblasts and smooth muscle, and 
attract and activate inflammatory cells. The result is chronic inflammation comprising a 
constant excess of growth factor receptors, increased cytokine and growth factor production, 
infiltration of inflammatory cells and Th2 polarization. The view is completed by the idea 
of improper activity of genes that were supposed to be silenced after birth, since many of 
the mediators involved in asthma are also important during morphogenesis (Bousquet et 
al. 2004). This leads in time to a dynamic state named remodelling, including pathological 
changes in epithelial cells and the ECM as this one type of chronic wound healing continues 
(Bousquet et al. 2004, Laitinen et al. 2000). Thymic stromal lymphopoietin (TLSP), which is 
secreted by bronchial epithelial cells in response to threats and damage in vitro (Allakhverdi 
et al. 2007), is able to induce a Th2-type response, promoting DCs and mast cells (Allakhverdi 
et al. 2007, Soumelis et al. 2002). Furthermore, asthmatics have been reported to display 
increased expression of TLSP in biopsies (ying et al. 2005). 
Localization of the expression of many asthma susceptibility genes to the mesenchyme 
and epithelium has supported this view of the EMTU (Holgate et al. 2009). One gene with 
probably the strongest evidence and most positive studies is a member of the membrane 
bound metalloproteases, a disintegrin and metalloproteinase domain 33, ADAM33 (Holgate 
et al. 2006, Van Eerdewegh et al. 2002).  It is preferably expressed in mesenchymal cells in 
adults, especially in smooth muscle, and during morphogenesis. Its expression is increased 
in asthma and has been implicated in pathogenesis (Haitchi et al. 2009, Jie et al. 2009). To 
further strengthen this view, inflammation and remodelling already exists in infants who 
will develop asthma in the future (Baena-Cagnani et al. 2007). Furthermore, glucocorticoid 
treatment of children with atopic parents or only symptoms of asthma but no asthma 
diagnosis do not reverse the natural progression of the disease (Holgate 2008). Some other 
theories concentrated more on inflammation have also considered the epithelium as the 
origin (Holtzman et al. 2002, Lambrecht and Hammad 2010).
1.2.6 mouse models
Remodelling in the lung has been shown in a chronic allergic mouse model, but structural 
changes in the acute phase have, as expected, been minimal (Christie et al. 2004, Kumar et 
al. 2004, McMillan and Lloyd 2004). Remodelling persists in the mouse lung, even after 
antigen exposure is terminated and inflammation disappears (Kumar et al. 2004). In addition 
to the larger airways, remodelling changes in mouse lung have also appeared in the lung 
parenchyma (Hirota et al. 2006, Xisto et al. 2005). Thus, mice might make a good model 
30
for studying the mechanisms of remodelling. However, remodelling has always been a 
consequence of artificial sensitisation and inflammation as in classical view of remodelling, 
because mice do not naturally develop asthma.
 
1.2.7 Tenascin-C
Tenascins are ECM glycoproteins. Four isoforms have been recognised in vertebrates: tenascin-C, 
tenascin-X, tenascin-R and tenascin-w (Brellier et al. 2009, Jones and Jones 2000, Tucker and 
Chiquet-Ehrismann 2009). Tenascin-y is the avian homologue of tenascin-X. Each of the tenascins 
has a unique temporal and spatial expression pattern. They consist of similar motifs: 1) heptad 
repeats (an amino-terminal oligomerization domain), 2) EGF-like repeats, 3) FN type III repeats, 
and 4) a fibrinogen-like globular carboxy terminal. Tenascin-C polypeptides form a hexabrachion, 
which was first discovered from the tenascin family. Tenascin-C has different splice variants, 
resulting in different compositions of FN III repeats in a species-, tissue- and time-specific manner. 
Because it is usually expressed quite transiently, the expression pattern has been relatively difficult 
to study. Its expression can be modulated by many factors, including growth factors, mechanical 
stress, inflammatory mediators and MMPs, which are all involved in the pathogenesis of asthma. 
Depending on the molecules tenascin-C interacts with, it can promote adhesion, cell migration or 
growth, or inhibit all of the above (Jones and Jones 2000). Tenascin-C is usually quite antiadhesive 
and promotes the detachment and migration of cells. Thus, in addition to morphogenesis, it is very 
important in cancer development, wound healing and inflammatory diseases. 
Tenascin-C participates in development and remodelling in the lung (Jones and Jones 2000, Roth-
Kleiner et al. 2004). In the developing lung, tenascin-C is needed for branching morphogenesis of 
the bronchial tree (Kaarteenaho-wiik et al. 2001, Lambropoulou et al. 2009, Roth-Kleiner et al. 
2004, young et al. 1994). It is first expressed more in mesenchymal cells, then in the canalicular 
phase in and near epithelial cells, after which expression is gradually down-regulated. It almost 
disappears after alveolarisation (Kaarteenaho-wiik et al. 2001, Lambropoulou et al. 2009). In 
human adult bronchi, BM is negative or faintly positive for tenascin-C in healthy controls, but 
its expression is markedly increased in asthma in the stable phase and even immediately after 
specific antigen challenge (Amin et al. 2000, Kariyawasam et al. 2007, Laitinen et al. 1997, Phipps 
et al. 2004, weinacker et al. 1995). The accumulation of tenascin-C is stronger in atopic than in 
nonatopic asthma patients and correlates with inflammatory cell numbers in the lamina propria 
(Amin et al. 2003, Karjalainen et al. 2003). The tenascin-C-positive percentage of the lamina 
reticularis has been shown to correlate with the recovery from histamine challenge (Tsurikisawa 
et al. 2010). A coding single nucleotide polymorphism (SNP) in an alternatively spliced FNIII 
repeat of tenascin-C has been linked to adult asthma in the Japanese population (Matsuda et al. 
2005). Furthermore, neuropeptide S –  neuropeptide S receptor 1 (NPSR1) signalling increases 
tenascin-C expression, and the NPSR1 gene is a susceptibility gene for asthma (Orsmark-Pietras 
et al. 2008).
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In an OVA-induced mouse model of allergic airway inflammation and in patients with 
atopic asthma, the Th2 type of inflammation prevails in the airways. It has been shown 
that leukotrienes, IL-13, IL-4, TNF-α and IFN-γ upregulate tenascin-C production in vitro 
(Altraja et al. 2008, Harkonen et al. 1995, Lee et al. 2001b, Rettig et al. 1994, Syed et al. 2005, 
yuyama et al. 2002). Furthermore, tenascin-C can modulate cytokine expression (Midwood 
and Orend 2009). Glucocorticoid treatment has been shown to reduce the thickness of the 
tenascin-C layer (Laitinen et al. 1997). OVA induces tenascin-C expression and Th2-type 
inflammation, while tenascin-C-deficient mice show attenuated Th2- type inflammation in the 
lung in response to OVA (Nakahara et al. 2006). Thus, it appears that tenascin-C might have 
multiple roles in inflammation in the airways. It might be more an inflammatory mediator 
than a structural protein in adults. TGF-β is also a known inducer of expression for tenascin-C 
(Jones and Jones 2000). TGF-β is known to bridge the transition from Th2-type inflammation          
to fibrosis, but independent mediators exists (Lee et al. 2001a, Takayama et al. 2006). The 
cyclic strain that is exerted on the airway wall during bronchoconstricition induces tenascin-C 
production through changes in the actin cell skeleton (Sarasa-Renedo et al. 2006). 
1.2.8 laminins
Laminins are large heterotrimeric glycoproteins composed of one α, one β and one γ chain,       
forming cruciform, T-shaped or rod-like structures. Five α chains, three β chains and three 
γ chains have been identified in vertebrates that actually participate in the formation of 
known laminins (Aumailley et al. 2005, Colognato and yurchenco 2000, Durbeej 2010, 
Miner 2008, Scheele et al. 2007). At least 15 laminin trimers have been discovered. The 
nomenclature is presently systematic, as can be seen in Table 4 (Aumailley et al. 2005). For 
instance, laminin composed of α1, β1 and γ1 chains is named laminin 111. A and B are used 
to designate splice variants of the chains. Laminins are situated in the BM in various tissues. 
They self-polymerise under the epithelium, which is guided by α chains and connections 
to cells. Similarly to tenascins, laminins have a tightly regulated temporospatial expression 
pattern. They are important for tissue homeostasis, since they participate in directing cell 
differentiation, movement, shape and survival. They may even promote bacterial invasion. 
Laminins communicate with cells through integrin and non-integrin receptors on the cell 
surfaces. Laminins and their interactions with cells have gained considerable interest among 
cancer researchers. Mutations in laminin genes may lead to serious defaults in phenotypes. A 
deficiency of laminin α2 may cause muscular dystrophy (Guo et al. 2003), and a deficiency of 
laminin β2 congenital nephrotic syndrome with neuromuscular and ocular defects (Zenker et 
al. 2004). Mutations in human LAMA2 and LAMB2 genes associated with the diseases have 
been found for both (Matejas et al. 2010, Oliveira et al. 2008). 
In healthy adult human lungs, α3, α5, β1, β3, γ1, γ2 chains have been revealed in the bronchial 
BM (Amin et al. 2005, Petajaniemi et al. 2002, Virtanen et al. 1996, Virtanen et al. 2000). 
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Because of problems with antibody specificity, some older papers claim expression of 
laminin α1 chain in adults in the bronchial BM, but this is actually laminin α5. The laminin 
α5 chain and laminin 111, at least, are critical for lung development (Nguyen and Senior 
2006). During morphogenesis, α2 and β2 chains are also expressed under the bronchial 
epithelium. The laminin α2 chain disappears during the early pseudoglandular stage of 
development, while laminin β2 is expressed at least until the end of the canalicular period. 
During the former, branching morphogenesis and cell type specialisation occur, while in the 
latter phase the real respiratory portion of the lungs begins to form. 
Table 4. Nomenclature for laminins





α3Aβ3γ2 Laminin-332 or -3A32 Laminin-5 or 5A
α3Bβ3γ2 Laminin-3B32 Laminin-5B
α3Aβ1γ1 Laminin-311 or -3A11 Laminin-6 or -6A








Adapted from Aumailley et al. (2005)
Laminin α2 and β2 chains re-emerge in asthma (Altraja et al. 1��6). The laminin β2 chain 
is sometimes seen in healthy controls, but laminin α2 is only evident in asthma. Laminin 
α2 is usually expressed together with laminin β2, while laminin β2 is often expressed 
alone.  Laminin α2 is a selective adhesion substrate for myofibroblasts in foetal mouse 
lung, as fibronectin serves as a platform for the whole mesenchymal cell population in vitro 
(Flores-Delgado et al. 1��8). The stretch-induced expression of the laminin α2 chain is 
known to promote the transition of mesenchymal cells to the smooth muscle cell phenotype 
by down-regulation of RhoA, which is a GTPase needed in the reorganisation of the actin 
cytoskeleton (Beqaj et al. 2002, Relan et al. 1999). Binding to endogenous laminin seems 
to be needed for changes in mature ASM cells in (Tran et al. 2006). No actual association 
between increased numbers of myofibroblasts and the laminin α2 chain has been shown in 
asthma. No functional results on the importance of laminin β2 in the development of the 
lungs have, to my knowledge, been published. The laminin α2 chain is usually not expressed 
alone in asthma, but always with the β2 chain (Altraja et al. 1��6). In congenital muscular 
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hypertrophy, a defiency of the laminin α2 chain reduces the expression of laminin β2, 
probably reflecting the guidance of laminin assembly by α chains (Cohn et al. 1��7).
1.2.9 relationship between inflammation and remodelling
In mouse models, inflammation precedes remodelling and requires long-term challenge 
(Kumar et al. 2004). As described above, the concepts of asthma pathogenesis based 
mainly on the mechanisms found in mouse models also consider inflammation to precede 
remodelling in humans (Holgate 2008). However, the order of appearance of inflammation 
and remodelling in human asthma has not been definitively established (Baena-Cagnani 
et al. 2007). For instance, children with respiratory symptoms destined to develop asthma 
already have remodelling changes in the lung (Pohunek et al. 2005). The role and the exact 
timing of the remodelling in the pathogenesis of asthma remain to be elucidated. 
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2. aims of the study
The overall aim of the research presented in this thesis was to investigate airway inflammation 
and the expression of laminins and tenascin-C in airway remodelling in different types 
of asthma, and in asymptomatic smokers in comparison to healthy non-smokers. we 
hypothesized that:
I) asymptomatic smokers would have disturbed inflammatory balance in the 
airways compared to non-smokers;
II) airway inflammation in diisocyanate-induced asthma (DIA) patients with 
persistent NSBHR would differ from that in patients without NSBHR after the 
cessation of exposure and treatment with ICS; 
III) we would find in vivo regulators of tenascin-C expression in asthma by 
investigating the association between Th polarisation and tenascin-C expression 
in an animal model of allergic asthma utilizing STAT4 and STAT6 knockout 
(KO) mice; and
IV) we could relate the development of clinical asthma to the laminin expression 
profile in the bronchial BM by studying subjects with newly diagnosed asthma, 
those with asthma symptoms but not fulfilling the criteria for an asthma 
diagnosis and healthy controls.
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3. materials and methods
The animal studies were approved by Ethics Committee of the Finnish Institute of 
Occupational Health (FIOH) (Helsinki, Finland) and the State Provincial Office of Southern 
Finland (Helsinki, Finland). The human studies were approved by the Ethics Committee of 
the Department of Medicine, Helsinki University Central Hospital (Helsinki, Finland), the 
Ethics Committee of the North Karelia Central Hospital (Joensuu, Finland) and the Ethics 
Committee on Human Research at the University of Tartu (Tartu, Estonia). All subjects gave 
informed consent
3.1 Subjects (I-II, IV)
3.1.1 Healthy subjects, asymptomatic ex-smokers and 
smokers
The healthy controls were volunteers from the regions of Helsinki University Central 
Hospital (HUCH) (n = 15) (I–II) and Tartu University Hospital (n = 8) (IV). Common 
exclusion criteria were a pulmonary or other disease, atopic symptoms, and an acute 
respiratory infection within the previous 4 weeks. All the healthy subjects included had 
spirometry results within normal limits, normal laboratory tests and no allergies. Allergies 
and atopy were excluded by history and negative skin prick tests (IV) or IgE measurements 
(I–II). In addition, subjects underwent a histamine provocation test to exclude BHR (I–II) 
or performed a 2-week PEF follow-up (IV). Among the controls recruited from the HUCH 
region (I–II), there were 5 smokers, 2 ex-smokers and 8 non-smokers. The controls from 
Tartu (IV) were all non-smokers. 
3.1.2 patients
we studied altogether 67 asthmatics of various types, who were divided into the following 
three groups:
Patients with DIA (n = 17) (II) were recruited at FIOH. The diagnosis was made after specific 
challenge with the DI to which patient had been exposed to, as described earlier (Piirila et al. 
2000). Exposure to DIs was terminated after the diagnosis or before because of respiratory 
symptoms. This was a follow-up study, and patients went on budesonide 1600 µg/day (Astra 
Zeneca, Södertälje, Sweden) after the first bronchoscopy. Some patients had been using ICS 
before the study and the medication was discontinued for 17.5 d (mean, range 6–60) before 
the first examination. After 1 year, adjustments of the medication were allowed according 
to the patients’ needs. Examinations were repeated on study visits after 6 months and 2–3 
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years. Smoking was permitted: 4/17 patients were smokers and 7/17 were ex-smokers. None 
of the patients changed their smoking habits during the study. 
Patients with symptoms but without an asthma diagnosis (n = 15) (IV) were recruited from 
the region of HUCH. Inclusion criteria were an elevated serum ECP concentration (> 500 
µg/l), asthma symptoms (wheezing, cough or dyspnoea), but no asthma according to lung 
function tests. Asthma was excluded by PEF follow-up with diurnal variation <20% and 
FEV1 and PEF reversibility <15%. Exclusion criteria were significant systemic disease and 
respiratory infection within the 4 weeks before the study visit. The patients with asthma 
symptoms used no inhaled or oral steroids, cromones, methylxanthines or long-acting β2-
agonists for 4 weeks, no long-acting antihistamines or nasal corticosteroids for 6 weeks and 
no short-acting antihistamines for 2 weeks before the study.
Patients with mild asthma (n = 35) (IV) had received an asthma diagnosis <2 years previously. 
The diagnosis was made according to international criteria (National Heart Lung and Blood 
Institute, National Asthma Education and Prevention Program. April 1997). Patients were 
recruited from the regions of HUCH and the North Karelia Central Hospital. Additional 
inclusion criteria were active asthma symptoms and BHR 1 week before or at the study visit. 
Patients with asthma exacerbation during the preceding four weeks were excluded. The 
asthma medications were discontinued as follows: long-acting β2-agonists or leukotriene 
inhibitors for 4 weeks, antihistamines for 2 weeks and inhaled or oral steroids for the 2 
months before the study. Atopy was screened by skin prick testing.
3.1.3 lung functions
All participants performed a spirometry according to international standards (Quanjer et al. 
1993). The diffusing capacity and total lung capacity were measured from all participants in 
studies I and II. Finnish reference values of Viljanen (Viljanen et al. 1982) were used in both 
aforementioned procedures. NSBHR was assessed by a histamine challenge test according 
to Sovijärvi et al. (Sovijarvi et al. 1993). In addition, DIA patients (II) were challenged 
with DIs and control substances to confirm the diagnosis 48h before the bronchoscopy as 
described earlier (Piirila et al. 2000). 
3.1.4 Bronchoscopy
Fibreoptic bronchoscopy (Olympus BF-XT30) was performed according to international 
guidelines (National Institutes of Health 1991) after local anaesthesia with lidocaine. BAL 
was sampled according to Taskinen et al. (1992) and the bronchial biopsies were taken with 
cupped forceps from untouched areas. 
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3.2 OVA- induced mouse model of allergic airway 
inflammation (III)
3.2.1 animals
wild-type (wT) Balb/c mice were purchased from M&B (Denmark). STAT4-/- and STAT6-
/- mice of the same Balb/c background were obtained from Jackson Laboratories (Bar 
Harbor, Maine, USA). All the mice were housed at the Finnish Institute of Occupational 
Health under pathogen-free conditions and kept on an OVA-free diet. 
3.2.2 sensitisation and challenge 
All the mice were sensitised with intraperitoneal (i.p.) injection of 50 μg of OVA emulsified 
in aluminium hydroxide on days 0 and 14. On days 28, 29 and 30 the mice were challenged 
with nasally inhaled phosphate buffered saline (PBS) (controls) or 50 μg of OVA under 
isoflurane inhalation anaesthesia. 
3.2.3 airway responsiveness and sample collection and 
preparation
A single-chamber whole-body phletysmograph (wBP) (Buxco Technologies, Troy, Ny, 
USA) was used to assess airway responsiveness 24 hours after the last airway challenge 
as described earlier (Hamelmann et al. 1997). Unrestrained mice were first exposed to 
nebulised PBS to record the baseline enhanced pause (Penh) values, and then to increasing 
concentrations of metacholine (Mch) (Sigma-Aldrich, UK). Airway responsiveness was 
expressed as absolute Penh values. Penh is a value obtained through a mathematical formula 
based on the flow curve of wBP. 
After airway challenge, the mice were killed by isoflurane overdose. The hepatic vein was 
drained, the chest cavity opened and the lungs were lavaged. A fraction of the bronchoalveolar 
lavage (BAL) sample was cytospun on a slide and stained with MayGrünwald-Giemsa 
(MGG) stain for inflammatory cell counting. Half of the right lung embedded in TissueTek 
OCT Compound and the left lung were quick-frozen for immunohistological and RNA 




The primary antibodies used in this research with working dilutions are listed on Table 5. All 
the immunohistochemical studies were carried out with quick-frozen specimens, except the 
measurement of the tenascin-C layer in DIA patients (unpublished). The tissue integrity was 
better in paraffin-embedded biopsies, but there were much greater problems with antibody 
binding. Quick-frozen samples were sectioned at 6 µm with a cryostat and paraffin blocks at 
room temperature (RT) onto glass slides. The integrity of the lung samples was confirmed 
with routine haematoxylin-eosin staining. Negative controls were handled as follows, but 
the primary antibodies were omitted. All the antibodies have been characterised and most 
of them have been used for a number of years in laboratory research at the Department of 
Anatomy of the Institute of Biomedicine, University of Helsinki. 
3.3.1 Tenascin-C and laminins (III‒IV and unpublished 
data)
Indirect immunofluoresence was used to visualize antibody binding to tenascin-C and 
laminins. For indirect immunofluoresence, slides were fixed with acetone at -20 °C for 10 
min and rinsed in PBS. The slides were then incubated with primary antibody at RT for 30 
min followed by rinsing and incubation with the appropriate FITC-conjugated IgG secondary 
antibody (Jackson ImmunoResearch Laboratories Europe, UK). Finally, the slides were 
rinsed and mounted in sodium veronal buffered glycerol. Tenascin-C immunoreactivity was 
graded in the mouse lung from 0–4 as follows: 0 = no reactivity, 1 = weak reactivity, 2 = 
intermediate reactivity, 3 = strong reactivity, 4= very strong reactivity. All the samples were 
coded.
Paraffin-embedded sections were used to measure the thickness of the tenascin-C layer in 
DIA patients and controls. First, the slides were deparaffinised in xylene and hydrated in 
a degrading alcohol series. Pepsin treatment was used for antigen retrieval. The APAAP 
protocol (below) was then followed without the fixing. The sections were photographed 
under a light microscope and the open source software ImageJ was used to measure the 
thickness of the tenascin-C layer. 
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Table 5. Monoclonal antibodies used in this research
Antigen Antibody Ref./Company Dilution Studies
Cleaved ECP (eosinophils) EG2 Pharmacia, Uppsala, Sweden 1:50 I,II
Mast cell tryptase 
(mastcells)
AA1 Dako 1:500 I,II
CD 163 (macrophages) Ber-MAC3 Dako 1:50 I,II
Neutrophil elastase 
(neutrophils)
NP57 Dako 1:2000 I,II
CD3 (lymphocytes) T3-4B5 Dako 1:1000 I,II
CD4 MT310 Dako 1:40 I,II
CD8 DK25 Dako 1:1000 I,II
Recombinant human IL-4 1842-01 Genzyme, Cambridge, MA, USA 1:50 I,II
Tenascin-C 100EB2 Howeedy et al. 1990 none III
Tenascin-C paraffin 
embedded samples
143DB7 Soini et al. 1992 1:1 up
Tenascin-C (mouse) MTn-12 Sigma-Aldrich, Aufderheide and Ekblom 1988 1:200 III
Laminin α2 chain 5H2 Leivo and Engvall 1988 1:800 IV
Laminin α2 chain (mouse) 4H82 Sorokin et al. 1997 1:2 up
Laminin α3 chain BM2 Rousselle et al. 1991 1:400 IV
Laminin α5 chain 4C7 Engvall et al. 1986, specificity Tiger et al. 1997 1:1000 IV
Laminin β1 chain 114DG10 Virtanen et al. 1997 none IV
Laminin β2 chain C4 Hunter et al. 1989 1:2000 IV
Laminin β2 chain (mouse) lamβ21117 Sasaki et al. 2002 1:1600 up
Laminin β3 chain 6F12 Marinkovich et al. 1992 1:300 IV
Laminin γ1 chain 2E8 Engvall et al. 1990 1:300 IV
Laminin γ2 chain 
(inlaminin-332)
GB3 Matsui et al. 1995 1:4 IV
In parentheses is given either the cell type that the antibody was used to detect or the target species if other 
than human. up = unpublished data
3.3.2 Inflammatory cells in biopsies (I‒II)
The alkaline phosphatase–anti-alkaline phosphatase (APAAP) (Dako, Glostrup, Denmark) 
technique was used to detect inflammatory cells in biopsies, except eosinophils. For APAAP, 
sections were fixed in acetone at RT for 10 min and rinsed with Tris-buffered saline between every 
step in the procedure. They were incubated with the primary antibody for 1 h followed by the APAAP 
protocol according to the manufacturer’s instructions. New Fuchsin (Sigma, St Louis, MO, USA) 
was used for colour development. Levamisole was used to block endogenous alkaline phosphatise 
activity. Slides were counterstained with haematoxylin and mounted in Eukitt mounting medium 
(Fluka Biochemika, Buchs, Switzerland). To visualize antibody binding to eosinophil cationic 
protein, the Vectastain Elite avidin-biotin complex (ABC) kit (Vector Laboratories, Burlingame, 
CA, USA) with DAB development was used according to manufacturer’s instructions. Sections 
for ABC were fixed with paraformaldehyde. Slides were counterstained with haematoxylin and 
mounted in Eukitt (Fluka BioChemika, Buchs, Switzerland). 
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Cell densities were counted with the Autocad program 10.1 (Autodesk Inc., Sausalito, CA, 
USA), as described earlier (Laitinen et al. 1997).
3.4 Real-time quantitative RT-PCR (I‒III)
Total RNA from the cells and the lungs was extracted using Trizol Reagent (Gibco BRL, 
Grand Island, Ny, USA) (I–II) or Eurozol Reagent (Euroclone, Italy) (III) according to 
the manufacturer’s protocol. In studies I–II the total RNA was handled with DNAase I 
(Roche, Munich, Germany) to remove the contaminating DNA. The total amount of RNA 
was measured with spectrophotometry. RNA was reverse transcribed into cDNA with 
MultiScribe reverse transcriptase or a High Capacity cDNA Reverse Transcription Kit 
(Applied Biosytems, Foster City, CA, USA), with random hexameres as primers, according 
to manufacturer’s instructions.  
The relative quantitative real-time polymerase reverse transcriptase chain reaction (RT-
PCR) was performed with an Applied Biosystems AbiPrism 7700 Sequence Detector 
System or 7500 Fast Real-Time PCR system according to the manufacturer’s instructions. 
TaqMan probes were used. At the 5’ end of the Taqman probe is attached a reporter dye, 
a fluorophore (in our probes FAM or VIC), and at the 3’ end a quencher (in our probes 
TAMRA). As long as the quencher and fluorophore are close to each other, fluorescence 
signals by the fluorophore are quenched by the quencher. As the polymerisation proceeds, 
the probe attached to the template is cleaved and fluorophore is free to emit fluorescence. 
Thus, following up the accumulation of PCR products is possible in real time by continuous 
monitoring of the increase in fluorescence of the reporter dye (FAM). More PCR products 
mean more cDNA template. VIC-labelled ribosomal RNA 18S was used as an endogenous 
control for each sample to ensure that the samples were comparable with each other. The 
fluorescence signals were also standardized to the internal passive reference ROX to 
correct non-PCR-related fluorescence fluctuations. The comparative threshold cycle (Ct) 
method was used for relative quantification. The threshold was manually adjusted based 
on amplification curves. The difference between the threshold cycles of the target reporter 
dye and 18S for each sample was calculated (dCts). The threshold cycle is the number of 
the PCR cycle when the reporter dye fluorescence is greater than the adjusted threshold, i.e. 
the accumulation of PCR products is significant. The corresponding calibrator value (dCtc) 
was subtracted from dCts, resulting in ddCt, which was used in formula 2-ddCt. Results were 
represented either as these values (RU = relative expression unit) or as fold differences 
compared to controls.
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All the primers and probes were purchased from Applied Biosystems. Human predeveloped 
PCR primers and probes were obtained as separate assay reagents (eotaxin, RANTES, IL-
18, IL-13, IL-6, TNF beta, MIP 3 α, MDC, MIP 1 beta, IL 16, MIP 1alpha, TGF-β1 and 
18 S rRNA) or were preattached to the Cytokine Gene Expression Plate I (IL-1α, IL-1beta, 
IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p35, IL-12p40, IL-15, IFN-γ, and TNF-α). Murine 
PCR primers and probes for cytokines (TNF-α, IL-4 and IFN-γ) were also predeveloped. 
Laminin and tenascin-C primers and probes were generated with PrimerExpress version 1.5 
software and ordered from Applied Biosystems. The sequences for self-designed laminin 
and tenascin-C primers and probes are listed in Table 6.





Tenascin-C (Tnc) ACC ATG CTG AGA TAG ATG TTC CAA A
CTT GAC AGC AGA AAC ACC AAT CC
ACC ACA CTC ACA GGT CTA AGG CCC GG
Laminin α2 chain (Lama2) CTG CTG TCT TAT CTT GAT TTC CTA AGG
GAG GAC CAA CTC CAG AGC AGA AT
TAT GGC TTC AGC ATC CTG GAC AAG CC
Laminin β2 chain (Lamb2) CGT GAG GAC TGC ATT CAG AAC TC
GCG TGT CCG CCT TGA TCT A
CAC TGA CAT GGC AAG GCG CCA TT
3.5 Cells (III)
MRC-9 cells, purchased from ATCC (Manassas, VA, USA), were cultured in MEM 
supplemented with 10% FBS, 2 mM glutamine, 0.1 mM nonessential amino acids, 1.5 g/L of 
sodium pyruvate and antibiotics (Gibco, Invitrogen, Life Technologies, Carlsbad, CA, USA) 
at 37 °C in 5% CO2. Cells were stimulated with TNF-α (10 ng/ml) (Biosource International, 
Camarillo, CA, USA) at 37 °C for 3 and 9 hours.
Primary human dermal fibroblasts isolated from adult skin were purchased from Gibco and 
cultured in Medium 106 (Gibco) supplemented with LSGS (low serum growth supplement) 
and antibiotics (Gibco) at 37 °C in 5% CO2. Cells were stimulated with TNF-α (20 ng/ml), 
IFN-γ (500 IU/ml, Immuno Tools, Friesoythe, Germany) and with both for 2, 6 and 18 
hours.
3.6 Western blotting (III)
western blotting from whole cell extracts and concentrated cell supernatants was performed 
to show differences in tenascin-C expression in cell culture. Human primary fibroblasts 
stimulated with TNF-α and IFN-γ were lysed in protein lysis buffer containing 10 mM Tris 
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(pH 7.4), 150 mM NaCl and 25% ethylene glycol supplemented with complete mini protease 
inhibitor mixture (Roche Diagnostic, Indianapolis, IN). The cell extract was homogenized 
with ultrasound sonicator (Sanyo Electronics, San Diego, CA). Proteins in cell lysates and 
cell culture supernatants were separated with SDS-PAGE on 12% gels and transferred onto 
Immobilon-P Transfer Membranes (Millipore). Membranes were blocked with 5% non-
fat milk in PBS. Membranes were incubated with monoclonal mouse antihuman antibody 
against tenascin-C followed with HRP-conjugated polyclonal goat anti-mouse Igs (Dako). 
Proteins were visualized by a Luminescent Image Analyzer (Image Quant LAS4000mini, 
GE Healthcare, Sweden).
3.7 Statistics
The data were analysed with GraphPad Prism software (GraphPad Software, Inc., CA, 
USA) and/or SPSS 12.0 for windows (SPSS Inc., Chicago, IL, USA). Comparisons between 
groups were performed with the Kruskal-wallis test, the Mann-whitney U-test or the 
unpaired two-tailed Student’s t-test when appropriate. To assess the correlation between 
parameters, Spearman correlation coefficients were determined (I). The wilcoxon one-
sample signed rank test was used when comparing patients’ results between examinations 
(II). when several simultaneous comparisons were made, Bonferroni’s correction of the 
p-values was applied (II). The chi-squared test was applied to compare the expression of the 
Lm chains between the two patient groups (IV). Values for measurements are expressed as 
the mean ± the standard error of the mean (SEM) (III) or the standard deviation (SD) (I–II) 
and the median with the range (II). P values < 0.05 were considered significant. Bonferroni-
corrected levels of significance are reported when necessary. 
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4. results and discussion
4.1 Inflammation 
4.1.1 asymptomatic smokers (i)
The effect of chronic smoking on inflammation of the airways before the development of 
COPD has not been very extensively studied and the results have been contradictory. Thus, 
we compared the numbers of inflammatory cells and mRNA expression of inflammatory 
mediators in the BAL samples between non-smokers and asymptomatic smokers.
BAL cells – increased number of macrophages
The number of macrophages was significantly higher in the BAL samples of smokers 
compared to non-smokers, which is consistent with earlier studies (Barbers et al. 1987, 
Hagiwara et al. 2001, Kotani et al. 2000, Linden et al. 1993). In vitro, mouse alveolar 
macrophages and human peripheral blood monocytes were shown to be able to adhere to 
collagen IV, an essential component of the bronchial membrane, which had been altered by 
smoke extract compounds (Kirkham et al. 2003). This presents a subtle way for macrophages 
to gather in the airways of smokers. Macrophages are central to the development of COPD, 
as they participate in innate and adaptive immunity and secrete MMPs, directly destroying 
the tissue (Tetley 2002). we found no difference between the groups in the numbers of 
lymphocytes, neutrophils or eosinophils in the BAL. The CD4+/CD8+ ratio was also 
similar. In previous studies, the ratio of CD4+ to CD8+ cells has been shown to decrease 
in asymptomatic smokers (Ekberg-Jansson et al. 2000, wallace et al. 1994). An elevated 
number of CD8+ cells is a key feature of COPD (Cosio and Agusti 2010).
Attenuated expression of mRNA for inflammatory mediators
mRNA expression for 8 out of 23 studied inflammatory mediators in BAL cells was lower 
in asymptomatic smokers than in non-smokers (Table 7). Cytokines with very low mRNA 
expression near the detection limit were not included when interpreting the results. As the 
macrophages were the largest cell population and we evaluated the relative quantity of 
mRNA in BAL cells, not the protein in BALF, it can be assumed that most of the attenuated 
expression of inflammatory mediators was due to macrophages with impaired function. 
Protein might additionally be secreted to the airway lumen by stationary cells. we found also 
a negative correlation of cytokines and chemokines with decreased expression in smokers 
and the number of macrophages in BALF. A positive correlation was detected between FEV1 
as a percentage of the predicted value and the cytokines and chemokines. In the following, 
those cytokines and chemokines with a lower level of expression in smokers than in non-
smokers as well as those most relevant to the pathogenesis of COPD are discussed.
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Among the studied CC chemokines, mRNA expression of CCL3, CCL4, CCL5 and CCL20 
was suppressed in smokers compared to non-smokers. However, results from previous 
studies contradict our findings. The BALF CCL4 protein content has been shown to be 
similar in smokers and non-smokers, while CCL3 has been undetectable (Capelli et al. 
1999). we examined changes in mRNA expression in BAL cells, which might explain the 
differing results. In another study, mRNA expression of CCL3 was increased in the bronchial 
epithelium but not in macrophages in smokers with airflow limitation in comparison to those 
without airflow limitation and non-smokers (Fuke et al. 2004). In our study, the majority 
of the cells were macrophages. Furthermore, in the study of Fuke et al. (2004), many of 
the patients were ex-smokers and were operated because of other lung pathology. In our 
study, ex-smokers were excluded and none of the subjects had any pulmonary symptoms 
or disease. The expression of CCL5 mRNA and the number of eosinophils has been found 
to be strongly increased in chronic bronchitis during exacerbations and slightly increased 
in patients with stable chronic bronchitis in comparison with healthy non-smoking controls 
in bronchial biopsies (Zhu et al. 2001).  CCL4 and CCL5 are ligands for CCR5, and 
CCL20 binds to CCR6. CCR5- and CCR6-negative mice have an attenuated inflammatory 
response to cigarette smoke (Bracke et al. 2006, Bracke et al. 2007), emphasising the role of 
chemokines in cigarette smoke-induced lung injury.
IL-6 was the only proinflammatory cytokine with significantly lower mRNA expression in 
smokers than in non-smokers in our study. Supporting our results, the IL-6 protein content 
of the BALF has been shown to be lower in smokers than in non-smokers (McCrea et al. 
1994), although contradictory results have again been published (Kuschner et al. 1996). 
Kotani et al. (Kotani et al. 2000) found no difference in the IL-6 mRNA expression of 
alveolar macrophages under anaesthesia.
Our results demonstrated no difference in TNF-α mRNA expression in BAL cells between 
smokers and non-smokers. TNF-α has been extensively investigated in COPD. In earlier 
studies, TNF-α has been found to be increased in the sputum and plasma of COPD patients 
compared to healthy subjects (Keatings et al. 1��6, Takabatake et al. 2000). TNF-α levels 
have also been shown to be increased in the plasma of healthy smokers compared to non-
smokers (Petrescu et al. 2010). Furthermore, TNF-α receptor polymorphisms have been 
suggested in the pathogenesis of COPD (Molfino 2004). Cigarette smoke has been shown to 
elicit a greater response in TNF-α expression in the bronchial epithelial cells of COPD patients 
and non-smokers than in those of asymptomatic smokers (Mills et al. 1999). Conversely, in 
a study by Lim et al. (2000), alveolar macrophages of smokers released more TNF-α than 
those of non-smokers. Inflammation and tissue damage caused by CS is inhibited in TNF-α-
deficient mice (Churg et al. 2002). Interestingly, no studies showing elevated concentrations 
of TNF-α in the BALF of COPD patients or smokers could be found.
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Increased expression of CXCL8 in the airways is one of the most consistent findings in COPD 
(Chung 2001). In our study, CXC chemokine CXCL8 showed a tendency towards lowered 
expression in smokers compared to non-smokers, but the difference was not significant. 
This is consistent with previous results of BALF protein expression showing no change or 
decreased expression of CXCL8 in BALF in smokers compared to non-smokers (McCrea 
et al. 1994, Tanino et al. 2002) but contradictory results have also been published (Mio et 
al. 1997, Ohta et al. 1998). However, stimulated and unstimulated alveolar macrophages 
of smokers have been shown to secrete less CXCL8 than those of non-smokers or COPD 
patients (Culpitt et al. 2003, Ohta et al. 1998, Tanino et al. 2002). Most of our cells were 
macrophages and we examined mRNA in cells, not the protein content in BALF. Kotani 
et al. (2000) also found no difference in the mRNA expression of CXCL8 in BAL cells 
between smokers and non-smokers in patients under anaesthesia. CS stimulates CXCL8 
release from bronchial epithelial cells in vitro in non-smokers and in COPD patients, but not 
in asymptomatic smokers (Mills et al. 1999, Mio et al. 1997). Thus, it seems that elevated 
expression of CXCL8 in the alveolar space and cells is related more to clinical disease 
progression than to the effects of long-term cigarette smoke exposure in vivo.
In our study, healthy smokers showed a significant decrease in the expression of Th1 cytokine 
IFN-γ and Th2 cytokine IL-13 mRNA compared to healthy non-smokers. However, the 
difference in the expression of mRNA for IFN-γ was probably not biologically relevant 
(Table 7). Moreover, mRNA expression of IL-13 was quite low. In a mouse model, IL-
13 and IFN-γ have been observed to cause emphysema to some extent through matrix 
metalloproteinase and cathepsin-mediated mechanisms, also making them candidate 
mediators in COPD (wang et al. 2000, Zheng et al. 2000). 
Expression of TNF-β was also lower in smokers than in non-smokers. TNF-β/lymphotoxin 
α is a member of the TNF superfamily and a Th1-type cytokine secreted by lymphocytes 
(Aggarwal 2003). It is structurally very similar to TNF-α but has functionally different 
properties, although both act via the same receptors TNFR1 and TNFR2. TNF-β has been 
much less studied than TNF-α. Polymorphisms of the TNF-β gene have been linked to 
various inflammatory diseases, but not to asthma or COPD. 
46





















































































































































0.2      bd    
0.4      bd    






0.2      bd

































bd = Borderline of detection. Expression is reported as relative expression units. 
No influence on inflammatory cells in biopsies
In the bronchial biopsy specimens, no significant differences were observed between the 
smokers and the non-smokers in the differential cell counts in the lamina propria, as in the 
study by Lams et al. (2000). A similar bronchoscopy study but with a higher number of patients 
by Amin et al. (2003) revealed elevated numbers of macrophages, neutrophils, eosinophils 
and mast cells in biopsies in asymptomatic smokers in comparison with never smokers. 
Subjects in the study by Lams et al. had better lung function than in our study or in that of 
Amin et al. Additionally, the small number and younger age of subjects in our study, and 
the section area used in cell calculations may explain the differences. Elevated inflammatory 
cell counts in bronchial biopsies or lung resections are a consistent finding from patients 
with COPD or chronic bronchitis (Di Stefano et al. 1998, Lams et al. 2000, O’Shaughnessy 
et al. 1997, Saetta et al. 1993). Inflammatory cells, especially CD8+ cells, are often inversely 
correlated with the FEV1 as a percentage of the predicted in all smokers (Di Stefano et al. 
1998, Ekberg-Jansson et al. 2000, Isajevs et al. 2011, Lams et al. 2000, O’Shaughnessy et al. 
1997). Larger and smaller airways react differently to smoking (Battaglia et al. 2007, Isajevs 
et al. 2011). Unfortunately, the lung resection samples used to examine changes in the small 
airways were from patients operated to remove various lung tumours, which are sometimes 
not defined more precisely. There is evidence that lung cancer modifies the inflammation 
in the airways (Hoser et al. 2003, Matanic et al. 2003). Furthermore, if a tumour is present 
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in one lung, the other is also affected. Isajevs et al (2011) also recently detected increased 
numbers of inflammatory cells in larger airways from smokers in comparison to non-smokers, 
but the patients were operated for lung pathology. Studies on lung resection samples have 
additionally shown inflammation in the small airways in smokers without COPD. It has 
been reported that there are elevated numbers of macrophages, neutrophils, activated and 
total eosinophils as well as a decreased CD4+/CD8+ T-cell ratio in the submucosa of the 
smaller airways in smokers compared to non-smokers (Isajevs et al. 2011, Lams et al. 1998). 
As COPD is a disease of the smaller airways, the changes in the periphery of the lungs may 
be more important, but also more difficult to determine.
4.1.2 diisocyanate-induced asthma (ii)
The long-term prognosis of occupational DIA is not very good. Studies on inflammation in 
the airway are sparse. Thus, we examined biopsies and BAL in relation to clinical parameters 
in a 2- to 3-year follow-up. In addition to the cessation of exposure to DIs, patients used ICS 
treatment throughout the follow-up. The second and third study visits were a mean of 7.9 
and 33.5 months after the first study visit, respectively. we lost 5 of 17 patients during the 
follow-up. The histamine challenge test was lacking from two patients at the second visit 
and from one patient at the third visit.  In addition, a couple of mRNA samples and biopsies 
were discarded because of poor quality. There was a significant decline in the absolute 
forced vital capacity (FVC) of 300 ml (p = 0.015), but not in FVC as a percentage of the 
predicted value during the follow up. There was also an almost significant decline in FEV1 
of 290 ml (p = 0.023, Bonferroni-corrected level of significance p < 0.02), but not in FEV1 
as a percentage of the predicted value. Declining lung function, despite treatment and the 
cessation of exposure, has also been reported in previous studies (Padoan et al. 2003, Piirila 
et al. 2000, Pisati et al. 2007). The annual decrease in lung function of DIA patients in our 
study was greater than that reported for smokers (Fletcher and Peto 1977, Lee and Fry 2010). 
The decrease was even less in smokers than non-smokers. whether this was a coincidence 
or actually related to biology remains undetermined in this study. One explanation might be 
that smokers gained additional benefit from ICS (Pauwels et al. 1999). DIs are irritative, and 
even short exposure to low concentrations can cause measurable changes in airway function 
(Vandenplas et al. 1999). Thus, the long-term follow-up results are not very surprising, even 
though all the patients were receiving treatment. 
Elevated number of IL-4-positive cells and increasing numbers of macrophages 
in the lamina propria
Eosinophils were slightly elevated from 0.5% to 1% in patients with DIA in the BALF 
compared to controls at the first visit (p = 0.012, Bonferroni corrected level of significance 
p < 0.01), with no difference in other cell lines or total cells. Previous research has also 
shown a slight increase in BAL eosinophils in DIA (Fabbri et al. 1987, Paggiaro et al. 1990). 
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The total number of cells and percentage of lymphocytes decreased by a half between the 
first and the second examinations during the ICS treatment. 
The number of macrophages in the biopsies was significantly higher in DIA patients in the 
second (n = 9) and third (n = 7) examinations than in controls (n = 14). Elevated numbers 
of mononuclear cells have been found in a previous study under the epithelium, despite 
the cessation of exposure (Saetta et al. 1992). At least HDI modifies the morphology and 
gene expression of peripheral blood mononuclear cells (PBMC), which implies a role for 
mononuclear cells in the pathogenesis of DIA even without adaptive immunity (wisnewski 
et al. 2008). Patients with DIA (n = 12) had more IL-4-secreting cells in the lamina propria 
than controls (n = 13) at the first and second study visits. This is consistent with previous 
results (Maestrelli et al. 1997). The number of IL-4-positive cells decreased nonsignificantly 
on follow-up while patients were on ICS, and we found no difference in IL-4-positive cells 
between controls and patients (n = 9) in the third examination. IL-4-positive cells correlated 
with NSBHR almost significantly in the second examination (ρ = -0.56, p = 0.058), but in the 
third examination (n = 6) NSBHR was strongly correlated with CD3+ (ρ = -0.88, p = 0.021) 
and CD4+ (ρ = -0.�4, p = 0.005) cells. In a study by Jones et al. (2006), no increase in IL-4 
mRNA was observed after acute active challenge with DIA in situ in bronchial biopsies from 
patients exposed predominantly to HDI. However, IL-5 mRNA was increased in comparison 
to control challenge accompanied by a nonsignificant increase in CD4+ cells, eosinophils and 
neutrophil elastase staining in their study. CD4+ cells were also increased in comparison to 
controls. As in our study, the numbers of DI-specific IgE-positive patients were quite low. In 
our study, bronchoscopy was performed at the first visit 48 h after the challenge, as opposed to 
24 h in the study by Jones et al. (2006). Although the timing of the bronchoscopy was different 
in our study, the possible effect of specific challenge testing on the inflammatory cell numbers 
in the first examination cannot be excluded. Interestingly, in the study by Jones et al. (2006), 
patients with both negative and positive specific inhalation challenge test results mounted 
similar inflammation in response to active challenge. In the same study, an increase in cells 
positive for IL-4 mRNA was seen in other atopic asthmatics after specific challenge for their 
allergens, in contrast to DIA patients. Protein expression was not studied, which might explain 
the differing results. No data on ICS use was provided, either.
Persistent NSBHR is associated with elevated expression of mRNA for TNF-α, 
IL-6 and IL-15 in BAL cells
In DIA patients, NSBHR decreased during the follow-up in accordance with previous results 
(Padoan et al. 2003, Piirila et al. 2000, Pisati et al. 2007). However, consistently with previous 
studies, 5 out of 11 patients still had NSBHR at the third examination. Hyperreactive patients 
displayed a higher expression of TNF-α (p = 0.017), IL-6 (p = 0.014) and IL-15 (p = 0.012) 
mRNA in BAL cells than non-hyperreactive ones. These patients were on ICS using budesonide 
800-1600 μg/d or fluticasone 1000 μg/d. None of the hyperreactive patients were smokers. 
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TNF-α, IL-6 and IL-15 have been implicated in the pathogenesis of allergic asthma, and 
TNF-α and IL-6 additionally in DIA. TDI has been shown to induce IL-6 expression in 
human bronchial epithelial cells (Mattoli et al. 1��0), although TNF-α was not examined 
in that study. The lack of TNF-α attenuated Th2 inflammation and airway hyperreactivity 
in a mouse model of TDI-induced DIA (Matheson et al. 2002). TNF-α also has an impact 
on glucocorticoid responsiveness, which is interesting, since all our patients with DIA 
were using ICS. In the study of Franchimont et al. (1999), pretreatment of human whole-
blood cell cultures with TNF-α inhibited the suppression of LPS-induced IL-6 secretion by 
dexamethasone. This was mediated through down-regulation of glucocorticoid receptors 
(GR) on monocytes. Subsequently, the pathways and interactions of TNF-α and GRs leading 
to resistance to glucocorticoids have been revealed in great detail (Van Bogaert et al. 2010). 
Patients still hyperreactive at the end of the follow-up in this study may be classified as at 
least having slightly glucocorticoid-resistant asthma. At least five out of seventeen enrolled 
patients with DIA fitted this category, further emphasising the poor prognosis. In our study, 
cytokines were quantified in BAL cells, which were mainly macrophages. PBMCs from DIA 
patients have been shown to secrete more TNF-α in vitro under antigen challenge (Lummus 
et al. 1998). Most of those patients were exposed to HDI. In human patients with mild 
asthma, TNF-α inhalation elicits increased NSBHR to metacholine along with increased 
expression of cytokines, including IL-15 (Thomas and Heywood 2002). IL-15 inhibits 
apoptosis of eosinophils by stimulating the expression of the powerful eosinophil survival 
factor granulocyte-macrophage colony stimulating factor (GM-SCF) (Hoontrakoon et al. 
2002). The exact role of eosinophils, even in human atopic asthma, is still open after decades 
of research, but they appear to have a role in the pathogenesis of airway hyperreactivity, 
among other effects, at least in severe eosinophilic asthma (Rothenberg and Hogan 2006). 
In accordance with this, IL-15 antibodies were shown to abrogate OVA-induced airway 
hyperreactivity and allergic inflammation in Balb/c mice (Ruckert et al. 2005). TNF-α might 
be the key to hyperreactivity in our DIA patients, although this needs to be confirmed. TNF-
α inhibitors might provide help for these patients. 
we found no difference in the expression of the studied cytokines and chemokines 
between DIA patients and controls in any examination. Neither was there any change in 
inflammatory mediators between visits. when all patients were analysed together, cytokines 
and chemokines did not correlate with NSBHR or the results of other pulmonary function 
tests. The specific challenge testing might have influenced the mRNA expression in the 
first examination, as shown by Jones et al. (2006). However, as the results for patients were 
similar to those for controls, this seems unlikely. 
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4.1.3 mouse model of allergic asthma (iii)
WT mice
First, we aimed to demonstrate that, as expected, OVA induces allergic inflammation in the 
airways in wT Balb/c mice. OVA-sensitized mice exhibited vigorous lung eosinophilia, 
a strong Th2-type cytokine response, and increased airway reactivity to inhaled Mch. A 
significant and prominent influx of eosinophils and lymphocytes in the BAL was observed 
in OVA-challenged mice. The mRNA levels of proinflammatory cytokines (TNF-α, IL-
6, IL-1β), Th2 cytokines (IL4, IL5, IL13) and CCL11 were significantly increased in the 
lung OVA-challenged mice compared to PBS-challenged mice with modestly increased 
expression of IFN-γ. Haematoxylin-eosin stained lung samples exhibited collections 
of inflammatory cells. NSBHR to inhaled Mch was significantly increased in the OVA-
challenged mice group compared to PBS-challenged controls measured as Penh. The main 
results are summarised in Table 7 and Figure 1. 
KO mice
STAT4-/- and STAT6 -/- mice had attenuated inflammation in response to OVA, with 
similarities and differences. Cell calculations in biopsies were not carried out, but the 
influx of eosinophils and lymphocytes in BAL was suppressed in KO mice. The number of 
eosinophils was especially low in STAT6-/- mice and that of lymphocytes in STAT4-/- mice. 
In STAT6-/- mice, more neutrophils were instead seen. STAT4-/- animals were similarly 
or more hyperreactive compared to wT mice, while STAT6-/- mice showed attenuated 
hyperreactivity. The main results are summarised in Table 8 and Figure 1. 
Table 8. BALF cell numbers of PBS- and OVA-challenged mice. 
WT STAT4-/- STAT6-/-
PBS (n=8) OVA (n=8) PBS (n=8) OVA (n=9) PBS (n=8) OVA (n=8)
eosinophils
(million/l)
0.2 ± 0.36 105.35 ± 27.43 *** 0.28 ± 0.33 80.97 ± 32.79 *** 0.03 ± 0.09 1.45 ± 1.31 **
lymphocytes
(million/l)
0.09 ± 0.16 18.14 ± 5.75 ** 0.2 ± 0.35 1.59 ± 1.07 ** 0.02 ± 0.04 3.37 ± 1.64 ***
macrophages
(million/l)
20.02 ± 0.57 22.5 ± 9.8 60.34 ± 21.32 25.89 ± 15.42 * 22.05 ± 6.83 24.46 ± 11.59
neutrophils
(million/l)
0.2 ± 0.35 2.79 ± 2.11 ** 2.14 ± 0.71 6.09 ± 3.14 ** 0.47 ± 0.44 38.29 ± 14.61 ***
Comparisons were made between PBS- and OVA-challenged mice within the WT, STAT4-/- and STAT6-/- 
groups. *p < 0.05, **p < 0.01, ***p < 0.001. 
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figure 1. Expression of mRNA for cytokines in PBS- and OVA-challenged WT, STAT4-/- and STAT6-/- mice.
RU = relative expression unit. *p < 0.05, **p < 0.01, ***p < 0.001
In a recent study by Chapoval et al. (2011), some interesting remarks were made on 
inflammation and NSBHR in STAT6-/- mice. Their Penh results showed higher NSBHR to 
Mch in PBS-challenged control STAT6-/- mice than in OVA-challenged wT mice, suggesting 
naïve hyperreactivity in STAT6-/- mice. The difference was quite clear. Their experimental 
protocol was similar enough to ours, although the number of mice was almost one-half lower. 
we performed the same analysis. we found a difference at one concentration point of Mch, but 
the groups were otherwise similar (data not shown). It is a general view that when conclusions 
are drawn on changes in NSBHR, they should be confirmed with another method than wBP. 
Changes in wBP might simply reflect variation in the respiratory pattern caused by metacholine 
(see Shortcomings of the substudies section). Chapoval et al. (2011) found no difference in 
NSBHR between OVA- and PBS-challenged STAT6-/- mice, similarly to our results. 
Interestingly, both STAT4-/- and STAT6-/- mice exhibited an attenuated response to OVA 
as measured in mRNA expression of Th2 cytokines and CCL11 in lung tissue. For STAT6-
/- this is not surprising. However, allergen-challenged STAT4-/- mice have shown decreased 
expression of chemokines, not Th2 cytokines, in BALF (Kim et al. 2010b, Raman et al. 2003). 
we studied mRNA expression in lung tissue, which might explain the difference. The most 
striking difference between STAT4-/- and STAT6 -/- mice was the absence of OVA-stimulated 
TNF-α and IFN-γ expression in STAT4-/- mice. As STAT4 induces the expression of IFN-γ and 
the Th1 phenotype of CD4+ cells (Pfitzner et al. 2004), was this an expected result. Th1 cells are 
able to induce allergic airway inflammation and NSBHR in mice under suitable conditions after 
OVA challenge (Hayashi et al. 2007). These wide disturbances in the allergic inflammation of 
STAT4-/- mice raise interest in the role of STAT4 in allergic airway inflammation. 
52
4.2 Expression of tenascin-C 
4.2.1 wT mice (iii)
First, we examined whether the expression of tenascin-C changed after OVA challenge. 
Tenascin-C mRNA levels were significantly increased in the lung tissue of OVA-sensitized 
wT mice compared to controls. In the immunohistological analysis, tenascin-C was strongly 
up-regulated in the alveolar BM as small spots throughout the parenchyma of OVA-challenged 
mice. Staining of the bronchial basement membrane with tenascin-C was negative in both 
groups. In patients with asthma the expression of tenascin-C is increased in the bronchial BM, 
which was not seen in this OVA-induced model of allergic airway inflammation (Laitinen et 
al. 1��7, Nakahara et al. 2006). In our study, TGF-β1 mRNA levels were similar in OVA- 
and PBS-challenged mice (unpublished). Although the importance and over-expression of 
TGF-β1 is well established in asthma under provocation, and it is known to stimulate the 
expression of tenascin-C in the airways (Bosse and Rola-Pleszczynski 2007, Doerner and 
Zuraw 200�), an increase in tenascin-C and TGF-β2, but not TGF-β1, has also been seen 
under the epithelium in atopic human beings after allergen challenge (Torrego et al. 2007). 
Furthermore, numerous other mediators for increased expression of tenascin-C are readily 
available in the airways of OVA-challenged mice such as IL-4, IL-13, TNF-α and IFN-γ 
(Flood-Page et al. 2003a, Harkonen et al. 1995, Makhluf et al. 1996, Nakahara et al. 2006, 
Rettig et al. 1994, Syed et al. 2005).
4.2.2 sTaT4-/- and sTaT6-/- mice (iii)
we next aimed to examine whether tenascin-C expression changed in KO mice with defects 
in Th1 (STAT4-/-) and Th2-type responses (STAT6-/-) to find in vivo regulators of tenascin-
C expression. This was the first time that the regulation of tenascin-C expression has been 
studied using STAT4 and STAT6 KO animals. Most mediators of tenascin-C expression 
have been found in vitro. To our surprise, the expression of tenascin-C in STAT6-/- mice was 
quite similar to that of wT mice, although nonsignificant suppression of immunoreactivity 
was seen in semiquantitative analysis. In contrast, the attenuated mRNA expression and 
immunoreactivity of tenascin-C in STAT4-/- mice was clear. As the most important factor 
separating OVA-challenged STAT4-/- and STAT6-/- mice was the low expression of TNF-α 
and IFN-γ in STAT4-/- animals, we examined whether these cytokines stimulated tenascin-
C expression from human dermal fibroblasts and foetal lung fibroblasts. TNF-α is known to 
induce tenascin-C production in both lung fibroblasts and bronchial epithelial cells (Harkonen 
et al. 1��5, Nakamura et al. 2004). Furthermore, TNF-α and IFN-γ have been shown to 
induce tenascin-C expression synergistically with cyclic strain in interstitial cells from aortic 
valves spoiled by rheumatic fever (Jiang et al. 2009). Foetal MRC-9 showed a nearly 3-fold 
increase in the expression of tenascin-C mRNA in response to TNF-α. Because these were 
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foetal cells and tenascin-C is mostly a foetal protein, we also wanted to demonstrate the 
same results with cells from adult tissues and with IFN-γ from human dermal fibroblasts. As 
suspected, the increase in expression was not as clear as with foetal cells, but significantly 
increased expression (determined as at least a 2-fold increase) was seen with TNF-α and 
TNF-α + IFN-γ after 6 h. Some synergism was seen. Protein expression was determined 
after 18 hours of incubation with the combination and showed an increase. Incubation with 
IFN-γ alone elicited much weaker mRNA expression of tenascin-C than the combination of 
TNF-α and IFN-γ. 
4.2.3 dia (unpublished data)
To examine whether tenascin-C overexpression in BM is also a feature in DIA in comparison 
to controls, we measured the thickness of the tenascin-C layer in the bronchial BM. The 
tenascin-C layer of the bronchial membrane was measured from paraffin embedded biopsies 
as a small preliminary study to determine whether DIA patients have similar tenascin-C 
expression to atopic or other non-atopic patients (Karjalainen et al. 2003, Laitinen et al. 1997). 
The study began in the 1990s, and some of the frozen samples were too old to be analysed, as 
measurement of tenascin-C was not included in the original study design. Furthermore, the 
paraffin-embedded samples were often of better quality and the morphology was also better. 
Unfortunately, paraffin sections were available for only 13 patients and mostly from one 
examination, which varied. Thus, all the 19 samples from 13 patients were compared with 
the controls. Including only a particular visit would have considerably reduced the number 
of available samples for analysis.  
Most of the controls were only faintly reactive. All the strong reactivity was found among 
DIA patients. we found a slight difference between DIA patients and controls in the 
thickness of tenascin-C layer (Figure 2). However, the mean thickness in DIA patients was 
2.8 μm when in chronic asthma and newly diagnosed non-atopic asthma it has been shown 
to be 8 μm and 6.3 μm, respectively (Karjalainen et al. 2003, Laitinen et al. 1��7). None 
of the DIA patients had a tenascin-C layer more than 6 μm in thickness. Although different 
antibodies were used, the mean thickness of the tenascin-C layer in the BM of controls was 
at a similar level as detected in a previous study (Laitinen et al. 1997). when the intensity of 
the immunoreactivity was semiquantitatively assessed, no difference was detected between 
the patients and the controls. Furthermore, there was no difference between the visits or 
hyperreactive and non-hyperreactive patients. Thus, according to our results, tenascin-C is 
not a very good marker in DIA.  
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figure 2. Immunoreactivity of tenascin-C in DIA patients. A. The thickness of tenascin-C immunoreactivity in 
the bronchial basement membrane. Results are expressed as mean ± SEM. μm = micrometre. B–E. Tenascin-C 
visualised with APAAP in paraffin-embedded sections. Non-smoking (B) and smoking (C) control subjects had 
a thin bronchial basement membrane (arrow) with varying tenascin-C reactivity. In contrast, DIA patients had 
a thick basement membrane at the beginning of the follow-up (D), also with varying tenascin-C reactivity. The 
thickness of the bronchial basement membrane decreased during the follow-up and treatment with ICS in some 








n=8 n = 19
µ
m
4.3 Expression of laminin α2 and β2 chains 
4.3.1 mice (unpublished data)
In addition to tenascin-C, we examined the expression of laminin α2 and β2 chains in acute 
allergic airway inflammation in mice. we aimed to relate the changes to human asthma 
and possibly find regulators of laminin expression. Laminin α2 and β2 were selected 
because of our previous results in human asthma patients (Altraja et al. 1996). Expression 
of laminin α2 and β2 mRNA was significantly decreased in OVA-sensitized wT mice 
(Figure 3A). However, no difference was found in immunoreactivity between the OVA- and 
PBS-challenged mice. Moreover, no change was seen in laminin expression between the 
OVA- and PBS-challenged STAT4-/- and STAT6-/- mice (data not shown) in mRNA or 
immunoreactivity. The staining pattern was similar to wT mice.
Immunoreactivity of laminin α2 and β2 chains in the lung was similar to that reported in 
earlier studies (Sasaki et al. 2002, Sorokin et al. 1997). Laminin β2 was detected in various 
BMs, including alveolar structures (Figure 3B and C). It was expressed in the BM under 
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the epithelium, and in the BM surrounding the bronchial smooth muscle in the bronchi 
as well as in the bronchioles. In the large arterioles and veins it was evident in several 
layers. Mesenchymes were seen as completely unreactive areas around the blood vessels 
and the bronchi. Laminin α2 (Figure 3C and D) was only found in some alveolar structures 
and bronchial BM. Some immunoreactivity for the laminin α2 chain was detected in the 
bronchial smooth muscle. It was not expressed in the innermost layer of the arterioles, but 
stained the arterial smooth muscle similarly to the staining pattern of the laminin β2 chain. 
we studied quite acute allergic airway inflammation, and remodelling is more related to 
chronic models, which might explain why no changes were seen in laminin expression in 
immunohistochemistry, while mRNA expression was decreased. Furthermore, the laminin 
expression pattern in mice markedly differs from that in humans, which makes it impossible 
to study the appearance of the laminin α2 chain in asthma, because it already is expressed 
in the bronchial BM. In asthma patients, laminin α2 is expressed in the bronchial BM, 
while controls are negative (Altraja et al. 1996). The amount of laminin protein expression 
might be worth examining in the mouse models of asthma, but based on our preliminary 
results in RT-PCR and immunohistochemistry we assumed that it would not give any new 
information, at least in this mouse model. In healthy humans, laminin β2 expression in the 
lung and especially in the bronchial BM is also minor compared to that in mice (Altraja et 
al. 1996). Increased expression of laminin 111 in the mouse lung after OVA challenge has 

































































figure 3. Laminin α2 chain and laminin β2 chain expression in wildtype mice. The relative mRNA expression 
of laminin α2 (D) and β2 (A) chains was lower in the lung of ovalbumin-challenged than control mice. Mouse 
lung immunoreactivity to laminin β2 in the controls (B) and in the OVA-challenged mice (C), as well as to laminin 
α2 (E and F respectively), was similar. * p < 0.05, **p < 0.01, ***p < 0.001. n = 8 mice/group RU = relative 
expression unit. Results are expressed as mean ± SEM.
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4.3.2 Patients (IV)
we hypothesised that patients with diagnosed asthma might have increased co-expression of 
laminin α2 and β2 chains in comparison to patients with asthma-like symptoms and controls, 
and that the laminin α2 chain would mostly be seen in patients with asthma. Biopsies of 
sufficient quality were available for all 8 controls, 26/35 patients with asthma for less than 
2 years, and 12/15 patients with asthma symptoms. The bronchial BM of all patients with 
asthma and asthma symptoms was positive for the laminin β2 chain. In contrast, 6 out of 8 
controls were negative. Immunoreactivity was seen as a more or less continuous line under 
the epithelium. Laminin α2 chain was expressed in the bronchial BM in only one patient 
with asthma symptoms, 14 out of 26 patients with asthma and none of the controls. The 
immunoreactivity for laminin α2 was present as a fragmented line under the epithelium. 
Electron microscopy and double stainings were not performed, but the expression was at 
the upper margin of the BM, which corresponds to the lamina densa. The laminin α2 and β2 
chains were co-expressed in the same patients who had immunoreactivity for the α2 chain. 
We found no difference in the expression patterns of α3, α5, β1, β3, γ1 or γ2. The thickness 
of the laminin-positive layer for these normally expressed chains was not defined, because 
we were looking for differences in spatial chain expression. These results confirmed our 
hypothesis that the laminin expression pattern differentiated patients with diagnosed asthma 
from those with asthma-like symptoms and from controls. 
The results strengthened our previous view that the expression of the laminin β2 chain is 
followed by laminin α2 chain expression in asthma. This sequence is the reverse of that 
seen during development (Altraja et al. 1996, Virtanen et al. 1996). Longitudinal studies are 
needed to clarify the role of laminin α2 and β2 in the development of asthma. As laminins 
are most probably secreted as heterotrimers, laminin121 is replaced by laminin 221. As the 
change occurs in the BM and not in ASM, this probably does not affect the submucosa. 
However, laminin α2 in the BM might be a good substrate for adhesion of actively secreting 
myofibroblasts (Tran et al. 2006), thus directly influencing inflammation and further 
remodelling. Moreover, LTD4 has been shown to increase laminin β2 expression in bronchial 
epithelial cells, connecting the increased expression directly to airway inflammation in 
asthma (Altraja et al. 2008).
In contrast to our results, Amin et al. (Amin et al. 2005) showed immunoreactivity for the 
laminin α2 chain in and stronger reactivity for the β2 chain the bronchial BM in healthy               
controls than in the present study. All their articles on the thickness of the laminin and 
tenascin-C layers have shown at least two times thicker immunoreactivities than our studies 
(Amin et al. 2000, Amin et al. 2005). In our studies we have tested different planimetric 
methods and obtained comparable results not depending on the method (Autocad/planimetric 
table and ImageJ/computer screen planimetria). At least 4–5 researchers in our group have 
gained similar results on the thickness of tenascin-C layer in the bronchial BM of controls 
57
in different studies. Furthermore, considering the scales, it is very difficult to believe that 
the mean thickness of the tenascin-C layer would be over 15 μm in asthmatics and over 10      
μm in controls (Amin et al. 2000). Moreover, in their laminin publication, the photograph              
of laminin γ2 showed almost a fragmented line and somehow the mean thickness was still 2              
μm in controls (Amin et al. 2005). This may naturally be due to selection of certain areas in                  
the picture to highlight the result. 
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5. general discussion
5.1 Why are macrophages inactive in smokers? 
Macrophages appeared very quiescent in the airway lumen in our study, despite the vast 
numbers of them gathering in the airways of smokers. without a specialised immune 
response, the development of adaptive immunity would be impaired. This may explain the 
recurring respiratory infections of smokers. As macrophages are the key link between innate 
and adaptive immunity as well as being able to sequester MMPs directly, causing tissue 
damage, this might be one mechanism to control the inflammation and protect the tissue from 
the destruction seen in COPD (Tetley 2002). Mills et al.(1999) hypothesized that the lowered 
cytokine release of cells from smokers compared to non-smokers and COPD patients could 
be a defence mechanism against the ongoing inflammation and development of COPD. It 
has been proposed during the past few years that COPD could be an autoimmune disease 
(Cosio and Agusti 2010). Smoking might be just one of the triggers or predisposing factors. 
These hypotheses need to be tested with further studies, but might explain why the reactions 
of the cells differ between subjects and cell lines (Smith et al. 2010). Rather than comparing 
smokers with and without COPD at one time point, there is a need for longitudinal studies 
where individuals are studied at multiple time points during the course of the disease. 
5.2 Mice models: do we need them?
we used a mouse model and knockouts to study the expression of tenascin-C in allergic 
airway inflammation. Animal models have been a hot topic in meetings on respiratory 
medicine during recent years. They are used in studying the underlying mechanisms of 
diseases. Most of the pathogenetic mechanisms of asthma have been revealed using animal 
models (Kips and Pauwels 1999, Takeda and Gelfand 2009). Cell cultures are much too 
simplified to be used alone. However, animal models are not without problems. First, the 
best model for a given question should be found to mimic the responses in human. No 
animal model so far has precisely replicated the features of human asthma and probably 
never will. For example, chronic exposure models with OVA would be better for studying 
remodelling (Kumar et al. 2008), but what phase of human asthma does, for instance, 8 
weeks of sensitisation represent? Mice do not have spontaneous asthma. Still, much valuable 
information can be obtained from animal models if the results are interpreted correctly, as 
reviewed in an article by Finkelman et al.(Finkelman and wills-Karp 2008). Obtaining the 
same information on the regulation of tenascin-C expression in vivo as in this study would 
have been very difficult without a mouse model. KO animals are not without problems, 
either. when one gene is suppressed, others might take over its actions. Furthermore, the 
time frame when a certain factor is turned on and off might be crucial in the development 
of an allergic response, and the opposite action might occur at another time point, as shown 
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with the IL-12-STAT4-IFN-γ pathway (Meyts et al. 2006). As human asthma takes time to 
develop, the disease is likely to result from very complex networks functioning together. 
It is not enough to attenuate eosinophilic inflammation or block one cytokine. This is also 
becoming evident in mouse models of allergic airway inflammation: blocking the action of 
STAT6 (Foster et al. 2003) might not be enough, and other independent pathways exists 
(wills-Karp and Finkelman 2008) that affect the asthma phenotype, such as those involving 
STAT4 in this study (Kim et al. 2010b). 
5.3 Diversity of asthma: DIA
During the years I have studied airway pathology, the diversity of asthma has become very 
evident (Hargreave and Nair 2009). There is an increasing need for individualised treatment, 
especially if ICS are not sufficient to control the disease. Asthma is a very common disease. 
Individualised treatment calls for cheap and non-invasive determination of the problem to 
target, i.e. phenotyping. Enormous non-targeted trials for new drugs might not be the right 
way to gain the most benefit from new drugs. we need further studies on the markers related 
to different forms of asthma. In fact, phenotyping projects are ongoing and already providing 
new methods to differentiate specific features of different asthma types (Brasier et al. 2010). 
DIA is a very good example of a diverse form of asthma, as it has common features with 
allergic and non-allergic asthma, and because of the declining lung function despite ICS, 
new drugs would be welcome. The sensitizing agent is not a protein, as in classic allergic 
asthma. One might also expect the pathogenesis to be different. Some have DI-specific IgE 
while others do not, and as in the case of allergic asthma, not all patients with elevated 
levels of DI-specific IgE develop reversible airway obstruction (Liu and wisnewski 2003, 
Pronk et al. 2007). Those DIA patients still hyperreactive at the end of the follow-up in our 
study during ICS had very different findings in comparison to those without hyperreactivity, 
which is very important for further treatment. As DIA is relatively uncommon, co-operation 
between centres is needed to perform larger studies. Thus the results would be more generally 
applicable. 
5.4 Activation of the developmental mechanisms in 
asthma
It is not known what induces expression of laminin α2 and β2 chains in asthma. The 
laminin α2 chain was not present in the BM of healthy mature airways at all in this study. 
Increased expression of the laminin β2 chain was already recorded in patients with asthma-
like symptoms, and the laminin α2 chain differentiated asthma patients from patients with 
symptoms but no asthma diagnosis. The expression pattern of laminin α2 and β2 chains 
in the bronchial BM appeared to be reversed in comparison to that occurring during lung 
development. Our study was cross-sectional. Thus, it was not possible to draw definitive 
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conclusions on the role of the laminin α2 and β2 chains in the development of asthma. 
Compared to collagen, tenascin-C and fibronectin situated in the lamina reticularis of the 
bronchial BM, the importance of the laminin α2 and β2 chains in the thickening of the 
airway wall is minor. However, they are an essential part of the EMTU as they are situated 
in the BM and convey information from the epithelium to the mesenchyma, and vice versa. 
It might be assumed that the re-expression of these laminin chains is one marker of the 
reactivated (or unsilenced) developmental genes, which cannot be without consequences 
(Bousquet et al. 2004), but no functional evidence exists. Considering that the expression of          
laminins is quite different in mice, as shown in this study and previously, we have one easy 
and economical method less to study the expression of laminins. Once laminins emerge, 
it takes time until they disappear, even without any existing external stimuli. Thus, they 
could be mediators for chronic inflammation and further fibrosis during the “silent phase” of 
asthma. Tenascin-C is a protein with similar and different properties compared to laminins. 
It is also important in development, but its expression is much more transient, including 
in asthma (Kariyawasam et al. 2007). Tenascin-C emerges after allergen challenge and is           
down-regulated with inflammation, while other remodelling changes remain (Kariyawasam 
et al. 2007). Thus, tenascin-C behaves more as an inflammatory mediator than a structural 
protein. As mice have a similar pattern of tenascin-C expression to humans, they are a good               
species to study the regulation of tenascin-C in vivo. The expression of tenascin-C is also 
strongly regulated by inflammatory mediators, as additionally demonstrated here, and it has 
been shown to possess many immunomodulatory activities (Jiang et al. 2009, Nakahara et      
al. 2006, Ruegg et al. 1989, Tucker and Chiquet-Ehrismann 2009). As tenascin-C is already    
faintly expressed in most controls, an increase in the thickness of the tenascin-C layer in 
atopic asthma may only reflect the changes in the thickness of the lamina reticularis. 
5.5 Shortcomings of the substudies
The major limitation of the first study was the small number of subjects. Performing invasive 
procedures such as a bronchoscopy with biopsies on healthy subjects must be well reasoned. 
The number of patients in the subanalysis of the DIA patients was also quite small, mostly 
attributed to the rarity of the disease. However, biopsy studies on DIA patients have also 
previously been very restricted in size, and this was among the biggest biopsy studies solely 
on DIA patients. At least the negative results with such a small number of subjects as we had 
should be interpreted with caution. 
we examined mRNA expression for cytokines and chemokines in the BAL cells or lung 
tissue in studies I–III without looking into changes in protein expression in vivo. Protein is 
the actual effector. Protein quantification from the BALF is not entirely without problems, 
either. BAL samples are a mix of a wide variety of substances, especially from smokers. 
while the BALF from non-smokers is quite clear, the fluid from smokers is a brownish gel. 
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In vivo proteins are degraded much more easily than mRNA or DNA, and antibody binding 
might be disturbed, for instance, in ELISA. This can be overcome by isolating the cells of 
interest and studying the protein expression in primary cell cultures, but then again one has 
to consider the problems with ex vivo studies when interpreting the results. It would have 
been interesting to examine the mRNA expression of inflammatory mediators in the lung 
tissue of the patients (study II), but only a few samples were available for mRNA analysis.
It cannot be excluded that the lung function of the smokers had begun to decrease, because 
FEV1 and FVC1 were significantly lower in smokers than in non-smokers as a percentage of 
the reference values. However, the smoking subjects cannot be regarded to have developed 
signs of COPD according to the GOLD standards (GOLD 2008). 
The most reliable way to investigate the effects of medication is to plan a blinded randomised 
placebo-controlled study with enough power. DIA has a poor prognosis, despite the ICS and 
cessation of exposure. Rendering patients without medication for 6 months to years would 
have not been possible in this study and would have been unethical. Although the intention 
was also to examine the effect of corticosteroids in the treatment of DIA, it was impossible 
to separate the natural progression of the disease from the effects of ICS in our study. 
Although there is evidence that Penh is at least to some extent related to changes in airway 
resistance and bronchoconstriction (Zhang et al. 2009), some have raised concern because 
there are too many confounding factors (Lundblad et al. 2002) and results should be 
confirmed with invasive measurements. In this thesis, wBP and Penh were not used to 
assess the bronchoconstriction per se, but to demonstrate, as one parameter among others, 
that the OVA-induced allergic airway inflammation model is valid. Elevated Penh has also 
been shown to correlate with invasive measurements of lung function in the FIOH laboratory 
in this mouse model. 
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6. Conclusions
Smokers showed higher number of macrophages but decreased cytokine and chemokine 
mRNA expression in BAL cells compared to non-smokers. This suggests that the smokers 
have dysfunctional macrophages in the lower airways incapable of producing inflammatory 
mediators, especially chemokines, that are involved in the activation of other inflammatory 
cells. This may contribute to the recurring respiratory infections of smokers. whether this 
is a protective or harmful effect in relation to other airway pathology is still not known and 
calls for futher studies. 
Occupational DIA is a unique type of asthma with a poor prognosis. Patients with NSBHR 
despite the cessation of exposure and ICS treatment showed increased mRNA expression 
of mainly macrophage-derived cytokines IL-6, IL-15 and TNF-α in the BAL cells as a sign 
of ongoing inflammation in comparison to those without hyperreactivity after 2–3 years of 
follow-up. These might be markers for a poor prognosis and targets for future treatment. 
Tenascin-C expression was only slightly increased in the bronchial BM in DIA patients. No 
correlation was found between tenascin-C expression and hyperreactivity. Tenascin-C may 
not therefore be a useful marker in DIA patients.  
In the mouse model of acute allergic airway inflammation, STAT4-/- mice showed attenuated 
expression of tenascin-C in the lung, which was related to low expression of IFN-γ and 
TNF-α. In STAT6-/- mice with impaired Th2-type immunity, tenascin-C expression was 
quite similar to WT mice. Furthermore, fibroblasts stimulated by TNF-α and IFN-γ showed 
increased expression of tenascin-C in vitro. Thus, OVA-induced tenascin-C expression 
was regulated by mediators important in the Th1-type rather than the Th2-type immune 
response.
We found that the laminin β2 and α2 chains are over-expressed very early in the development 
of asthma in the bronchial BM and are associated with NSBHR. As the laminin α2 chain was 
only expressed in patients with asthma, while the expression of laminin β2 was also more 
frequent in patients with asthma symptoms than in healthy controls, the laminin α2 chain 
may be related to the development of clinical asthma. Longitudinal studies are needed to 
confirm this. Disturbed expression of laminins is a fine example of remodelling processes 
taking place in asthmatic airways and reflects the similarities between lung development and 
remodelling in asthma. 
63
acknowledgments
This study was carried out at the Institute of Biomedicine, Department of Anatomy, 
University of Helsinki, and the Department of Medicine, Division of Respiratory Diseases, 
Helsinki University Central Hospital. Some of the work was also performed at the Finnish 
Institute of Occupational Health (FIOH), Helsinki. Financial support was provided by the 
Sigfrid Juselius Foundation, the Ida Montin Foundation, the Väinö ja Laina Kivi Foundation 
and the Finnish Medical Foundation.  
All the people in my life from my dance teachers and colleagues at the clinic to my closest 
relatives and friends have made this possible and are thanked. However, here are a few 
people to whom my deepest gratitude goes: 
Most of all, I want to thank the supervisors of this thesis, Professor Lauri A. Laitinen and 
Docent Annika Laitinen, for the privilege of working with them. Annika, you introduced 
me to science and research. It changed my view of the world and medicine. I still remember 
the first conversations over ten years ago. Lauri, you had always clear vision that this 
thesis would be completed. your practical advice in writing and presenting the results was 
invaluable. I would have never done this without you both and your encouragement through 
the years, especially during the times when I was already giving up. 
Professor Ismo Virtanen, who passed away during the summer 2010, was most of all a 
scientist. His enthusiasm towards his work and science was an inspiration for students and 
young researchers, including me. He is also thanked for providing the facilities to work and 
for being my boss for years. 
The excellent reviewers, Professor Riitta Lahesmaa and Professor Eeva Moilanen, are 
thanked for their invaluable comments and interest in improving this thesis, despite the 
limited timeframe.
Dr Roy Siddall is thanked for the flexible language revision with a very tight schedule!
“The Boss” of Unit of Excellence for Immunotoxicology, Research Professor Harri Alenius 
at FIOH, is gratefully acknowledged for all the help with the articles and his vision during 
recent years, as well as giving me the opportunity to carry out experiments at the FIOH. The 
whole “posse” at FIOH is acknowledged for the great atmosphere and assistance with every 
problem. Marja-Leena Majuri and Piia Karisola, you were indispensible. you gave me the 
best guidance with methods and help with everything, from hands-on teaching to drafting 
the articles. 
64
All the co-authors are thanked for providing the expertise on their own fields. Especially 
Docent Päivi Piirilä, without whom I probably would never had known anything about DIA, 
for providing her patient material and knowledge. For support and invaluable comments 
when drafting the article, Professor Alan Altraja, Docent Henrik wolff, Professor Tari 
Haahtela, Professor Anssi Sovijärvi, Docent Mika Mäkelä, Dr Ari Lindqvist, Dr Eeva-Maija 
Nieminen, Docent Maija Halme, Dr Tuomo Kava and Dr Timo Mäntylä. For also sharing 
some of the burden of the experiments, Marina Leino, Kristiina Sirola and Terhi Savinko at 
the FIOH are thanked. 
All my colleagues at the Institute of Biomedicine during the years for support and 
colleagueship. Particularly at the Department of Anatomy, Professor Heikki Hervonen, Suvi 
Viranta-Kovanen and Nils Bäck for discussions and sharing experiences on teaching and 
life. Charlie’s Angels, Minna Takkunen, Noora Skants and Sissi Katz, are also thanked for 
support, encouragement and friendship during this whole project.
All the skilful staff at the Dept of Anatomy are thanked for their assistance, support and 
company during the years. In particular, Hanna wennäkoski for friendship also outside the 
workplace, in addition to help with the immunohistochemistry and keeping the lab organised; 
Marja-Leena Piirainen for helping with antibodies and cell culture; Pipsa Kaipainen for 
introducing various methods; Anne Reijula and Aili Takkinen for providing the basic 
stainings; Outi Rauanheimo for discussions and help with everything I ever asked; Mikko 
Liljeström and Mika Hukkanen for taking good care of the imaging unit; Reijo Karppinen 
and Hannu Kamppinen for the photography service; and Kaisu Laine and Pirjo Salminen for 
instrument maintenance.  
Kerstin Ahlskog and Minna Veneranta for introducing me to clinical lung research. 
All the chief physicians in the clinics I have worked at for providing free time for research 
when needed. And of course, all the other colleagues for their support and patience…
All the personnel involved in teaching. Especially Aulis Martonen and Ritva Henriksson 
at the student affairs office for assistance with various problems. Teaching coordinator 
Katriina Laurén is thanked for invaluable help, most of all in organising an extra course in 
spring 2010.
My teachers before the university, particularly Säde-Sylvia Verho and Heikki Koskinen. 
Some teachers see the forest, some see the trees. 
My family for everything. The moments around our kitchen table have always been full of 
life and encouragement. Mum and aunt Eeva, to whom this thesis is dedicated. you have 
provided the ground and seed and always believed in me. Mamma, you still live in my 
65
memories. The best little brother in the world, Juho, for always being there. My godmother 
and aunt Iitu, and my cousins Heta and Iira for all their support and friendship. Seppo for an 
endless supply of lame jokes. Eno for discussions and company.
All my friends, you know who you are. Nothing can replace you and your support during the 
years. Especially those who probably know me better than I know myself and have provided 
countless shared moments to remember over the years: Velda, Irina and her family, Lepa, 
Jenni N and her family, Jenni S and Stella. I hope that there are still many more to come.
Eelis, Netta and Emil, my godchildren for reminding me of the basics in life. And their 
parents for letting me be a part of their lives.
My Janne, for loving me and showing it in all aspects of life every day, especially during the 




Abraham wM, Sielczak Mw, wanner A, Perruchoud AP, Blinder L, Stevenson JS, Ahmed 
A and yerger LD. Cellular markers of inflammation in the airways of allergic sheep with 
and without allergen-induced late responses. Am Rev Respir Dis 138:1565-1571, 1988. 
Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev 
Immunol 3:745-756, 2003. 
Akimoto T, Numata F, Tamura M, Takata y, Higashida N, Takashi T, Takeda K and Akira 
S. Abrogation of Bronchial Eosinophilic Inflammation and Airway Hyperreactivity in     
Signal Transducers and Activators of Transcription (STAT)6-deficient Mice. J Exp Med 
187:1537-1542, 1998. 
Alcorn JF, Crowe CR and Kolls JK. TH17 cells in asthma and COPD. Annu Rev Physiol 
72:495-516, 2010. 
Allakhverdi Z, Comeau MR, Jessup HK, yoon BR, Brewer A, Chartier S, Paquette N, Ziegler 
SF, Sarfati M and Delespesse G. Thymic stromal lymphopoietin is released by human 
epithelial cells in response to microbes, trauma, or inflammation and potently activates 
mast cells. J Exp Med 204:253-258, 2007. 
Allen JE, Bischof RJ, Sucie Chang Hy, Hirota JA, Hirst SJ, Inman MD, Mitzner w and 
Sutherland TE. Animal models of airway inflammation and airway smooth muscle 
remodelling in asthma. Pulm Pharmacol Ther 22:455-465, 2009.     
Altraja A, Laitinen A, Virtanen I, Kampe M, Simonsson BG, Karlsson SE, Hakansson L, 
Venge P, Sillastu H and Laitinen LA. Expression of laminins in the airways in various        
types of asthmatic patients: a morphometric study. Am J Respir Cell Mol Biol 15:482-
488, 1996. 
Altraja S, Kadai M, Rekker E and Altraja A. Synthesis of tenascin and laminin beta2 chain 
in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 
receptor. Respir Res 9:44, 2008. 
Amin K, Ekberg-Jansson A, Lofdahl CG and Venge P. Relationship between inflammatory 
cells and structural changes in the lungs of asymptomatic and never smokers: a biopsy 
study. Thorax 58:135-142, 2003. 
Amin K, Janson C, Seveus L, Miyazaki K, Virtanen I and Venge P. Uncoordinated production 
of Laminin-5 chains in airways epithelium of allergic asthmatics. Respir Res 6:110, 
2005. 
Amin K, Ludviksdottir D, Janson C, Nettelbladt O, Bjornsson E, Roomans GM, Boman G, 
Seveus L and Venge P. Inflammation and structural changes in the airways of patients 
with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med 162:2295-
2301, 2000. 
67
Antoniou KM, Ferdoutsis E and Bouros D. Interferons and their application in the diseases 
of the lung. Chest 123:209-216, 2003. 
Aoshiba K, Tamaoki J and Nagai A. Acute cigarette smoke exposure induces apoptosis of 
alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 281:L1392-401, 2001. 
Aufderheide E and Ekblom P. Tenascin during gut development: appearance in the 
mesenchyme, shift in molecular forms, and dependence on epithelial-mesenchymal 
interactions. J Cell Biol 107:2341-2349, 1988. 
Aumailley M, Bruckner-Tuderman L, Carter wG, Deutzmann R, Edgar D, Ekblom P, Engel 
J, Engvall E, Hohenester E, Jones JC, Kleinman HK, Marinkovich MP, Martin GR, 
Mayer U, Meneguzzi G, Miner JH, Miyazaki K, Patarroyo M, Paulsson M, Quaranta V, 
Sanes JR, Sasaki T, Sekiguchi K, Sorokin LM, Talts JF, Tryggvason K, Uitto J, Virtanen 
I, von der Mark K, wewer UM, yamada y and yurchenco PD. A simplified laminin 
nomenclature. Matrix Biol 24:326-332, 2005. 
Baena-Cagnani C, Rossi GA and Canonica Gw. Airway remodelling in children: when does 
it start? Curr Opin Allergy Clin Immunol 7:196-200, 2007. 
Barbers RG, Gong H,Jr, Tashkin DP, Oishi J and wallace JM. Differential examination 
of bronchoalveolar lavage cells in tobacco cigarette and marijuana smokers. Am Rev 
Respir Dis 135:1271-1275, 1987. 
Bardana EJ,Jr. 10. Occupational asthma. J Allergy Clin Immunol 121:S408-411, 2008. 
Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 343:269-280, 2000. 
Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid 
Biochem Mol Biol 120:76-85, 2010. 
Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin 
Immunol 119:1055-1062, 2007. 
Barnes PJ and Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 
373:1905-1917, 2009. 
Barnes PJ. Neutrophils Find Smoke Attractive. Science 330:40-41, 2010. 
Bates JH, Rincon M and Irvin CG. Animal models of asthma. Am J Physiol Lung Cell Mol 
Physiol 297:L401-410, 2009. 
Battaglia S, Mauad T, van Schadewijk AM, Vignola AM, Rabe KF, Bellia V, Sterk PJ and 
Hiemstra PS. Differential distribution of inflammatory cells in large and small airways 
in smokers. J Clin Pathol 60:907-911, 2007. 
Behera AK, Kumar M, Lockey RF and Mohapatra SS. Adenovirus-mediated interferon 
gamma gene therapy for allergic asthma: involvement of interleukin 12 and STAT4 
signaling. Hum Gene Ther 13:1697-1709, 2002. 
68
Bentley AM, Maestrelli P, Saetta M, Fabbri LM, Robinson DS, Bradley BL, Jeffery PK, 
Durham SR and Kay AB. Activated T-lymphocytes and eosinophils in the bronchial 
mucosa in isocyanate-induced asthma. J Allergy Clin Immunol 89:821-829, 1992. 
Beqaj S, Jakkaraju S, Mattingly RR, Pan D and Schuger L. High RhoA activity maintains 
the undifferentiated mesenchymal cell phenotype, whereas RhoA down-regulation by 
laminin-2 induces smooth muscle myogenesis. J Cell Biol 156:893-903, 2002. 
Berkman N, Robichaud A, Krishnan VL, Roesems G, Robbins R, Jose PJ, Barnes PJ 
and Chung KF. Expression of RANTES in human airway epithelial cells: effect of 
corticosteroids and interleukin-4, -10 and -13. Immunology 87:599-603, 1996. 
Berry M, Brightling C, Pavord I and wardlaw A. TNF-alpha in asthma. Curr Opin Pharmacol 
7:279-282, 2007. 
Bocek P, Jr., Foucras G and Paul wE. Interferon gamma Enhances Both In Vitro and In Vivo 
Priming of CD4+ T Cells for IL-4 Production. J Exp Med 199:1619-1630, 2004. 
Bonilla FA and Oettgen HC. Adaptive immunity. J Allergy Clin Immunol 125:S33-40, 
2010. 
Booth BH, Patterson R and Talbot CH. Immediate-type hypersensitivity in dogs: cutaneous, 
anaphylactic, and respiratory responses to ascaris. J Lab Clin Med 76:181-189, 1970. 
Borish LC and Steinke Jw. 2. Cytokines and chemokines. J Allergy Clin Immunol 111:
S460-475, 2003. 
Bosse y and Rola-Pleszczynski M. Controversy surrounding the increased expression of 
TGF beta 1 in asthma. Respir Res 8:66, 2007. 
Boulet LP, Boutet M, Laviolette M, Dugas M, Milot J, Leblanc C, Paquette L, Cote J, Cartier 
A and Malo JL. Airway inflammation after removal from the causal agent in occupational 
asthma due to high and low molecular weight agents. Eur Respir J 7:1567-1575, 1994. 
Bousquet J, Jacot w, yssel H, Vignola AM and Humbert M. Epigenetic inheritance of fetal 
genes in allergic asthma. Allergy 59:138-147, 2004. 
Bousquet J, Jeffery PK, Busse ww, Johnson M and Vignola AM. Asthma. From 
bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care 
Med 161:1720-1745, 2000. 
Bracke KR, D’hulst AI, Maes T, Demedts IK, Moerloose KB, Kuziel wA, Joos GF and 
Brusselle GG. Cigarette smoke-induced pulmonary inflammation, but not airway 
remodelling, is attenuated in chemokine receptor 5-deficient mice. Clin Exp Allergy 
37:1467-1479, 2007. 
Bracke KR, D’hulst AI, Maes T, Moerloose KB, Demedts IK, Lebecque S, Joos GF and 
Brusselle GG. Cigarette smoke-induced pulmonary inflammation and emphysema are 
attenuated in CCR6-deficient mice. J Immunol 177:4350-4359, 2006. 
69
Bradding P, walls AF and Holgate ST. The role of the mast cell in the pathophysiology of 
asthma. J Allergy Clin Immunol 117:1277-1284, 2006. 
Brasier AR, Victor S, Ju H, Busse ww, Curran-Everett D, Bleecker E, Castro M, Chung KF, 
Gaston B, Israel E, wenzel SE, Erzurum SC, Jarjour NN and Calhoun wJ. Predicting 
intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines. 
Clin Transl Sci 3:147-157, 2010. 
Brellier F, Tucker RP and Chiquet-Ehrismann R. Tenascins and their implications in diseases 
and tissue mechanics. Scand J Med Sci Sports 19:511-519, 2009. 
Byers DE and Holtzman MJ. Alternatively activated macrophages as cause or effect in 
airway disease. Am J Respir Cell Mol Biol 43:1-4, 2010. 
Campo P, wisnewski AV, Lummus Z, Cartier A, Malo JL, Boulet LP and Bernstein DI. 
Diisocyanate conjugate and immunoassay characteristics influence detection of specific 
antibodies in HDI-exposed workers. Clin Exp Allergy 37:1095-1102, 2007. 
Capelli A, Di Stefano A, Gnemmi I, Balbo P, Cerutti CG, Balbi B, Lusuardi M and Donner 
CF. Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic 
bronchitics. Eur Respir J 14:160-165, 1999. 
Casola A, Henderson A, Liu T, Garofalo RP and Brasier AR. Regulation of RANTES 
promoter activation in alveolar epithelial cells after cytokine stimulation. Am J Physiol 
Lung Cell Mol Physiol 283:L1280-1290, 2002. 
Chapoval SP, Dasgupta P, Smith EP, Detolla LJ, Lipsky MM, Kelly-welch AE and Keegan 
AD. STAT6 Expression in Multiple Cell Types Mediates the Cooperative Development 
of Allergic Airway Disease. J Immunol 186:2571-2583, 2011. 
Chiba y, Todoroki M and Misawa M. Interleukin-4 upregulates RhoA protein via an 
activation of STAT6 in cultured human bronchial smooth muscle cells. Pharmacological 
Research 61:188-192, 2010. 
Christie PE, Jonas M, Tsai CH, Chi Ey and Henderson wR,Jr. Increase in laminin expression 
in allergic airway remodelling and decrease by dexamethasone. Eur Respir J 24:107-
115, 2004. 
Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl 34:50s-
59s, 2001. 
Churg A, Dai J, Tai H, Xie C and wright JL. Tumor necrosis factor-alpha is central to acute 
cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir 
Crit Care Med 166:849-854, 2002. 
Cohn RD, Herrmann R, wewer UM and Voit T. Changes of laminin beta 2 chain expression 
in congenital muscular dystrophy. Neuromuscul Disord 7:373-378, 1997. 
70
Colognato H and yurchenco PD. Form and function: the laminin family of heterotrimers. 
Dev Dyn 218:213-234, 2000. 
Commins SP, Borish L and Steinke Jw. Immunologic messenger molecules: cytokines, 
interferons, and chemokines. J Allergy Clin Immunol 125:S53-72, 2010. 
Conti P and DiGioacchino M. MCP-1 and RANTES are mediators of acute and chronic 
inflammation. Allergy Asthma Proc 22:133-137, 2001. 
Cosio BG and Agusti A. Update in chronic obstructive pulmonary disease 2009. Am J Respir 
Crit Care Med 181:655-660, 2010. 
Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE and Barnes PJ. 
Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages 
from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 
167:24-31, 2003. 
Curiel RE, Lahesmaa R, Subleski J, Cippitelli M, Kirken RA, young HA and Ghosh P. 
Identification of a Stat-6-responsive element in the promoter of the human interleukin-4 
gene. Eur J Immunol 27:1982-1987, 1997. 
D’Acquisto F, Maione F and Pederzoli-Ribeil M. From IL-15 to IL-33: the never-ending list 
of new players in inflammation. Is it time to forget the humble aspirin and move ahead? 
Biochem Pharmacol 79:525-534, 2010. 
de Marco R, Accordini S, Marcon A, Cerveri I, Anto JM, Gislason T, Heinrich J, Janson 
C, Jarvis D, Kuenzli N, Leynaert B, Sunyer J, Svanes C, wjst M, Burney P and for the 
European Community Respiratory Health Survey (ECRHS). Risk Factors for Chronic 
Obstructive Pulmonary Disease in a European Cohort of young Adults. Am J Respir 
Crit Care Med 2010. Oct 8 [epub ahead of print]. 
Dekkers BG, Schaafsma D, Tran T, Zaagsma J and Meurs H. Insulin-induced laminin 
expression promotes a hypercontractile airway smooth muscle phenotype. Am J Respir 
Cell Mol Biol 41:494-504, 2009. 
Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, Mapp CE, Fabbri 
LM, Donner CF and Saetta M. Severity of airflow limitation is associated with severity 
of airway inflammation in smokers. Am J Respir Crit Care Med 158:1277-1285, 1998. 
Dinarello CA. Proinflammatory cytokines. Chest 118:503-508, 2000. 
Dippolito R, Foresi A, Chetta A, Castagnaro A, Malorgio R, Marangio E and Olivieri D. 
Eosinophils in induced sputum from asymptomatic smokers with normal lung function. 
Respir Med 95:969-974, 2001. 
Dodge IL, Carr Mw, Cernadas M and Brenner MB. IL-6 production by pulmonary dendritic 
cells impedes Th1 immune responses. J Immunol 170:4457-4464, 2003. 
71
Doerner AM and Zuraw BL. TGF-beta1 induced epithelial to mesenchymal transition 
(EMT) in human bronchial epithelial cells is enhanced by IL-1beta but not abrogated by 
corticosteroids. Respir Res 10:100, 2009. 
Driscoll KE. Macrophage inflammatory proteins: biology and role in pulmonary inflammation. 
Exp Lung Res 20:473-490, 1994. 
Durbeej M. Laminins. Cell Tissue Res 339:259-268, 2010. 
Ebina M, Takahashi T, Chiba T and Motomiya M. Cellular hypertrophy and hyperplasia of 
airway smooth muscles underlying bronchial asthma. A 3-D morphometric study. Am 
Rev Respir Dis 148:720-726, 1993. 
Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, Romieu I, 
Silverman EK, Balmes JR and Committee on Nonsmoking COPD, Environmental and 
Occupational Health Assembly. An official American Thoracic Society public policy 
statement: Novel risk factors and the global burden of chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med 182:693-718, 2010. 
Ekberg-Jansson A, Andersson B, Avra E, Nilsson O and Lofdahl CG. The expression of 
lymphocyte surface antigens in bronchial biopsies, bronchoalveolar lavage cells and 
blood cells in healthy smoking and never-smoking men, 60 years old. Respir Med 
94:264-272, 2000. 
Elo LL, Järvenpää H, Tuomela S, Raghav S, Ahlfors H, Laurila K, Gupta B, Lund RJ, 
Tahvanainen J, Hawkins RD, Orešič M, Lähdesmäki H, Rasool O, Rao KV, Aittokallio 
T and Lahesmaa R. Genome-wide Profiling of Interleukin-4 and STAT6 Transcription 
Factor Regulation of Human Th2 Cell Programming. Immunity 32:852-862, 2010. 
Eming SA, Krieg T and Davidson JM. Inflammation in wound repair: molecular and cellular 
mechanisms. J Invest Dermatol 127:514-525, 2007. 
Engvall E, Davis GE, Dickerson K, Ruoslahti E, Varon S and Manthorpe M. Mapping of 
domains in human laminin using monoclonal antibodies: localization of the neurite-
promoting site. J Cell Biol 103:2457-2465, 1986. 
Engvall E, Earwicker D, Haaparanta T, Ruoslahti E and Sanes JR. Distribution and isolation 
of four laminin variants; tissue restricted distribution of heterotrimers assembled from 
five different subunits. Cell Regul 1:731-740, 1990. 
Evans MJ, Van winkle LS, Fanucchi MV and Plopper CG. The attenuated fibroblast sheath 
of the respiratory tract epithelial-mesenchymal trophic unit. Am J Respir Cell Mol Biol 
21:655-657, 1999. 
Fabbri LM, Boschetto P, Zocca E, Milani G, Pivirotto F, Plebani M, Burlina A, Licata B 
and Mapp CE. Bronchoalveolar neutrophilia during late asthmatic reactions induced by 
toluene diisocyanate. Am Rev Respir Dis 136:36-42, 1987. 
72
Finkelman FD and wills-Karp M. Usefulness and optimization of mouse models of allergic 
airway disease. J Allergy Clin Immunol 121:603-606, 2008. 
Fitzpatrick AM, Teague wG, Burwell L, Brown MS, Brown LA and NIH/NHLBI Severe 
Asthma Research Program. Glutathione oxidation is associated with airway macrophage 
functional impairment in children with severe asthma. Pediatr Res 69:154-159, 2011. 
Fletcher C and Peto R. The natural history of chronic airflow obstruction. Br Med J 1:1645-
1648, 1977. 
Flood-Page P, Menzies-Gow A, Phipps S, ying S, wangoo A, Ludwig MS, Barnes N, 
Robinson D and Kay AB. Anti-IL-5 treatment reduces deposition of ECM proteins in 
the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 
112:1029-1036, 2003a. 
Flood-Page PT, Menzies-Gow AN, Kay AB and Robinson DS. Eosinophil’s role remains 
uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am 
J Respir Crit Care Med 167:199-204, 2003b. 
Flores-Delgado G, Bringas P and warburton D. Laminin 2 attachment selects myofibroblasts 
from fetal mouse lung. Am J Physiol 275:L622-630, 1998. 
Foster PS, Hogan SP, Ramsay AJ, Matthaei KI and young IG. Interleukin 5 deficiency 
abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma 
model. J Exp Med 183:195-201, 1996. 
Foster PS, webb DC, yang M, Herbert C and Kumar RK. Dissociation of T helper type 2 
cytokine-dependent airway lesions from signal transducer and activator of transcription 
6 signalling in experimental chronic asthma. Clin Exp Allergy 33:688-695, 2003. 
Franchimont D, Martens H, Hagelstein M, Louis E, Dewe w, Chrousos GP, Belaiche J 
and Geenen V. Tumor Necrosis Factor alpha Decreases, and Interleukin-10 Increases, 
the Sensitivity of Human Monocytes to Dexamethasone: Potential Regulation of the 
Glucocorticoid Receptor. J Clin Endocrinol Metab 84:2834-2839, 1999. 
Fuke S, Betsuyaku T, Nasuhara y, Morikawa T, Katoh H and Nishimura M. Chemokines 
in bronchiolar epithelium in the development of chronic obstructive pulmonary disease. 
Am J Respir Cell Mol Biol 31:405-412, 2004. 
Garcia-Aymerich J, Gomez FP, Benet M, Farrero E, Basagana X, Gayete A, Pare C, Freixa X, 
Ferrer J, Ferrer A, Roca J, Galdiz JB, Sauleda J, Monso E, Gea J, Barbera JA, Agusti A, 
Anto JM and on behalf of the PAC-COPD Study Group. Identification and prospective 
validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. 
Thorax 2010. Dec 21 [epub ahead of print]. 
Gavett SH, Chen X, Finkelman F and wills-Karp M. Depletion of murine CD4+ T lymphocytes 
prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J 
Respir Cell Mol Biol 10:587-593, 1994. 
73
Gibson PG and Simpson JL. The overlap syndrome of asthma and COPD: what are its 
features and how important is it? Thorax 64:728-735, 2009. 
Global strategy for asthma management and prevention [homepage on the Internet]. The 
Global Initiative for Asthma (GINA) [updated 2009; cited 2010 Nov 22]. Available 
from: http://www.ginasthma.com.
Global strategy for the diagnosis, management and prevention of COPD [homepage on the 
Internet]. The Global initiative for chronic Obstructive Lung Disease (GOLD) [updated 
2008; cited 2011 Jan 28]. Available from: http://www.goldcopd.com.
Gordon SB and Read RC. Macrophage defences against respiratory tract infections. Br Med 
Bull 61:45-61, 2002. 
Grol MH, Gerritsen J, Vonk JM, Schouten JP, Koeter GH, Rijcken B and Postma DS. Risk 
factors for growth and decline of lung function in asthmatic individuals up to age 42 
years. A 30-year follow-up study. Am J Respir Crit Care Med 160:1830-1837, 1999. 
Guo LT, Zhang XU, Kuang w, Xu H, Liu LA, Vilquin JT, Miyagoe-Suzuki y, Takeda 
S, Ruegg MA, wewer UM and Engvall E. Laminin alpha2 deficiency and muscular 
dystrophy; genotype-phenotype correlation in mutant mice. Neuromuscul Disord 
13:207-215, 2003. 
Hagiwara E, Takahashi KI, Okubo T, Ohno S, Ueda A, Aoki A, Odagiri S and Ishigatsubo y. 
Cigarette smoking depletes cells spontaneously secreting Th(1) cytokines in the human 
airway. Cytokine 14:121-126, 2001. 
Haitchi HM, Bassett DJ, Bucchieri F, Gao X, Powell RM, Hanley NA, wilson DI, Holgate 
ST and Davies DE. Induction of a disintegrin and metalloprotease 33 during embryonic 
lung development and the influence of IL-13 or maternal allergy. J Allergy Clin Immunol 
124:590-597.e1-11, 2009. 
Halayko AJ and Solway J. Molecular mechanisms of phenotypic plasticity in smooth muscle 
cells. J Appl Physiol 90:358-368, 2001. 
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro w, Sousa A, Marshall RP, 
Bradding P, Green RH, wardlaw AJ and Pavord ID. Mepolizumab and exacerbations of 
refractory eosinophilic asthma. N Engl J Med 360:973-984, 2009. 
Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG and Gelfand Ew. 
Noninvasive Measurement of Airway Responsiveness in Allergic Mice Using Barometric 
Plethysmography. Am J Respir Crit Care Med 156:766-775, 1997. 
Hargreave FE and Nair P. The definition and diagnosis of asthma. Clin Exp Allergy 39:1652-   
1658, 2009. 
Harkonen E, Virtanen I, Linnala A, Laitinen LL and Kinnula VL. Modulation of fibronectin   
and tenascin production in human bronchial epithelial cells by inflammatory cytokines 
in vitro. Am J Respir Cell Mol Biol 13:109-115, 1995. 
74
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM and weaver 
CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from 
the T helper type 1 and 2 lineages. Nat Immunol 6:1123-1132, 2005. 
Hayashi N, yoshimoto T, Izuhara K, Matsui K, Tanaka T and Nakanishi K. T helper 1 
cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung 
fibrosis by IFN-gamma and IL-13 production. Proc Natl Acad Sci U S A 104:14765-
14770, 2007. 
Herrick CA, Xu L, wisnewski AV, Das J, Redlich CA and Bottomly K. A novel mouse 
model of diisocyanate-induced asthma showing allergic-type inflammation in the lung 
after inhaled antigen challenge. J Allergy Clin Immunol 109:873-878, 2002. 
Hirota JA, Ask K, Fritz D, Ellis R, wattie J, Richards CD, Labiris R, Kolb M and Inman 
MD. Role of STAT6 and SMAD2 in a model of chronic allergen exposure: a mouse 
strain comparison study. Clin Exp Allergy 39:147-158, 2009. 
Hirota J, Ellis R and Inman M. Regional differences in the pattern of airway remodeling 
following chronic allergen exposure in mice. Respir Res 7:120, 2006. 
Hirshman CA, Malley A and Downes H. Basenji-Greyhound dog model of asthma: reactivity 
to Ascaris suum, citric acid, and methacholine. J Appl Physiol 49:953-957, 1980. 
Hoeck J and woisetschlager M. STAT6 mediates eotaxin-1 expression in IL-4 or TNF-
alpha-induced fibroblasts. J Immunol 166:4507-4515, 2001. 
Holgate ST. Pathogenesis of asthma. Clin Exp Allergy 38:872-897, 2008. 
Holgate ST and Davies DE. Rethinking the pathogenesis of asthma. Immunity 31:362-367, 
2009. 
Holgate ST, Davies DE, Lackie PM, wilson SJ, Puddicombe SM and Lordan JL. Epithelial-
mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 
105:193-204, 2000. 
Holgate ST, Holloway J, wilson S, Bucchieri F, Puddicombe S and Davies DE. Epithelial-
mesenchymal communication in the pathogenesis of chronic asthma. Proc Am Thorac 
Soc 1:93-98, 2004. 
Holgate ST, Roberts G, Arshad HS, Howarth PH and Davies DE. The role of the airway 
epithelium and its interaction with environmental factors in asthma pathogenesis. Proc 
Am Thorac Soc 6:655-659, 2009. 
Holgate ST, yang y, Haitchi HM, Powell RM, Holloway Jw, yoshisue H, Pang yy, 
Cakebread J and Davies DE. The genetics of asthma: ADAM33 as an example of a 
susceptibility gene. Proc Am Thorac Soc 3:440-443, 2006. 
75
Holt PG and Strickland DH. Interactions between innate and adaptive immunity in asthma 
pathogenesis: new perspectives from studies on acute exacerbations. J Allergy Clin 
Immunol 125:963-972, 2010. 
Holtzman MJ, Morton JD, Shornick LP, Tyner Jw, O’Sullivan MP, Antao A, Lo M, Castro 
M and walter MJ. Immunity, inflammation, and remodeling in the airway epithelial 
barrier: epithelial-viral-allergic paradigm. Physiol Rev 82:19-46, 2002. 
Hoontrakoon R, Chu Hw, Gardai SJ, wenzel SE, McDonald P, Fadok VA, Henson PM 
and Bratton DL. Interleukin-15 inhibits spontaneous apoptosis in human eosinophils via 
autocrine production of granulocyte macrophage-colony stimulating factor and nuclear 
factor-kappaB activation. Am J Respir Cell Mol Biol 26:404-412, 2002. 
Hoser G, Domagala-Kulawik J, Droszcz P, Droszcz w and Kawiak J. Lymphocyte subsets 
differences in smokers and nonsmokers with primary lung cancer: a flow cytometry 
analysis of bronchoalveolar lavage fluid cells. Med Sci Monit 9:BR310-315, 2003. 
Hoshino A, Tsuji T, Matsuzaki J, Jinushi T, Ashino S, Teramura T, Chamoto K, Tanaka 
y, Asakura y, Sakurai T, Mita y, Takaoka A, Nakaike S, Takeshima T, Ikeda H and 
Nishimura T. STAT6-mediated signaling in Th2-dependent allergic asthma: critical 
role for the development of eosinophilia, airway hyper-responsiveness and mucus 
hypersecretion, distinct from its role in Th2 differentiation. Int Immunol 16:1497-1505, 
2004. 
Howard TD, Koppelman GH, Xu J, Zheng SL, Postma DS, Meyers DA and Bleecker ER. 
Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. 
Am J Hum Genet 70:230-236, 2002. 
Howeedy AA, Virtanen I, Laitinen L, Gould NS, Koukoulis GK and Gould VE. Differential 
distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab Invest 
63:798-806, 1990. 
Howell JE and McAnulty RJ. TGF-beta: its role in asthma and therapeutic potential. Curr 
Drug Targets 7:547-565, 2006. 
Hunter DD, Shah V, Merlie JP and Sanes JR. A laminin-like adhesive protein concentrated 
in the synaptic cleft of the neuromuscular junction. Nature 338:229-234, 1989. 
Huttunen R, Heikkinen T and Syrjanen J. Smoking and the outcome of infection. J Intern 
Med 2010. Nov 26 [epub ahead of print]. 
Hylkema MN, Hoekstra MO, Luinge M and Timens w. The strength of the OVA-induced 
airway inflammation in rats is strain dependent. Clin Exp Immunol 129:390-396, 2002. 
Isajevs S, Taivans I, Svirina D, Strazda G and Kopeika U. Patterns of Inflammatory Responses 
in Large and Small Airways in Smokers with and without Chronic Obstructive Pulmonary 
Disease. Respiration 2011. Jan 12 [epub ahead of print]. 
76
James A and Carroll N. Airway smooth muscle in health and disease; methods of measurement 
and relation to function. Eur Respir J 15:782-789, 2000. 
Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive 
pulmonary disease. Proc Am Thorac Soc 1:176-183, 2004. 
Jiang L, wei XF, yi DH, Xu P, Liu H, Chang Q, yang SM, Li ZF, Gao HB and Hao GJ. 
Synergistic effects of cyclic strain and Th1-like cytokines on tenascin-C production by 
rheumatic aortic valve interstitial cells. Clin Exp Immunol 155:216-223, 2009. 
Jie Z, Jin M, Cai y, Bai C, Shen y, yuan Z, Hu y and Holgate S. The effects of Th2 cytokines 
on the expression of ADAM33 in allergen-induced chronic airway inflammation. Respir 
Physiol Neurobiol 168:289-294, 2009. 
Jirapongsananuruk O, Donahue HL, Trumble AE and Leung Dy. The modulation of 
cytokine and IgE production by tumor necrosis factor-beta in atopic dermatitis. J Invest 
Dermatol 114:200-203, 2000. 
Johnson JR, wiley RE, Fattouh R, Swirski FK, Gajewska BU, Coyle AJ, Gutierrez-Ramos 
JC, Ellis R, Inman MD and Jordana M. Continuous exposure to house dust mite elicits 
chronic airway inflammation and structural remodeling. Am J Respir Crit Care Med 
169:378-385, 2004. 20031103 [epub ahead of print]. 
Jones FS and Jones PL. The tenascin family of ECM glycoproteins: structure, function, and 
regulation during embryonic development and tissue remodeling. Dev Dyn 218:235-
259, 2000. 
Jones MG, Floyd A, Nouri-Aria KT, Jacobson MR, Durham SR, Taylor AN and Cullinan 
P. Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin 
Immunol 117:663-669, 2006. 
Jones PL and Jones FS. Tenascin-C in development and disease: gene regulation and cell 
function. Matrix Biol 19:581-596, 2000. 
Kaarteenaho-Wiik R, Kinnula V, Herva R, Paakko P, Pollanen R and Soini y. Distribution 
and mRNA expression of tenascin-C in developing human lung. Am J Respir Cell Mol 
Biol 25:341-346, 2001. 
Kaplan MH, Schindler U, Smiley ST and Grusby MJ. Stat6 Is Required for Mediating 
Responses to IL-4 and for the Development of Th2 Cells. Immunity 4:313-319, 1996. 
Kariyawasam HH, Aizen M, Barkans J, Robinson DS and Kay AB. Remodeling and airway 
hyperresponsiveness but not cellular inflammation persist after allergen challenge in 
asthma. Am J Respir Crit Care Med 175:896-904, 2007. 
Karjalainen EM, Lindqvist A, Laitinen LA, Kava T, Altraja A, Halme M and Laitinen A. 
Airway inflammation and basement membrane tenascin in newly diagnosed atopic and 
nonatopic asthma. Respir Med 97:1045-1051, 2003. 
77
Karol MH. The development of an animal model for TDI asthma. Bull Eur Physiopathol 
Respir 23:571-576, 1987. 
Keatings VM, Collins PD, Scott DM and Barnes PJ. Differences in interleukin-8 and 
tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive 
pulmonary disease or asthma. Am J Respir Crit Care Med 153:530-534, 1996. 
Kim EG, Shin HJ, Lee CG, Park Hy, Kim yK, Park Hw, Cho SH, Min KU, Cho ML, Park 
SH and Lee Cw. DNA methylation and not allelic variation regulates STAT6 expression 
in human T cells. Clin Exp Med 10:143-152, 2010a. 
Kim yS, Choi SJ, Choi JP, Jeon SG, Oh Sy, Lee BJ, Gho yS, Lee CG, Zhu Z, Elias JA 
and Kim yK. IL-12-STAT4-IFN-gamma axis is a key downstream pathway in the 
development of IL-13-mediated asthma phenotypes in a Th2 type asthma model. Exp 
Mol Med 42:533-546, 2010b. 
Kips JC and Pauwels RA. The use of knockouts to study determinants of airway 
hyperresponsiveness. Allergy 54:903-908, 1999. 
Kirkham PA, Spooner G, Ffoulkes-Jones C and Calvez R. Cigarette smoke triggers 
macrophage adhesion and activation: role of lipid peroxidation products and scavenger 
receptor. Free Radic Biol Med 35:697-710, 2003. 
Kirschvink N and Reinhold P. Use of alternative animals as asthma models. Curr Drug 
Targets 9:470-484, 2008. 
Kotani N, Hashimoto H, Sessler DI, yoshida H, Kimura N, Okawa H, Muraoka M and 
Matsuki A. Smoking decreases alveolar macrophage function during anesthesia and 
surgery. Anesthesiology 92:1268-1277, 2000. 
Kotani N, Kushikata T, Hashimoto H, Sessler DI, Muraoka M and Matsuki A. Recovery of 
intraoperative microbicidal and inflammatory functions of alveolar immune cells after a 
tobacco smoke-free period. Anesthesiology 94:999-1006, 2001. 
Kruegel J and Miosge N. Basement membrane components are key players in specialized 
extracellular matrices. Cell Mol Life Sci 67:2879-2895, 2010. 
Kumar RK and Foster PS. Modeling allergic asthma in mice: pitfalls and opportunities. Am 
J Respir Cell Mol Biol 27:267-272, 2002. 
Kumar RK, Herbert C and Foster PS. The “classical” ovalbumin challenge model of asthma 
in mice. Curr Drug Targets 9:485-494, 2008. 
Kumar RK, Herbert C and Kasper M. Reversibility of airway inflammation and remodelling 
following cessation of antigenic challenge in a model of chronic asthma. Clin Exp 
Allergy 34:1796-1802, 2004. 
Kuperman DA and Schleimer RP. Interleukin-4, interleukin-13, signal transducer and 
activator of transcription factor 6, and allergic asthma. Curr Mol Med 8:384-392, 2008. 
78
Kurup VP, Mauze S, Choi H, Seymour Bw and Coffman RL. A murine model of allergic 
bronchopulmonary aspergillosis with elevated eosinophils and IgE. J Immunol 148:3783-
3788, 1992. 
Kuschner wG, D’Alessandro A, wong H and Blanc PD. Dose-dependent cigarette smoking-
related inflammatory responses in healthy adults. Eur Respir J 9:1989-1994, 1996. 
Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I and Laitinen LA. Tenascin is increased 
in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J 
Respir Crit Care Med 156:951-958, 1997. 
Laitinen A, Karjalainen EM, Altraja A and Laitinen LA. Histopathologic features of early 
and progressive asthma. J Allergy Clin Immunol 105:S509-513, 2000. 
Laitinen LA, Heino M, Laitinen A, Kava T and Haahtela T. Damage of the airway epithelium 
and bronchial reactivity in patients with asthma. Am Rev Respir Dis 131:599-606, 
1985. 
Lambrecht BN and Hammad H. The role of dendritic and epithelial cells as master regulators 
of allergic airway inflammation. Lancet 376:835-843, 2010. 
Lambropoulou M, Limberis V, Koutlaki N, Simopoulou M, Ntanovasilis D, Vandoros GP, 
Tatsidou P, Kekou I, Koutsikogianni I and Papadopoulos N. Differential expression of 
tenascin-C in the developing human lung: an immunohistochemical study. Clin Exp 
Med 9:333-338, 2009. 
Lams BE, Sousa AR, Rees PJ and Lee TH. Subepithelial immunopathology of the large 
airways in smokers with and without chronic obstructive pulmonary disease. Eur Respir 
J 15:512-516, 2000. 
Lams BE, Sousa AR, Rees PJ and Lee TH. Immunopathology of the small-airway submucosa 
in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit 
Care Med 158:1518-1523, 1998. 
Lange P, Parner J, Vestbo J, Schnohr P and Jensen G. A 15-year follow-up study of ventilatory 
function in adults with asthma. N Engl J Med 339:1194-1200, 1998. 
Lee CG, Homer RJ, Zhu Z, Lanone S, wang X, Koteliansky V, Shipley JM, Gotwals P, 
Noble P, Chen Q, Senior RM and Elias JA. Interleukin-13 Induces Tissue Fibrosis by 
Selectively Stimulating and Activating Transforming Growth Factor beta1. J Exp Med 
194:809-822, 2001a. 
Lee JH, Kaminski N, Dolganov G, Grunig G, Koth L, Solomon C, Erle DJ and Sheppard 
D. Interleukin-13 Induces Dramatically Different Transcriptional Programs in Three 
Human Airway Cell Types. Am J Respir Cell Mol Biol 25:474-485, 2001b. 
Lee PN and Fry JS. Systematic review of the evidence relating FEV1 decline to giving up 
smoking. BMC Med 8:84, 2010. 
79
Leivo I and Engvall E. Merosin, a protein specific for basement membranes of Schwann cells, 
striated muscle, and trophoblast, is expressed late in nerve and muscle development. 
Proc Natl Acad Sci U S A 85:1544-1548, 1988. 
Li �, Wu B, Xiong H, Zhu C and Zhang L. Polymorphisms of STAT-6, STAT-4 and IFN-γ 
genes and the risk of asthma in Chinese population. Respir Med 101:1977-1981, 2007. 
Lim S, Roche N, Oliver BG, Mattos w, Barnes PJ and Fan Chung K. Balance of Matrix 
Metalloprotease-9 and Tissue Inhibitor of Metalloprotease-1 from Alveolar Macrophages 
in Cigarette Smokers . Regulation by Interleukin-10. Am J Respir Crit Care Med 
162:1355-1360, 2000. 
Linden M, Rasmussen JB, Piitulainen E, Tunek A, Larson M, Tegner H, Venge P, Laitinen LA 
and Brattsand R. Airway inflammation in smokers with nonobstructive and obstructive 
chronic bronchitis. Am Rev Respir Dis 148:1226-1232, 1993. 
Liu Q and wisnewski AV. Recent developments in diisocyanate asthma. Ann Allergy 
Asthma Immunol 90:35-41, 2003. 
Lloyd CM and Hessel EM. Functions of T cells in asthma: more than just T(H)2 cells. Nat 
Rev Immunol 10:838-848, 2010. 
Lummus ZL, Alam R, Bernstein JA and Bernstein DI. Diisocyanate antigen-enhanced 
production of monocyte chemoattractant protein-1, IL-8, and tumor necrosis factor-
alpha by peripheral mononuclear cells of workers with occupational asthma. J Allergy 
Clin Immunol 102:265-274, 1998. 
Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E, Larsson 
LG, Andersson S, Sandstrom T, Larsson K and Obstructive Lung Disease in Northern 
Sweden,Studies. Not 15 but 50% of smokers develop COPD?--Report from the 
Obstructive Lung Disease in Northern Sweden Studies. Respir Med 97:115-122, 2003. 
Lundblad LK, Irvin CG, Adler A and Bates JH. A reevaluation of the validity of unrestrained 
plethysmography in mice. J Appl Physiol 93:1198-1207, 2002. 
Lundy SK, Berlin AA and Lukacs Nw. Interleukin-12-independent down-modulation 
of cockroach antigen-induced asthma in mice by intranasal exposure to bacterial 
lipopolysaccharide. Am J Pathol 163:1961-1968, 2003. 
Macfarlane AJ, Kon OM, Smith SJ, Zeibecoglou K, Khan LN, Barata LT, McEuen AR, 
Buckley MG, walls AF, Meng Q, Humbert M, Barnes NC, Robinson DS, ying S and 
Kay AB. Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in 
late-phase allergic reactions in the lung and skin. J Allergy Clin Immunol 105:99-107, 
2000. 
Maestrelli P, Del Prete GF, De Carli M, D’Elios MM, Saetta M, Di Stefano A, Mapp CE, 
Romagnani S and Fabbri LM. CD8 T-cell clones producing interleukin-5 and interferon-
gamma in bronchial mucosa of patients with asthma induced by toluene diisocyanate. 
Scand J work Environ Health 20:376-381, 1994. 
80
Maestrelli P, di Stefano A, Occari P, Turato G, Milani G, Pivirotto F, Mapp CE, Fabbri 
LM and Saetta M. Cytokines in the airway mucosa of subjects with asthma induced by 
toluene diisocyanate. Am J Respir Crit Care Med 151:607-612, 1995. 
Maestrelli P, Occari P, Turato G, Papiris SA, Di Stefano A, Mapp CE, Milani GF, Fabbri LM 
and Saetta M. Expression of interleukin (IL)-4 and IL-5 proteins in asthma induced by 
toluene diisocyanate (TDI). Clin Exp Allergy 27:1292-1298, 1997. 
Maghni K, Lemiere C, Ghezzo H, yuquan w and Malo JL. Airway inflammation after 
cessation of exposure to agents causing occupational asthma. Am J Respir Crit Care 
Med 169:367-372, 2004. 
Makhluf HA, Stepniakowska J, Hoffman S, Smith E, LeRoy EC and Trojanowska M. IL-
4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J Invest 
Dermatol 107:856-859, 1996. 
Marinkovich MP, Lunstrum GP and Burgeson RE. The anchoring filament protein kalinin is 
synthesized and secreted as a high molecular weight precursor. J Biol Chem 267:17900-
17906, 1992. 
Matanic D, Beg-Zec Z, Stojanovic D, Matakoric N, Flego V and Milevoj-Ribic F. Cytokines 
in patients with lung cancer. Scand J Immunol 57:173-178, 2003. 
Matejas V, Hinkes B, Alkandari F, Al-Gazali L, Annexstad E, Aytac MB, Barrow M, 
Blahova K, Bockenhauer D, Cheong HI, Maruniak-Chudek I, Cochat P, Dotsch J, 
Gajjar P, Hennekam RC, Janssen F, Kagan M, Kariminejad A, Kemper MJ, Koenig 
J, Kogan J, Kroes Hy, Kuwertz-Broking E, Lewanda AF, Medeira A, Muscheites J, 
Niaudet P, Pierson M, Saggar A, Seaver L, Suri M, Tsygin A, wuhl E, Zurowska A, 
Uebe S, Hildebrandt F, Antignac C and Zenker M. Mutations in the human laminin 
beta2 (LAMB2) gene and the associated phenotypic spectrum. Hum Mutat 31:992-1002, 
2010. 
Matera MG, Calzetta L and Cazzola M. TNF-alpha inhibitors in asthma and COPD: we must 
not throw the baby out with the bath water. Pulm Pharmacol Ther 23:121-128, 2010. 
Matheson JM, Lemus R, Lange Rw, Karol MH and Luster MI. Role of tumor necrosis factor 
in toluene diisocyanate asthma. Am J Respir Cell Mol Biol 27:396-405, 2002. 
Matsuda A, Hirota T, Akahoshi M, Shimizu M, Tamari M, Miyatake A, Takahashi A, 
Nakashima K, Takahashi N, Obara K, yuyama N, Doi S, Kamogawa y, Enomoto T, 
Ohshima K, Tsunoda T, Miyatake S, Fujita K, Kusakabe M, Izuhara K, Nakamura y, 
Hopkin J and Shirakawa T. Coding SNP in tenascin-C Fn-III-D domain associates with 
adult asthma. Hum Mol Genet 14:2779-2786, 2005. 
Matsui C, Nelson CF, Hernandez GT, Herron GS, Bauer EA and Hoeffler wK. Gamma 
2 chain of laminin-5 is recognized by monoclonal antibody GB3. J Invest Dermatol 
105:648-652, 1995. 
81
Mattoli S, Miante S, Calabro F, Mezzetti M, Fasoli A and Allegra L. Bronchial epithelial 
cells exposed to isocyanates potentiate activation and proliferation of T-cells. Am J 
Physiol 259:L320-327, 1990. 
Mauad T, Bel EH and Sterk PJ. Asthma therapy and airway remodeling. J Allergy Clin 
Immunol 120:997-1009, 2007. 
Maurer M and von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 
36:1882-1886, 2004. 
Mautino G, Capony F, Bousquet J and Vignola AM. Balance in asthma between matrix 
metalloproteinases and their inhibitors. J Allergy Clin Immunol 104:530-533, 1999. 
McCrea KA, Ensor JE, Nall K, Bleecker ER and Hasday JD. Altered cytokine regulation in 
the lungs of cigarette smokers. Am J Respir Crit Care Med 150:696-703, 1994. 
McCusker CT, wang y, Shan J, Kinyanjui Mw, Villeneuve A, Michael H and Fixman ED. 
Inhibition of Experimental Allergic Airways Disease by Local Application of a Cell-
Penetrating Dominant-Negative STAT-6 Peptide. J Immunol 179:2556-2564, 2007. 
McMillan SJ and Lloyd CM. Prolonged allergen challenge in mice leads to persistent airway 
remodelling. Clin Exp Allergy 34:497-507, 2004. 
Meyers DA. Genetics of asthma and allergy: what have we learned? J Allergy Clin Immunol 
126:439-46, 2010. 
Meyts I, Hellings Pw, Hens G, Vanaudenaerde BM, Verbinnen B, Heremans H, Matthys P, 
Bullens DM, Overbergh L, Mathieu C, De Boeck K and Ceuppens JL. IL-12 contributes 
to allergen-induced airway inflammation in experimental asthma. J Immunol 177:6460-
6470, 2006. 
Midwood KS and Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell 
Commun Signal 3:287-310, 2009. 
Mills PR, Davies RJ and Devalia JL. Airway epithelial cells, cytokines, and pollutants. Am 
J Respir Crit Care Med 160:S38-43, 1999. 
Miner JH. Laminins and their roles in mammals. Microsc Res Tech 71:349-356, 2008. 
Mio T, Romberger DJ, Thompson AB, Robbins RA, Heires A and Rennard SI. Cigarette 
smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir 
Crit Care Med 155:1770-1776, 1997. 
Misawa M, Takenouchi K, Abiru T, yoshino y and yanaura S. Strain difference in an 
allergic asthma model in rats. Jpn J Pharmacol 45:63-68, 1987. 
Molfino NA. Genetics of COPD. Chest 125:1929-1940, 2004. 
Monteseirin J. Neutrophils and asthma. J Investig Allergol Clin Immunol 19:340-354, 
2009. 
82
Morishima y, Nomura A, Uchida y, Noguchi y, Sakamoto T, Ishii y, Goto y, Masuyama 
K, Zhang MJ, Hirano K, Mochizuki M, Ohtsuka M and Sekizawa K. Triggering the 
induction of myofibroblast and fibrogenesis by airway epithelial shedding. Am J Respir 
Cell Mol Biol 24:1-11, 2001. 
Mullings RE, wilson SJ, Puddicombe SM, Lordan JL, Bucchieri F, Djukanovic R, Howarth 
PH, Harper S, Holgate ST and Davies DE. Signal transducer and activator of transcription 
6 (STAT-6) expression and function in asthmatic bronchial epithelium. Journal of 
Allergy and Clinical Immunology, 108:832-838, 2001. 
Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave 
FE and O’Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum 
eosinophilia. N Engl J Med 360:985-993, 2009. 
Nakahara H, Gabazza EC, Fujimoto H, Nishii y, D’Alessandro-Gabazza CN, Bruno NE, 
Takagi T, Hayashi T, Maruyama J, Maruyama K, Imanaka-yoshida K, Suzuki K, 
yoshida T, Adachi y and Taguchi O. Deficiency of tenascin C attenuates allergen-
induced bronchial asthma in the mouse. Eur J Immunol 36:3334-3345, 2006. 
Nakamura y, Esnault S, Maeda T, Kelly EAB, Malter JS and Jarjour NN. Ets-1 Regulates 
TNF-alpha-Induced Matrix Metalloproteinase-9 and Tenascin Expression in Primary 
Bronchial Fibroblasts. J Immunol 172:1945-1952, 2004. 
National Heart Lung and Blood Institute, National Asthma Education and Prevention 
Program. Guidelines for the diagnosis and management of asthma. Bethesda, National 
Asthma Education and Prevention Program, National Heart Lung and Blood Institute; 
April 1997. 
National Institutes of Health. National Heart, Lung, and Blood Institute and National Institute 
of Allergy and Infectious Diseases, American Academy of Allergy and Immunology, 
American College of Chest Physicians, and American Thoracic Society. workshop 
summary and guidelines: Investigative use of bronchoscopy, lavage, and bronchial 
biopsies in asthma and other airway diseases. J Allergy Clin Immunol 88:808-814, 
1991. 
Neill DR, wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, Fallon 
PG, Pannell R, Jolin HE and McKenzie AN. Nuocytes represent a new innate effector 
leukocyte that mediates type-2 immunity. Nature 464:1367-1370, 2010. 
Nguyen NM and Senior RM. Laminin isoforms and lung development: All isoforms are not 
equal. Dev Biol 294:271-279, 2006. 
Niimi A, Matsumoto H, Amitani R, Nakano y, Mishima M, Minakuchi M, Nishimura K, 
Itoh H and Izumi T. Airway wall thickness in asthma assessed by computed tomography. 
Relation to clinical indices. Am J Respir Crit Care Med 162:1518-1523, 2000. 
Ohta T, yamashita N, Maruyama M, Sugiyama E and Kobayashi M. Cigarette smoking 
decreases interleukin-8 secretion by human alveolar macrophages. Respir Med 92:922-
927, 1998. 
83
Okayama y, Ra C and Saito H. Role of mast cells in airway remodeling. Curr Opin Immunol 
19:687-693, 2007. 
Oliveira J, Santos R, Soares-Silva I, Jorge P, Vieira E, Oliveira ME, Moreira A, Coelho T, 
Ferreira JC, Fonseca MJ, Barbosa C, Prats J, Ariztegui ML, Martins ML, Moreno T, 
Heinimann K, Barbot C, Pascual-Pascual SI, Cabral A, Fineza I, Santos M and Bronze-
da-Rocha E. LAMA2 gene analysis in a cohort of 26 congenital muscular dystrophy 
patients. Clin Genet 74:502-512, 2008. 
Olmez D, Babayigit A, Erbil G, Karaman O, Bagriyanik A, yilmaz O and Uzuner N. 
Histopathologic changes in two mouse models of asthma. J Investig Allergol Clin 
Immunol 19:132-138, 2009. 
Orsmark-Pietras C, Melen E, Vendelin J, Bruce S, Laitinen A, Laitinen LA, Lauener R, 
Riedler J, von Mutius E, Doekes G, wickman M, van Hage M, Pershagen G, Scheynius 
A, Nyberg F, Kere J and the PARSIFAL Genetics Study Group,. Biological and genetic 
interaction between Tenascin C and Neuropeptide S receptor 1 in allergic diseases. Hum 
Mol Genet 17:1673-1682, 2008. 
O’Shaughnessy TC, Ansari Tw, Barnes NC and Jeffery PK. Inflammation in bronchial 
biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes 
with FEV1. Am J Respir Crit Care Med 155:852-857, 1997. 
Ott MG, Jolly AT, Burkert AL and Brown wE. Issues in diisocyanate antibody testing. Crit 
Rev Toxicol 37:567-585, 2007. 
Padoan M, Pozzato V, Simoni M, Zedda L, Milan G, Bononi I, Piola C, Maestrelli P, 
Boschetto P and Mapp CE. Long-term follow-up of toluene diisocyanate-induced 
asthma. Eur Respir J 21:637-640, 2003. 
Paggiaro P, Bacci E, Paoletti P, Bernard P, Dente FL, Marchetti G, Talini D, Menconi GF 
and Giuntini C. Bronchoalveolar lavage and morphology of the airways after cessation 
of exposure in asthmatic subjects sensitized to toluene diisocyanate. Chest 98:536-542, 
1990. 
Panettieri RA,Jr. Airway smooth muscle: immunomodulatory cells that modulate airway 
remodeling? Respir Physiol Neurobiol 137:277-293, 2003. 
Park BL, Cheong HS, Kim LH, Choi yH, Namgoong S, Park HS, Hong SJ, Choi Bw, 
Lee JH, Park CS and Shin HD. Association analysis of signal transducer and activator 
of transcription 4 (STAT4) polymorphisms with asthma. J Hum Genet 50:133-138, 
2005a. 
Park H, Li Z, yang XO, Chang SH, Nurieva R, wang yH, wang y, Hood L, Zhu Z, Tian 
Q and Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by 
producing interleukin 17. Nat Immunol 6:1133-1141, 2005b. 
Park HS and Nahm DH. Prognostic factors for toluene diisocyanate-induced occupational 
asthma after removal from exposure. Clin Exp Allergy 27:1145-1150, 1997. 
84
Park Sw, Park JS, Lee yM, Lee JH, Jang AS, Kim DJ, Hwangbo y, Uh ST, Kim yH 
and Park CS. Differences in radiological/HRCT findings in eosinophilic bronchitis and 
asthma: implication for bronchial responsiveness. Thorax 61:41-47, 2006. 
Pascual RM and Peters SP. Airway remodeling contributes to the progressive loss of lung 
function in asthma: an overview. J Allergy Clin Immunol 116:477-486, 2005. 
Patterson R and Harris KE. IgE-mediated rhesus monkey asthma: natural history and 
individual animal variation. Int Arch Allergy Immunol 97:154-159, 1992. 
Paul wE and Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat 
Rev Immunol 10:225-235, 2010. 
Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. 
Crit Rev Biochem Mol Biol 27:93-127, 1992. 
Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB and Ohlsson SV. 
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive 
pulmonary disease who continue smoking. European Respiratory Society Study on 
Chronic Obstructive Pulmonary Disease. N Engl J Med 340:1948-1953, 1999. 
Payne DN, Rogers AV, Adelroth E, Bandi V, Guntupalli KK, Bush A and Jeffery PK. Early 
thickening of the reticular basement membrane in children with difficult asthma. Am J 
Respir Crit Care Med 167:78-82, 2003. 
Petajaniemi N, Korhonen M, Kortesmaa J, Tryggvason K, Sekiguchi K, Fujiwara H, Sorokin 
L, Thornell LE, wondimu Z, Assefa D, Patarroyo M and Virtanen I. Localization of 
laminin alpha4-chain in developing and adult human tissues. J Histochem Cytochem 
50:1113-1130, 2002. 
Petrescu F, Voican SC and Silosi I. Tumor necrosis factor-alpha serum levels in healthy 
smokers and nonsmokers. Int J Chron Obstruct Pulmon Dis 5:217-222, 2010. 
Pfitzner E, Kliem S, Baus D and Litterst CM. The role of STATs in inflammation and 
inflammatory diseases. Curr Pharm Des 10:2839-2850, 2004. 
Phipps S, Benyahia F, Ou TT, Barkans J, Robinson DS and Kay AB. Acute allergen-induced 
airway remodeling in atopic asthma. Am J Respir Cell Mol Biol 31:626-632, 2004. 
Piirila PL, Nordman H, Keskinen HM, Luukkonen R, Salo SP, Tuomi TO and Tuppurainen 
M. Long-term follow-up of hexamethylene diisocyanate-, diphenylmethane diisocyanate-
, and toluene diisocyanate-induced asthma. Am J Respir Crit Care Med 162:516-522, 
2000. 
Pisati G, Baruffini A, Bernabeo F, Cerri S and Mangili A. Rechallenging subjects with 
occupational asthma due to toluene diisocyanate (TDI), after long-term removal from 
exposure. Int Arch Occup Environ Health 80:298-305, 2007. 
85
Plopper CG and Hyde DM. The non-human primate as a model for studying COPD and 
asthma. Pulm Pharmacol Ther 21:755-766, 2008. 
Pohunek P, warner JO, Turzikova J, Kudrmann J and Roche wR. Markers of eosinophilic 
inflammation and tissue re-modelling in children before clinically diagnosed bronchial 
asthma. Pediatr Allergy Immunol 16:43-51, 2005. 
Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ and Locksley RM. 
Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl 
Acad Sci U S A 107:11489-11494, 2010. 
Price KS, Friend DS, Mellor EA, De Jesus N, watts GF and Boyce JA. CC chemokine 
receptor 3 mobilizes to the surface of human mast cells and potentiates immunoglobulin 
E-dependent generation of interleukin 13. Am J Respir Cell Mol Biol 28:420-427, 
2003. 
Pronk A, Preller L, Raulf-Heimsoth M, Jonkers IC, Lammers Jw, wouters IM, Doekes 
G, wisnewski AV and Heederik D. Respiratory symptoms, sensitization, and exposure 
response relationships in spray painters exposed to isocyanates. Am J Respir Crit Care 
Med 176:1090-1097, 2007. 
Pykalainen M, Kinos R, Valkonen S, Rydman P, Kilpelainen M, Laitinen LA, Karjalainen 
J, Nieminen M, Hurme M, Kere J, Laitinen T and Lahesmaa R. Association analysis 
of common variants of STAT6, GATA3, and STAT4 to asthma and high serum IgE 
phenotypes. J Allergy Clin Immunol 115:80-87, 2005. 
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R and yernault JC. Lung volumes 
and forced ventilatory flows. Report working Party Standardization of Lung Function 
Tests, European Community for Steel and Coal. Official Statement of the European 
Respiratory Society. Eur Respir J Suppl 16:5-40, 1993. 
Rachiotis G, Savani R, Brant A, MacNeill SJ, Newman Taylor A and Cullinan P. Outcome 
of occupational asthma after cessation of exposure: a systematic review. Thorax 62:147-
152, 2007. 
Raman K, Kaplan MH, Hogaboam CM, Berlin A and Lukacs Nw. STAT4 Signal Pathways 
Regulate Inflammation and Airway Physiology Changes in Allergic Airway Inflammation 
Locally Via Alteration of Chemokines. J Immunol 170:3859-3865, 2003. 
Redman TK, Rudolph K, Barr EB, Bowen LE, Muggenburg BA and Bice DE. Pulmonary 
immunity to ragweed in a Beagle dog model of allergic asthma. Exp Lung Res 27:433-
451, 2001. 
Relan NK, yang y, Beqaj S, Miner JH and Schuger L. Cell Elongation Induces Laminin 
alpha2 Chain Expression in Mouse Embryonic Mesenchymal Cells: Role in Visceral 
Myogenesis. J Cell Biol 147:1341-1350, 1999. 
86
Renz H, Smith HR, Henson JE, Ray BS, Irvin CG and Gelfand Ew. Aerosolized antigen 
exposure without adjuvant causes increased IgE production and increased airway 
responsiveness in the mouse. J Allergy Clin Immunol 89:1127-1138, 1992. 
Rettig wJ, Erickson HP, Albino AP and Garin-Chesa P. Induction of human tenascin 
(neuronectin) by growth factors and cytokines: cell type-specific signals and signalling 
pathways. J Cell Sci 107:487-497, 1994. 
Ricciardolo FL, Nijkamp F, De Rose V and Folkerts G. The guinea pig as an animal model 
for asthma. Curr Drug Targets 9:452-465, 2008. 
Roche wR, Beasley R, williams JH and Holgate ST. Subepithelial fibrosis in the bronchi of 
asthmatics. Lancet 1:520-524, 1989. 
Rothenberg ME and Hogan SP. The eosinophil. Annu Rev Immunol 24:147-174, 2006. 
Roth-Kleiner M, Hirsch E and Schittny JC. Fetal lungs of tenascin-C-deficient mice grow 
well, but branch poorly in organ culture. Am J Respir Cell Mol Biol 30:360-366, 2004. 
Rousselle P, Lunstrum GP, Keene DR and Burgeson RE. Kalinin: an epithelium-specific 
basement membrane adhesion molecule that is a component of anchoring filaments. J 
Cell Biol 114:567-576, 1991. 
Ruckert R, Brandt K, Braun A, Hoymann HG, Herz U, Budagian V, Durkop H, Renz H and 
Bulfone-Paus S. Blocking IL-15 prevents the induction of allergen-specific T cells and 
allergic inflammation in vivo. J Immunol 174:5507-5515, 2005. 
Ruegg CR, Chiquet-Ehrismann R and Alkan SS. Tenascin, an extracellular matrix protein, 
exerts immunomodulatory activities. Proc Natl Acad Sci U S A 86:7437-7441, 1989. 
Saetta M. Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit 
Care Med 160:S17-20, 1999. 
Saetta M, Di Stefano A, Maestrelli P, De Marzo N, Milani GF, Pivirotto F, Mapp CE and 
Fabbri LM. Airway mucosal inflammation in occupational asthma induced by toluene 
diisocyanate. Am Rev Respir Dis 145:160-168, 1992. 
Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A, Ciaccia A and Fabbri 
LM. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with 
chronic bronchitis. Am Rev Respir Dis 147:301-306, 1993. 
Saetta M, Maestrelli P, Di Stefano A, De Marzo N, Milani GF, Pivirotto F, Mapp CE and 
Fabbri LM. Effect of cessation of exposure to toluene diisocyanate (TDI) on bronchial 
mucosa of subjects with TDI-induced asthma. Am Rev Respir Dis 145:169-174, 1992. 
Sarasa-Renedo A, Tunc-Civelek V and Chiquet M. Role of RhoA/ROCK-dependent 
actin contractility in the induction of tenascin-C by cyclic tensile strain. Exp Cell Res 
312:1361-1370, 2006. 
87
Sasaki T, Mann K, Miner JH, Miosge N and Timpl R. Domain IV of mouse laminin beta1 
and beta2 chains. Eur J Biochem 269:431-442, 2002. 
Sauty A, Mauel J, Philippeaux MM and Leuenberger P. Cytostatic activity of alveolar 
macrophages from smokers and nonsmokers: role of interleukin-1 beta, interleukin-6, 
and tumor necrosis factor-alpha. Am J Respir Cell Mol Biol 11:631-637, 1994. 
Scheele S, Nystrom A, Durbeej M, Talts JF, Ekblom M and Ekblom P. Laminin isoforms in 
development and disease. J Mol Med 85:825-836, 2007. 
Schwarze J, Hamelmann E, Cieslewicz G, Tomkinson A, Joetham A, Bradley K and Gelfand 
Ew. Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness 
and lung eosinophilia after airway challenge in sensitized mice. J Allergy Clin Immunol 
102:86-93, 1998. 
Sehra S, Bruns HA, Ahyi AN, Nguyen ET, Schmidt Nw, Michels EG, von Bulow GU and 
Kaplan MH. IL-4 is a critical determinant in the generation of allergic inflammation 
initiated by a constitutively active Stat6. J Immunol 180:3551-3559, 2008. 
Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, 
unresolved issues and future directions. Curr Dir Autoimmun 11:180-210, 2010. 
Shimoda K, van Deursen J, Sangster My, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle 
Fw, Nosaka T, Vignali DA, Doherty PC, Grosveld G, Paul wE and Ihle JN. Lack of 
IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. 
Nature 380:630-633, 1996. 
Shin HJ, Park Hy, Jeong SJ, Park Hw, Kim yK, Cho SH, Kim yy, Cho ML, Kim Hy, Min 
KU and Lee Cw. STAT4 expression in human T cells is regulated by DNA methylation 
but not by promoter polymorphism. J Immunol 175:7143-7150, 2005. 
Singh P, Daniels M, winsett Dw, Richards J, Doerfler D, Hatch G, Adler KB and Gilmour 
MI. Phenotypic comparison of allergic airway responses to house dust mite in three rat 
strains. Am J Physiol Lung Cell Mol Physiol 284:L588-98, 2003. 
Smith LA, Paszkiewicz GM, Hutson AD and Pauly JL. Inflammatory response of lung 
macrophages and epithelial cells to tobacco smoke: a literature review of ex vivo 
investigations. Immunol Res 46:94-126, 2010. 
Soini y, Paakko P, Virtanen I and Lehto VP. Tenascin in salivary gland tumours. Virchows 
Arch A Pathol Anat Histopathol 421:217-222, 1992. 
Sorokin LM, Pausch F, Durbeej M and Ekblom P. Differential expression of five laminin 
alpha (1-5) chains in developing and adult mouse kidney. Dev Dyn 210:446-462, 1997. 
Soumelis V, Reche PA, Kanzler H, yuan w, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, 
Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, de waal-
Malefyt Rd R, Bazan F, Kastelein RA and Liu yJ. Human epithelial cells trigger dendritic 
cell mediated allergic inflammation by producing TSLP. Nat Immunol 3:673-680, 2002. 
88
Sovijarvi AR, Malmberg LP, Reinikainen K, Rytila P and Poppius H. A rapid dosimetric 
method with controlled tidal breathing for histamine challenge. Repeatability and 
distribution of bronchial reactivity in a clinical material. Chest 104:164-170, 1993. 
Sur S, Lam J, Bouchard P, Sigounas A, Holbert D and Metzger wJ. Immunomodulatory 
effects of IL-12 on allergic lung inflammation depend on timing of doses. J Immunol 
157:4173-4180, 1996. 
Syed F, Panettieri RA,Jr, Tliba O, Huang C, Li K, Bracht M, Amegadzie B, Griswold D, 
Li L and Amrani y. The effect of IL-13 and IL-13R130Q, a naturally occurring IL-13 
polymorphism, on the gene expression of human airway smooth muscle cells. Respir 
Res 6:9, 2005. 
Syrbe U, Hoffmann U, Schlawe K, Liesenfeld O, Erb K and Hamann A. Microenvironment-
Dependent Requirement of STAT4 for the Induction of P-Selectin Ligands and Effector 
Cytokines on CD4+ T Cells in Healthy and Parasite-Infected Mice. J Immunol 177:7673-
7679, 2006. 
Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, yuki H, Kato S and Tomoike 
H. The relationship between chronic hypoxemia and activation of the tumor necrosis 
factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir 
Crit Care Med 161:1179-1184, 2000. 
Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, Nagai H, 
Hotokebuchi T and Izuhara K. Periostin: a novel component of subepithelial fibrosis 
of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 
118:98-104, 2006. 
Takeda K and Gelfand Ew. Mouse models of allergic diseases. Curr Opin Immunol 21:660-
665, 2009. 
Takeda K, Tanaka T, Shi w, Matsumoto M, Minami M, Kashiwamura S, Nakanishi K, 
yoshida N, Kishimoto T and Akira S. Essential role of Stat6 in IL-4 signalling. Nature 
380:627-630, 1996. 
Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, Okada y, yamasawa F and 
Umeda A. Increased expression of inflammatory mediators in small-airway epithelium 
from tobacco smokers. Am J Physiol Lung Cell Mol Physiol 278:L906-913, 2000. 
Tanino M, Betsuyaku T, Takeyabu K, Tanino y, yamaguchi E, Miyamoto K and Nishimura 
M. Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary 
emphysema. Thorax 57:405-411, 2002. 
Taskinen E, Tukiainen P and Renkonen R. Bronchoalveolar lavage. Influence of cytologic 
methods on the cellular picture. Acta Cytol 36:680-686, 1992. 
Tetley TD. Macrophages and the pathogenesis of COPD. Chest 121:156S-159S, 2002. 
89
Theoharides TC and Kalogeromitros D. The critical role of mast cells in allergy and 
inflammation. Ann N y Acad Sci 1088:78-99, 2006. 
Thierfelder wE, van Deursen JM, yamamoto K, Tripp RA, Sarawar SR, Carson RT, 
Sangster My, Vignali DA, Doherty PC, Grosveld GC and Ihle JN. Requirement for 
Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171-
174, 1996. 
Thomas PS and Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with 
mild asthma. Thorax 57:774-778, 2002. 
Thorne PS and Karol MH. Association of fever with late-onset pulmonary hypersensitivity 
responses in the guinea pig. Toxicol Appl Pharmacol 100:247-258, 1989. 
Tiger CF, Champliaud MF, Pedrosa-Domellof F, Thornell LE, Ekblom P and Gullberg D. 
Presence of laminin alpha5 chain and lack of laminin alpha1 chain during human muscle 
development and in muscular dystrophies. J Biol Chem 272:28590-28595, 1997. 
Tillie-Leblond I, Montani D, Crestani B, de Blic J, Humbert M, Tunon-de-Lara M, Magnan 
A, Roche N, Ostinelli J and Chanez P. Relation between inflammation and symptoms in 
asthma. Allergy 64:354-367, 2009. 
Timpl R. Macromolecular organization of basement membranes. Curr Opin Cell Biol 8:618-
624, 1996. 
Torrego A, Hew M, Oates T, Sukkar M and Fan Chung K. Expression and activation of 
TGF-beta isoforms in acute allergen-induced remodelling in asthma. Thorax 62:307-
313, 2007. 
Tran T, McNeill KD, Gerthoffer wT, Unruh H and Halayko AJ. Endogenous laminin is 
required for human airway smooth muscle cell maturation. Respir Res 7:117, 2006. 
Tsurikisawa N, Oshikata C, Tsuburai T, Saito H, Sekiya K, Tanimoto H, Takeichi S, Mitomi 
H and Akiyama K. Bronchial reactivity to histamine is correlated with airway remodeling 
in adults with moderate to severe asthma. J Asthma 47:841-848, 2010. 
Tucker RP and Chiquet-Ehrismann R. The regulation of tenascin expression by tissue 
microenvironments. Biochim Biophys Acta 1793:888-892, 2009. 
Turvey SE and Broide DH. Innate immunity. J Allergy Clin Immunol 125:S24-32, 2010. 
Van Bogaert T, De Bosscher K and Libert C. Crosstalk between TNF and glucocorticoid 
receptor signaling pathways. Cytokine Growth Factor Rev 21:275-286, 2010. 
Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, Torrey D, Pandit 
S, McKenny J, Braunschweiger K, walsh A, Liu Z, Hayward B, Folz C, Manning SP, 
Bawa A, Saracino L, Thackston M, Benchekroun y, Capparell N, wang M, Adair R, 
Feng y, Dubois J, FitzGerald MG, Huang H, Gibson R, Allen KM, Pedan A, Danzig 
MR, Umland SP, Egan Rw, Cuss FM, Rorke S, Clough JB, Holloway Jw, Holgate 
90
ST and Keith TP. Association of the ADAM33 gene with asthma and bronchial 
hyperresponsiveness. Nature 418:426-430, 2002. 
Vandenplas O, Delwiche JP, Staquet P, Jamart J, Bernard A, Boulanger J, Delaunois L and 
Sibille y. Pulmonary effects of short-term exposure to low levels of toluene diisocyanate 
in asymptomatic subjects. Eur Respir J 13:1144-1150, 1999. 
Veldhoen M, Uyttenhove C, van Snick J, Helmby H, westendorf A, Buer J, Martin B, wilhelm 
C and Stockinger B. Transforming growth factor-beta ‘reprograms’ the differentiation of 
T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 9:1341-  
1346, 2008. 
Viljanen AA, Halttunen PK, Kreus KE and Viljanen BC. Spirometric studies in non-smoking,    
healthy adults. Scand J Clin Lab Invest Suppl 159:5-20, 1982. 
Virtanen I, Gullberg D, Rissanen J, Kivilaakso E, Kiviluoto T, Laitinen LA, Lehto VP and 
Ekblom P. Laminin alpha1-chain shows a restricted distribution in epithelial basement 
membranes of fetal and adult human tissues. Exp Cell Res 257:298-309, 2000. 
Virtanen I, Laitinen A, Tani T, Paakko P, Laitinen LA, Burgeson RE and Lehto VP. 
Differential expression of laminins and their integrin receptors in developing and adult 
human lung. Am J Respir Cell Mol Biol 15:184-196, 1996. 
Virtanen I, Lohi J, Tani T, Korhonen M, Burgeson RE, Lehto VP and Leivo I. Distinct 
changes in the laminin composition of basement membranes in human seminiferous 
tubules during development and degeneration. Am J Pathol 150:1421-1431, 1997. 
Walker w, Healey GD and Hopkin JM. RNA interference of STAT6 rapidly attenuates 
ongoing interleukin-13-mediated events in lung epithelial cells. Immunology 127:256-
266, 2009. 
Wallace JM, Oishi JS, Barbers RG, Simmons MS and Tashkin DP. Lymphocytic subpopulation 
profiles in bronchoalveolar lavage fluid and peripheral blood from tobacco and marijuana 
smokers. Chest 105:847-852, 1994. 
Wang yH, Voo KS, Liu B, Chen Cy, Uygungil B, Spoede w, Bernstein JA, Huston DP 
and Liu yJ. A novel subset of CD4(+) T(H)2 memory/effector cells that produce 
inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J 
Exp Med 207:2479-2491, 2010. 
Wang Z, Zheng T, Zhu Z, Homer RJ, Riese RJ, Chapman HA,Jr, Shapiro SD and Elias JA. 
Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp 
Med 192:1587-1600, 2000. 
Weinacker A, Ferrando R, Elliott M, Hogg J, Balmes J and Sheppard D. Distribution of 
integrins alpha v beta 6 and alpha 9 beta 1 and their known ligands, fibronectin and 
tenascin, in human airways. Am J Respir Cell Mol Biol 12:547-556, 1995. 
91
Weiss ST, DeMeo DL and Postma DS. COPD: problems in diagnosis and measurement. 
European Respiratory Journal - Supplement 41:4s-12s, 2003. 
Wenzel SE, Trudeau JB, Barnes S, Zhou X, Cundall M, westcott Jy, McCord K and Chu 
Hw. TGF-beta and IL-13 synergistically increase eotaxin-1 production in human airway 
fibroblasts. J Immunol 169:4613-4619, 2002. 
Westergren-Thorsson G, Larsen K, Nihlberg K, Andersson-Sjoland A, Hallgren O, Marko-
Varga G and Bjermer L. Pathological airway remodelling in inflammation. Clin Respir 
J 4 Suppl 1:1-8, 2010. 
Wills-Karp M and Finkelman FD. Untangling the complex web of IL-4- and IL-13-mediated 
signaling pathways. Sci Signal 1:pe55, 2008. 
Wisnewski AV, Herrick CA, Liu Q, Chen L, Bottomly K and Redlich CA. Human gamma/
delta T-cell proliferation and IFN-gamma production induced by hexamethylene 
diisocyanate. J Allergy Clin Immunol 112:538-546, 2003. 
Wisnewski AV, Liu Q, Liu J and Redlich CA. Human innate immune responses to 
hexamethylene diisocyanate (HDI) and HDI-albumin conjugates. Clin Exp Allergy 
38:957-967, 2008. 
Wynn TA. IL-13 effector functions. Annu Rev Immunol 21:425-456, 2003. 
Xisto DG, Farias LL, Ferreira HC, Picanco MR, Amitrano D, Lapa e Silva JR, Negri EM, 
Mauad T, Carnielli D, Silva LFF, Capelozzi VL, Faffe DS, Zin wA and Rocco PRM. 
Lung Parenchyma Remodeling in a Murine Model of Chronic Allergic Inflammation. 
Am J Respir Crit Care Med 171:829-837, 2005. 
Yamaguchi E, Itoh A, Furuya K, Miyamoto H, Abe S and Kawakami y. Release of tumor 
necrosis factor-alpha from human alveolar macrophages is decreased in smokers. Chest 
103:479-483, 1993. 
Yang D, Chen Q, Hoover DM, Staley P, Tucker KD, Lubkowski J and Oppenheim JJ. Many 
chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol 
74:448-455, 2003. 
Yang M, Kumar RK and Foster PS. Interferon-gamma and pulmonary macrophages 
contribute to the mechanisms underlying prolonged airway hyperresponsiveness. Clin 
Exp Allergy 40:163-173, 2010. 
Ying S, O’Connor B, Ratoff J, Meng Q, Mallett K, Cousins D, Robinson D, Zhang G, Zhao 
J, Lee TH and Corrigan C. Thymic stromal lymphopoietin expression is increased in 
asthmatic airways and correlates with expression of Th2-attracting chemokines and 
disease severity. J Immunol 174:8183-8190, 2005. 
Yoshimoto T. Basophils as T(h)2-inducing antigen-presenting cells. Int Immunol 22:543-
550, 2010. 
92
Young SL, Chang Ly and Erickson HP. Tenascin-C in rat lung: distribution, ontogeny and 
role in branching morphogenesis. Dev Biol 161:615-625, 1994. 
Yu M, Zheng X, witschi H and Pinkerton KE. The role of interleukin-6 in pulmonary 
inflammation and injury induced by exposure to environmental air pollutants. Toxicol 
Sci 68:488-497, 2002. 
Yuyama N, Davies DE, Akaiwa M, Matsui K, Hamasaki y, Suminami y, yoshida NL, 
Maeda M, Pandit A, Lordan JL, Kamogawa y, Arima K, Nagumo F, Sugimachi M, 
Berger A, Richards I, Roberds SL, yamashita T, Kishi F, Kato H, Arai K, Ohshima K, 
Tadano J, Hamasaki N, Miyatake S, Sugita y, Holgate ST and Izuhara K. Analysis of 
novel disease-related genes in bronchial asthma. Cytokine 19:287-296, 2002. 
Zenker M, Aigner T, wendler O, Tralau T, Muntefering H, Fenski R, Pitz S, Schumacher V, 
Royer-Pokora B, wuhl E, Cochat P, Bouvier R, Kraus C, Mark K, Madlon H, Dotsch J, 
Rascher w, Maruniak-Chudek I, Lennert T, Neumann LM and Reis A. Human laminin 
beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye 
abnormalities. Hum Mol Genet 13:2625-2632, 2004. 
Zhang Q, Lai K, Xie J, Chen G and Zhong N. Does unrestrained single-chamber 
plethysmography provide a valid assessment of airway responsiveness in allergic BALB/
c mice? Respir Res 10:61, 2009. 
Zheng T, Zhu Z, wang Z, Homer RJ, Ma B, Riese RJ,Jr, Chapman HA,Jr, Shapiro SD and 
Elias JA. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- 
and cathepsin-dependent emphysema. J Clin Invest 106:1081-1093, 2000. 
Zhu J, Qiu yS, Majumdar S, Gamble E, Matin D, Turato G, Fabbri LM, Barnes N, Saetta M 
and Jeffery PK. Exacerbations of Bronchitis: bronchial eosinophilia and gene expression 
for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care 
Med 164:109-116, 2001. 
Zimmermann N, Mishra A, King NE, Fulkerson PC, Doepker MP, Nikolaidis NM, 
Kindinger LE, Moulton EA, Aronow BJ and Rothenberg ME. Transcript Signatures in 
Experimental Asthma: Identification of STAT6-Dependent and -Independent Pathways. 
J Immunol 172:1815-1824, 2004. 






Helsinki University print 2011
